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‘The role of gastrin in the development of gastric preneoplastic and 
neoplastic changes’ 
Senthil Murugesan 
Abstract 
The hormone gastrin regulates gastric acid secretion and through its 
effects on cell proliferation, apoptosis and angiogenesis also regulates 
gastric epithelial and enterochromaffin-like (ECL) cell growth. The 
influence of various factors (host, bacterial and environmental) upon 
fasting serum gastrin concentrations and to what extent these factors 
interact to influence the progression of gastric preneoplastic pathology is 
not fully understood.  
Long standing hypergastrinaemia secondary to hypochlorhydria resulting 
from autoimmune gastritis can result in the development of ECL-cell 
hyperplasia. In some patients this progresses to type-1 gastric 
neuroendocrine tumour formation. The factors that influence this 
progression have not been fully characterised.  
The management of type-1 gastric neuroendocrine tumours is dependent 
on their size. However, there is still controversy regarding the optimal 
management of larger (> 1cm) tumours. Antrectomy is one option and the 
results of an octreotide suppression test (to determine gastrin dependency 
of type-1 gastric neuroendocrine tumours in order to predict response to 
antrectomy) have been reported in a single patient. 
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This aims of this thesis were to assess: 
1. The interaction between various factors (host, bacterial and 
environmental) that may influence fasting serum gastrin 
concentrations and the development of gastric preneoplastic 
pathology. 
2. The roles of certain factors in the progression of ECL-cell 
hyperplasia to type-1 gastric neuroendocrine tumours.  
3. The role of an octreotide suppression test in identifying patients with 
type-1 gastric neuroendocrine tumours who may benefit from 
antrectomy. 
In a large cohort of >1000 prospectively recruited patients, we 
demonstrated that in addition to H. pylori infection,  the presence of a host 
factor (advancing age), a bacterial virulence factor (cagA) and elevated 
fasting serum gastrin concentrations (>100pM) were significantly 
associated with the presence of gastric preneoplastic pathology. 
Concurrent proton pump inhibitor therapy was however not associated with 
the presence of gastric preneoplastic pathology.  
The interactions between H. pylori infection, proton pump inhibitor use and 
the presence of gastric preneoplastic pathology in determining fasting 
serum gastrin concentrations were found to be complex. In addition, other 
host and environmental factors also influenced fasting serum gastrin 
concentrations.  
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Although results from our study did not demonstrate any statistically 
significant associations, there did appear to be correlations between the 
presence of factors such as hypothyroidism, positive anti-gastric parietal 
and intrinsic factor antibodies and extent of gastric atrophy with the 
presence of more advanced degrees of gastric ECL-cell hyperplasia.  
Although a positive octreotide suppression test was associated with 
tumour regression following antrectomy in four patients with type-1 gastric 
neuroendocrine tumours, a fifth patient who had a positive test did not 
show tumour regression and needed additional surgery. 
In conclusion, gastrin appears to act as an important co-factor in the 
pathogenesis of epithelial and neuroendocrine neoplasia in the stomach, 
but interactions with other factors are complex.  
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1 Introduction 
 
1.1 Stomach – anatomy and physiology 
1.1.1 Gross anatomy of stomach 
The human stomach is a ‘J’ shaped organ of the gastrointestinal 
tract continuous with the oesophagus proximally and duodenum distally. 
Acting primarily as a reservoir of ingested food, it ensures a controlled 
release of food into the distal duodenum (which is of a smaller calibre), 
thereby controlling digestion and absorption of nutrients. The stomach is 
divided into four main anatomical regions (Fig 1-1): 
1. Cardia - located immediately distal to the oesophagogastric junction 
and the lower oesophageal sphincter 
2. Fundus - this is a dome shaped elevation of the stomach, projecting 
upwards above the cardia and the oesophagogastric junction and 
lying in contact with the left hemidiaphragm 
3. Corpus or body - the largest part of the stomach which  lies 
immediately distal to the fundus 
4. Antrum - the distal end of the stomach which continues into the 
duodenum through the pylorus. 
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The demarcation between the various regions is however often variable 
but these four regions correspond approximately with the mucosal 
histology. 
 
 
 
Figure 1-1: Cross sectional view of the human stomach showing the anatomic regions of 
the stomach. 
The line is drawn from the incisura angularis along the lesser curvature to an indistinct 
border between the antrum and corpus along the greater curvature (adapted from 
Sleisenger and Fordtran’s Gastrointestinal and Liver disease online 8th edition).  
 
1.1.2 Tissue layers of the stomach 
The stomach wall is composed of four layers: 
1. Mucosa - innermost and lines the gastric lumen 
2. Submucosa - lying immediately deep to the mucosa and containing 
connective tissue, arterioles, venules, lymphatics and the submucosal 
plexus 
3. Muscularis propria - contains three muscle layers namely the inner 
oblique, middle circular and outer longitudinal 
29 
 
4. Serosa - final and outermost layer which is a continuation of the 
peritoneal layer 
 
1.1.3 Mucosal cell types and function 
The gastric mucosa is composed of a layer of columnar epithelial 
cells measuring 20 to 40µm in height. These form the surface mucosal 
cells which secrete mucus, and are the same throughout the stomach. 
This surface layer is invaginated by gastric pits providing access to the 
lumen for gastric glands. The different regions of the stomach contain 
different types of gastric glands (Owen, 1986). 
1.1.3.1 Parietal or Oxyntic gland 
These are predominantly located in the gastric fundus and the body 
(corpus) and consist of parietal, chief (or peptic), mucous neck and 
endocrine cells. The primary function of the oxyntic gland is secretion of 
acid, intrinsic factor and other enzymes. The principal cell of the oxyntic 
gland is the parietal cell which secretes acid at a rate of 3x106  hydrogen 
ions per second, achieving a final hydrochloric acid concentration of 
160mmol/L (Kopic et al., 2010). The parietal cells also secrete intrinsic 
factor which is essential for the absorption of vitamin B12.  
A typical oxyntic gland is divided into three areas, namely the 
isthmus (where the surface mucous cells predominate), the neck 
(containing parietal and mucous neck cells) and the base (which consists 
predominantly of chief cells, but with some parietal and mucous neck cells) 
(Fig1-2).  
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Figure 1-2: Schematic representation of oxyntic gland containing mucous surface cells 
(MSC), mucous neck cells (MNC), enterochromaffin–like cells (ECL), acid secreting 
parietal cells (PC), somatostatin secreting D cells (D cells) and pepsin secreting chief 
cells (CC). 
(Adapted from Sleisenger and Fordtran’s Gastrointestinal and Liver disease online 8
th
 
edition). 
 
1.1.3.2 Antrum and pyloric glands 
The antrum (and pylorus) is lined by coiled glands containing 
epithelial and endocrine cells. The epithelial cells are predominantly mucus 
secreting; a small number of pepsinogen-II- secreting oxyntic cells are also 
found (Owen, 1986).  
1.1.3.3 Endocrine Cells 
The stomach contains several types of endocrine and endocrine-
like cells, many of which are involved in the regulation of gastric exocrine 
secretion. Gastrin cells (G cells) are located in the pyloric glands and 
somatostatin secreting D cells are located close to the G cells and are also 
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present in the corpus. Histamine secreting enterochromaffin-like cells (ECL 
cells) are seen only in the oxyntic glands in close proximity to parietal cells. 
ECL-like cells and mast cells which are located in the lamina propria of the 
gastric mucosa contain histamine, an important stimulator of gastric acid 
secretion. 
 
1.2 Gastric secretion 
The human stomach secretes water, electrolytes (including H+, K+, 
Na+, Cl- and HCO3-), enzymes and glycoproteins (intrinsic factor and 
mucins). These are summarised in table 1-1.  
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Exocrine product Function Secretory cell type 
Hydrochloric acid  Provides optimal pH 
for pepsin and 
gastric lipase 
activation 
 Duodenal iron 
absorption 
 Negative feedback 
inhibition of gastrin 
release 
 Stimulates 
pancreatic HCO3
-
release 
 Defence against 
ingested microbes 
Parietal cell, via the 
H
+
/K
+ 
- ATPase (the 
proton pump) 
Pepsins  Hydrolysis of dietary 
proteins 
 Vitamin B12 
separation  
Chief cell 
Gastric lipase  Early hydrolysis of 
dietary triglycerides 
Chief  cell 
Intrinsic factor  Vitamin B12 binding, 
for absorption at 
specific receptors in 
the terminal ileum 
Parietal cell 
Mucin and HCO3
-
  Protection against 
HCl and pepsins 
Mucous neck cell and 
chief cell 
 
Table 1-1: Gastric exocrine secretory products, secretory cell type and physiological 
functions. 
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1.2.1 Gastric acid secretion 
 Hydrochloric acid secretion in the stomach occurs under basal and 
stimulated conditions. Basal secretion follows a circadian pattern, with 
highest secretion occurring at night and lowest secretion being during the 
early morning hours. Cholinergic stimulation via the vagus nerve and 
histamine stimulation are the major stimulants of basal acid secretion. 
Stimulated acid secretion occurs primarily in three phases, which are 
named cephalic, gastric and intestinal depending on the site where the 
signal originates (Soll and Walsh, 1979). 
The cephalic phase refers to acid secretion in response to the sight, 
smell or taste of food by vagal nerve stimulation. The gastric phase is 
initiated as soon as food enters the stomach. This phase may be induced 
by two possible mechanisms. Firstly, the nutrients in the ingested food 
stimulate gastrin release, which in turn activates acid secretion (explained 
in detail in section 1.3.1) and secondly distension of the stomach 
stimulates stretch receptors and the subsequent stimulation of the vagal 
nerve results in acid secretion. The intestinal phase is initiated as food 
enters the intestine and is stimulated by intestinal distension and nutrient 
absorption      (Feldman and Richardson, 1986).  
During these phases, several series of pathways that inhibit acid 
secretion are also set into motion. These are predominantly mediated by 
somatostatin. 
The acid secreting parietal cell, located in the oxyntic gland, 
expresses receptors for several of the acid stimulants, namely the 
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histamine (H2) receptor, CCK-2 receptor (gastrin receptor) and 
acetylcholine (muscarinic M3) receptor. Stimulation of the H2 receptor 
following binding by histamine leads to activation of adenylate cyclase and 
an increase in cyclic AMP. The stimulation of the CCK-2 and M3 receptors 
results in the activation of the protein kinase C and phosphoinositide 
signalling pathways. These regulate several downstream pathways that 
control the acid secreting pump-H+/K+-ATPase (Schubert, 2009). 
 
1.2.2 The proton pump (H+/K+-ATPase) and acid secretion 
This enzyme is responsible for generating the high concentration of 
H+ (hydrogen) ions in the parietal cell. It is a membrane bound protein that 
consists of two subunits named α and β. The active catalytic site is found 
within the α-subunit.  
The proton pump is located within the secretory canaliculus and 
also in the nonsecretory cytoplasmic tubulovesicles. It utilises the energy 
from ATP (Adenosine triphosphate) to transfer H+ ions from the parietal 
cell cytoplasm to the secretory canaliculi in exchange for K+ (potassium). 
The nonsecretory cytoplasmic tubulovesicles are impermeable to K+ 
leading to an inactive pump at this location. In the resting state only 5% of 
the pumps are within the secretory canaliculus. Upon parietal cell 
stimulation, tubulovesicles are transferred to the secretory canalicular 
membrane, where about 60-70% of the pumps are activated. Proton 
pumps are then recycled back to the inactive state in cytoplasmic vesicles 
once parietal cell stimulation ceases (Schubert, 2009; Kopic et al., 2010). 
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Acid is generated within the parietal cell from the hydration of CO2 
to form H+ and HCO3
-, catalysed by the enzyme carbonic anhydrase. The 
H+ formed in this reaction is secreted by the proton pump in exchange for 
K+ and the HCO3
- is exchanged for Cl- thereby maintaining a slightly 
alkaline pH within the parietal cell (Fig 1-3). 
 
 
 
Figure 1-3: Model of gastric acid secretion by the parietal cell.  
 
1.2.3 Regulation of H+ secretion 
Several factors are involved in the complex regulation of acid 
secretion and these include both stimulators and inhibitors of gastric acid 
secretion. 
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1.2.3.1 Stimulators of acid secretion 
1.2.3.1.1 Gastrin 
Gastrin secreted by the G-cells of the antrum is the most potent 
stimulator of acid secretion. Luminal amino acids stimulate gastrin release. 
Gastrin then acts via CCK-2 receptors located on gastric ECL-cells to 
stimulate the release of stored histamine. This released histamine 
subsequently stimulates acid secretion from gastric parietal cells through 
binding to H2 receptors. The role played by gastrin in the regulation of 
gastric physiology is described in more detail in section 1.3. 
1.2.3.1.2 Acetylcholine, GRP and other neurotransmitters 
Acetylcholine 
Acetylcholine released from postganglionic neurons acts on the 
parietal cell muscarinic (M3) receptors to stimulate acid secretion. Its 
inhibition of somatostatin secretion by stimulation of M2 and M4 receptors 
on somatostatin D cells appears to be another mechanism by which it 
promotes acid secretion. Acetylcholine and cholinergic neurons also 
appear to mediate the acid secretion stimulated by gastric distension 
(gastric phase) and during the cephalic phase (Perez-Zoghbi et al., 2008). 
 
Gastrin releasing peptide (GRP) 
This is a 27-amino acid neuropeptide first recognised in 1975 
(McDonald et al., 1978). GRP has been shown to directly stimulate gastrin 
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release (Giraud et al., 1987), but it also stimulates somatostatin release 
thereby exhibiting both stimulatory and inhibitory effects on acid secretion. 
 
Other neurotransmitters 
Calcitonin gene related peptide (CGRP) (Manela et al., 1995) and 
pituitary adenylate cyclase-activating peptide (PACAP) (Li et al., 2000) 
have  also been shown to regulate gastric acid secretion in humans. 
1.2.3.1.3 Histamine and ECL-cells 
ECL-cells, located in the oxyntic mucosa, play a major role in 
gastric acid secretion. These cells synthesise histamine from histidine by 
the enzyme histidine decarboxylase (HDC). ECL-cells which have been 
stimulated by gastrin, cholecystokinin (CCK) or acetylcholine release 
stored histamine, which in turn stimulates parietal cells to produce acid via 
the H2 receptor (Fykse et al., 2006). 
The major inhibitor of ECL-cells is somatostatin. Histamine acting 
via H3 receptors can also inhibit histamine secretion via autocrine 
inhibition (Vuyyuru and Schubert, 1997). 
The major role played by histamine in the gastrin mediated 
stimulation of acid secretion has been demonstrated by studies in which 
depletion of histamine or targeted disruption of HDC eliminates the acid 
response to gastrin stimulation (Chen et al., 2006). 
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1.2.3.2 Inhibitors of acid secretion 
Several factors and mechanisms play a key role in the inhibition of 
gastric acid secretion: 
1.2.3.2.1 Negative feedback inhibition 
When the pH in the lumen of the stomach falls below 3 as a result 
of gastrin mediated acid release, further release of gastrin from G cells is 
inhibited. Amino acids that are stimulants for gastrin release are ionised by 
the secreted acid, thereby reducing their stimulatory effect on further 
gastrin release. 
1.2.3.2.2 Somatostatin 
Somatostatin is the main inhibitor of gastric acid production and is 
produced by the somatostatin secreting D cells, located in the oxyntic 
mucosa, in response to both a fall in the intraluminal pH of the stomach 
and also by gastrin. Circulating CCK (cholecystokinin) also appears to 
stimulate D-cells via CCK-1 receptors. Somatostatin probably inhibits 
parietal cells directly, but its major effects on acid secretion are mediated 
by inhibition of ECL-cells and G-cells. 
Somatostatin is synthesised from a 92-aminoacid precursor 
preprosomatostatin. This precursor is processed to somatostatin-14 and 
somatostatin-28 subunits, the former being predominantly distributed in the 
stomach and pancreatic islet cells, whereas the latter is present in the 
small intestine. In the stomach, somatostatin cells are closely coupled to 
their target cells and this provides a tonic restraint on acid secretion 
(Schubert et al., 1987). Somatostatin exerts its inhibitory effect on gastrin 
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secretion through its effects on the somatostatin subtype-2 receptor via the 
induction of menin, a tumour suppressor gene, which has been shown to 
directly inhibit gastrin gene expression (Mensah-Osman et al., 2008). 
1.2.3.2.3 Secretin 
Secretin has been shown to decrease acid secretion by its ability to 
suppress the release of gastrin and also by direct non-competitive 
inhibition of the action of gastrin at the parietal cell. Low luminal pH 
following meal stimulated acid secretion stimulates duodenal S cells to 
release secretin(Johnson and Grossman, 1969). The main effect of 
secretin is to stimulate the release of alkaline pancreatic juice which helps 
neutralise the acidic juice from the stomach. This results in negative 
feedback inhibition of further secretin release and also inhibition of antral 
gastrin release. Secretin receptors have also been shown on the surface 
of other neuroendocrine cells including gastrinomas and secretin can 
stimulate these cells to release gastrin. This forms the basis of the secretin 
stimulation test for diagnosing Zollinger Ellison syndrome (Berna et al., 
2006a). 
1.2.3.2.4 Nitric oxide and Dopamine 
Both nitric oxide and dopamine have been shown in animal studies to 
inhibit acid secretion. Ito et al. have shown increased acid production in 
rats in the presence of a nitric oxide synthase inhibitor (Ito et al., 2008). 
Similarly D2 receptors have been isolated in the stomach and the D2 
receptor agonist quinpirole has been shown to inhibit histamine and 
carbachol stimulated acid secretion in rats (Eliassi et al., 2008). 
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1.3 The hormone gastrin and its roles in the regulation of gastric acid 
secretion and development of gastric tumours 
The hormone gastrin has a well established role in the regulation of 
acid secretion. However it is now known that gastrin also plays a major 
part in regulating gastric epithelial cell proliferation, apoptosis, migration 
and invasion as well as gastric tumour angiogenesis.  
 
1.3.1 Gastrin synthesis and release 
The gene encoding gastrin is located at chromosome 17q21 (Ito et 
al., 1984). Gastrin is synthesised in its precursor form, preprogastrin, in the 
endoplasmic reticulum of gastrin (G)-cells, located in the gastric antrum. 
The hormone is mainly expressed in the gastric antrum, but there is 
evidence to suggest that the gene is also expressed in some colorectal 
tumours, pituitary gland and testis although at lower concentrations at the 
latter two sites (Wang and Dockray, 1999). Preprogastrin is subsequently 
enzymatically cleaved to progastrin which is stored in storage vesicles 
prior to secretion.  In these storage vesicles, progastrin undergoes 
phosphorylation and amidation to form both G34 and G17 amidated 
gastrins (Fig 1- 4).  
The amidated forms bind specifically to CCK-1 and CCK-2 (or CCK-
B) receptors. These belong to the G-protein coupled receptor family and 
gastrin exhibits greater binding affinity to the CCK-2 rather than the CCK-1 
receptor. CCK-2 receptors are located on the surface of parietal cells and 
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enterochromaffin-like (ECL) cells in the gastric corpus, as well as in certain 
cells in the pancreas, smooth muscle and brain. The effect of direct gastrin 
binding to CCK-2 receptors located on gastric parietal cells is still under 
investigation, but recent evidence suggests that it plays a role in the 
regulation of parietal cell maturation (Chen et al., 2000; Kirton et al., 2002). 
Gastrin is released in its amidated form from antral G-cells by 
various stimuli, including distension of the stomach following a meal, 
luminal contents especially aromatic amino acids, calcium and amines 
present in ingested food, vagal stimulation mediated by acetylcholine and 
by gastrin releasing peptide (GRP), a neurotransmitter (Schubert, 2009). 
 
 
 
Figure 1-4: Gastrin synthesis and secretion 
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1.3.2 Roles of Gastrin 
1.3.2.1 Acid secretion 
As discussed above, gastrin stimulates histamine release by 
stimulation of ECL-cells located in the region of the oxyntic glands through 
binding to CCK-2 receptors. The released histamine subsequently binds to 
the H2-receptors on parietal cells, which in turn are stimulated to release 
hydrochloric acid (Dockray, 2004; Schubert, 2009). This appears to be the 
main route by which gastrin stimulates acid secretion (Fig1-5). Gastrin also 
stimulates the synthesis and storage of histamine by ECL cells, by 
inducing histidine decarboxylase expression and also promotes the 
sequestration of histamine in secretory vesicles by stimulating the 
expression of vesicular monoamine transporter-2 (VMAT-2) in ECL cells 
(Dockray et al., 2001). As explained in section 1.3 and outlined in fig 1-5, 
there are many factors that stimulate the release of gastrin. 
Both somatostatin and secretin are thought to inhibit gastrin 
release. Somatostatin is released by gastric D cells in response to an 
acidic pH and therefore gastrin secretion is controlled by negative 
feedback inhibitory mechanisms. Secretin on the other hand acts through 
non-competitive inhibition of gastrin at the gastric parietal cell (Johnson 
and Grossman, 1969). 
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Figure 1-5: Role of inhibitors and stimulants of acid release 
 
1.3.2.2 Cellular proliferation, apoptosis, migration and angiogenesis 
Many of the effects of gastrin have been studied in a range of 
animal models and cell lines (Burkitt et al., 2009). Gastrin has been found 
to stimulate gastric epithelial cell proliferation and gastric gland elongation 
in hypergastrinaemic rodents (Kidd et al., 2000). It has also been shown to 
stimulate the proliferation of epithelial cells resulting in either parietal cell 
or ECL-cell hyperplasia. This may be secondary to a direct effect on ECL-
cells through CCK-2 receptor stimulation or by paracrine mechanisms 
mediated through signalling messengers and growth factors such as 
heparin-binding growth factor (HB-EGF) (Miyazaki et al., 1999). The effect 
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of gastrin on the angiogenic potential of endothelial cells has also been 
described. Gastrin acting through the CCK-2 receptor has been shown to 
enhance endothelial cell activity, probably mediated through enhanced 
expression of HB-EGF (Clarke et al., 2006). This pro-angiogenic effect 
may contribute to the role played by gastrin in gastric tumour development.    
The effects of gastrin on the gastric mucosa have recently become 
better understood by studying various transgenic and knockout mice. Mice 
in which either the gastrin gene (GAS KO mice) or the CCK-2 receptor 
have been deleted exhibit similar phenotypes, with decreased numbers of 
gastric parietal and ECL-cells   (Langhans et al., 1997). Gastric pH is 
elevated in such mice and they exhibit a poor acid secretory response to 
externally administered gastrin or histamine (Friis-Hansen et al., 1998; 
Miyazaki et al., 1999). By contrast, mice that over express gastrin (INS-
GAS–Insulin-Gastrin transgenic mice that over express gastrin in 
pancreatic β-cells and therefore have elevated serum concentrations of 
amidated gastrin) initially show increased parietal cell proliferation and acid 
secretion. Older INS-GAS mice (>20 months) show a tendency to 
developing gastric cancer and this process is greatly accelerated by 
concurrent infection with Helicobacter felis or Helicobacter  pylori (Wang et 
al., 2000; Fox et al., 2003). Progression to gastric atrophy was associated 
with decreased parietal cell numbers and subsequent hypochlorhydria. At 
20 months the INS-GAS mice showed increased gastric metaplasia, 
dysplasia and invasive carcinoma. This was associated with increased 
expression of growth factors including heparin binding epidermal growth 
factor (HB-EGF) and transforming growth factor alpha (TGFα). There was 
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also an associated decrease or cessation in the previously noted increase 
in ECL-cell numbers. Helicobacter felis co-infection led to accelerated 
progression to invasive carcinoma by 6 months (Wang et al., 2000). 
Gastrin also appears to modulate apoptosis by signalling through 
CCK-2 receptors. It appears to increase the susceptibility of normal gastric 
epithelial cells to apoptosis. Mastomys (rodents) treated with H2-receptor 
antagonists have been shown to have a 2-fold increase in apoptosis in the 
presence of hypergastrinaemia when compared to controls (Kidd et al., 
2000). Both Cui et al and Przemeck et al have also demonstrated that 
hypergastrinaemia increases the susceptibility to apoptosis in INS-GAS 
mice following exposure to either Helicobacter bacteria or gamma 
irradiation (Cui et al., 2006; Przemeck et al., 2008). In their study, 
Przemeck et al compared the effects of irradiation on gastric epithelial 
apoptosis in wild-type FVB/N mice and INS-GAS mice. INS-GAS mice 
consistently developed greater amounts of apoptosis both 6 hours and at 
48 hours following irradiation. This effect was diminished in those mice 
which were pre-treated with the CCK-2 receptor antagonist YM022, 
suggesting that the increased susceptibility to apoptosis rendered by 
gastrin was mediated via the CCK-2 receptor. What was also 
demonstrated in this study was that the precursor forms of gastrin namely 
progastrin and glycine-extended gastrins did not significantly increase 
gastric epithelial susceptibility to apoptosis. However glycine-extended 
gastrin has been shown to modulate the effects of concurrent Helicobacter 
infection in INS-GAS mice (Wang et al., 2000).  In humans, those with 
moderate hypergastrinaemia (defined in the study as a fasting serum 
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gastrin concentration of >150pM) were also shown to have more apoptosis 
in gastric corpus biopsies in the presence of Helicobacter  pylori infection  
(Przemeck et al., 2008).  
 The effect of gastrin on AGSGr cells (a gastric adenocarcinoma cell 
line stably expressing the CCK-2 receptor) suggests that gastrin also 
regulates cellular migration and invasion. Upon gastrin stimulation, AGSGr 
cells show changes in migration mediated via the CCK-2 receptor. This 
was observed when AGSGr cells where co-cultured in the presence of 
gastrin; however this effect was not seen in untransfected AGS cells 
(Noble et al., 2003). These effects on migration and invasion appear to be 
at least partially mediated by members if the matrix metalloproteinase 
(MMP) family of proteins especially MMP-7 and -9, both of which show 
increased expression in response to gastrin stimulation (Wroblewski et al., 
2002; Varro et al., 2007). 
 
1.3.2.3 The development of ECL-cell hyperplasia and gastric carcinoid 
tumours 
Gastric neuroendocrine tumours (type-1 carcinoid tumours) develop 
in some cases in response to chronic hypergastrinaemia (Fig 1-6). They 
arise from ECL-cells which are normally present in the oxyntic corpus 
mucosa of the stomach. Although hypergastrinaemia stimulates ECL-cells 
to increase in numbers, this stimulus alone appears to be insufficient to 
cause progression to carcinoid tumour formation. Pernicious anaemia or 
autoimmune atrophic gastritis is typically associated with the 
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hypergastrinaemia that is responsible for the development of type-1 gastric 
carcinoid tumours. In this condition, there is a net reduction in parietal cell 
numbers leading to gastric atrophy and subsequent hypo/achlorhydria. 
This results in ‘secondary’ hypergastrinaemia due to the loss of negative 
feedback inhibition of gastrin secretion (by acidic gastric juice). 
Achlorhydria results in an increase in the number of antral G-cells and 
subsequent hypergastrinaemia. Fasting serum gastrin concentrations are 
often >1000pM and result in ECL-cell hyperplasia. Prolonged stimulation 
results in progression of ECL hyperplasia to linear, nodular and 
adenomatoid hyperplasia and finally results in the development of frank 
carcinoid tumours.  
 
Normal gastric epithelium
Atrophic gastritis
ECL – cell hyperplasia 
(pernicious anaemia/chronic H pylori)
Dysplasia
Type-1 gastric carcinoid tumours
Hypochlorhydria
Hypergastrinaemia
Endogenous factors Environmental factors
 
Figure 1-6: Development of atrophic gastritis and progression to type-1 gastric carcinoid 
tumours 
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Type-2 gastric neuroendocrine tumours are seen in some patients 
with mutations in the MEN1 gene (Wermer, 1954). This gene codes for the 
610-amino acid protein menin which acts as a tumour suppressor  and 
mutations in this gene result in either a reduced expression or complete 
absence of menin  (Piecha et al., 2008). In type-2 gastric neuroendocrine 
tumours, there is inappropriate hypergastrinaemia in the presence of an 
acidic gastric juice as a result of a gastrinoma and Zollinger Ellison 
syndrome. Type-2 gastric neuroendocrine tumours are seen in about 20% 
of patients with MEN-1 and Zollinger Ellison syndrome (Gibril et al., 2004).  
Type-3 gastric neuroendocrine tumours, which are seen more 
commonly in men, are sporadic lesions which are larger than typical type-1 
and 2 tumours. They are associated with a normal gastric juice pH and a 
normal fasting serum gastrin concentration. These tumours have the 
greatest malignant potential compared to the type-1 and -2 tumours and 
are therefore associated with a poorer prognosis. 
Type-1 and -2 gastric neuroendocrine tumours are therefore 
associated with hypergastrinaemia. In type-1 tumours, ECL-cell 
hyperplasia is thought to be secondary to the direct proliferative effects of 
gastrin on ECL-cells. This hypergastrinaemia is secondary to the 
achlorhydria that results from gastric corpus atrophy. However, there are 
several other conditions that can also result in chronic hypergastrinaemia, 
including chronic PPI (proton pump inhibitor) use, vagotomy, chronic renal 
failure (table 1-2). However such conditions have not been shown to be 
associated with the development of gastric carcinoid tumours in humans, 
although rats exposed to chronic PPIs can develop gastric carcinoid 
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tumours. This therefore suggests that there are other co-factors involved in 
the progression of ECL-cell hyperplasia to frank carcinoid tumours. Factors 
that may promote this progression include concurrent bacterial 
colonisation of the stomach (due to the loss of the protective acid milieu), 
nitroso compounds in the ingested food and unopposed bile reflux. Gastrin 
has also been suggested to play an important role in mesenchymal 
signalling and in the remodelling of the extracellular matrix as discussed in 
section 3.2.2. 
1.3.2.4 Precursor gastrins and their role in gastrointestinal pathology 
The immediate precursors of amidated gastrin namely progastrin 
and the glycated gastrin (Gly-gastrin) have been identified in gastric 
neuroendocrine tumours and epithelial gastrointestinal cancers (Nemeth et 
al., 1993; Van Solinge et al., 1993). This finding suggests that the 
precursors of gastrin may play a role in the development of gastric 
neoplastic pathology. Although increased concentrations of Gly-gastrin 
have been demonstrated in adenomatous colonic polyps, so far no 
relationship has been established between the concentrations of Gly-
gastrin and stage of colorectal cancer or with serum gastrin concentrations 
(Siddheshwar et al., 2001).  
Animal studies have demonstrated the proliferative effect of Gly-
gastrin and mediation of action via receptors distinct from CCK-2 but this 
has not been demonstrated in human studies (Seva et al., 1994). 
So far there have been no reliable assays to measure serum 
concentrations of total gastrins. Most assays measure the biologically 
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active ‘amidated gastrin’ concentrations which mediate their effects by 
binding to the CCK-2 receptor.  
 
1.3.2.5 Causes of hypergastrinaemia 
The normal upper limit of fasting serum gastrin concentration in 
humans is usually recognised to be 40pM (Varro and Ardill, 2003). There 
are several causes of hypergastrinaemia which are summarised in the 
following table. 
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Acidic gastric pH 
1. Gastrinoma 
2. Antral predominant H. pylori infection 
3. Pyloric obstruction 
4. Renal failure and uraemia 
5. Post gastric resection with an intact antrum (eg. Billroth type II) 
Elevated gastric pH 
1. Chronic atrophic gastritis associated with pernicious anaemia 
(autoimmune gastritis) and chronic H. pylori infection (corpus 
predominant infection). 
2. Proton pump inhibitor  (PPI) therapy 
3. H2 receptor antagonist therapy 
4. Post vagotomy 
 
Table 1-2: Causes of hypergastrinaemia in relation to the pH of the stomach.  
 
1.3.2.5.1 Hypergastrinaemia associated with an acidic gastric pH: 
Hypergastrinaemia in the presence of an acidic gastric pH is most 
often due to a gastrin secreting tumour as seen in Zollinger Ellison 
syndrome (ZES). First described in 1955, the syndrome is characterised 
by the occurrence of multiple gastric and duodenal ulcers and diarrhoea in 
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association with the presence of pancreatic neuroendocrine tumours 
(Zollinger and Ellison, 1989). ZES may be sporadic or associated with the 
MEN (Multiple Endocrine Neoplasia) type-1 syndrome. The latter is 
characterised by adenomas in the pituitary and parathyroid glands as well 
as in the pancreas. MEN type-1 syndrome is inherited as an autosomal 
dominant disorder and results from the loss of menin, a tumour suppressor 
gene (Wermer, 1954). Fasting serum gastrin concentrations >1000pM in 
the presence of an acidic gastric pH are virtually confirmatory of ZES, but 
many patients have less profound hypergastrinaemia (Berna et al., 2006b). 
Patients with pyloric obstruction have also been reported to have 
markedly elevated fasting serum gastrin concentrations and relief of 
obstruction has been associated with normalisation of the elevated serum 
gastrin concentration (Feurle et al., 1972). Fasting serum gastrin 
concentrations are often found to be elevated from around twice the upper 
limit of normal to approximately 380pM (Tani and Shimazu, 1977). This 
suggests the possible role of mechanical factors, including stretch 
receptors, in influencing serum gastrin concentrations (Feurle et al., 1972). 
Most patients with chronic renal failure also exhibit 
hypergastrinaemia with about 10% exhibiting serum gastrin concentrations 
in the range often seen in ZES (Hallgren et al., 1978). Gastrin is partly 
cleared from the circulation by renal metabolism and the degree of 
hypergastrinaemia is often proportional to the severity of renal impairment 
(Korman et al., 1972). 
Excluded gastric antrum following incomplete excision of this 
portion of the stomach has also been found to be associated with 
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hypergastrinaemia, which is usually mild to moderate (2 to 3 times upper 
limit of normal). However with changes in surgical practice, this diagnosis 
is now extremely rare (Friesen and Tomita, 1981; Webster et al., 1978). 
 
1.3.2.5.2 Hypergastrinaemia associated with an elevated gastric pH 
Chronic atrophic gastritis secondary to either autoimmune gastritis 
(often associated with pernicious anaemia) or chronic H. pylori infection is 
the most common cause of elevated fasting serum gastrin concentrations 
(Orlando et al., 2007). The degree of hypergastrinaemia associated with 
both these conditions is usually moderate, although it can range from mild 
to severe (Korman et al., 1970). 
Both these conditions result in hypochlorhydria or achlorhydria due to 
the net loss of acid secreting parietal cells. The resulting loss of negative 
feedback inhibition causes unopposed gastrin release. Prolonged 
hypergastrinaemia stimulates ECL-cell hyperplasia and in some patients 
especially those with pernicious anaemia, this can progress to type-1 
gastric carcinoid tumour formation as detailed in section 3.2.3 (Annibale et 
al., 2001a; Burkitt and Pritchard, 2006).  
Proton pump inhibitor (PPI) therapy has also been associated with 
modest elevations in fasting serum gastrin concentrations (usually less 
than three times the upper limit of normal),  with only about 2% of patients 
on a PPI developing serum gastrin concentrations greater than 400pM 
(Jensen, 2006). It has been reported that PPI therapy does not appear to 
increase further the elevated fasting serum gastrin concentrations seen in 
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patients with ZES (Hirschowitz and Haber, 2001). Lamberts et al. 
demonstrated moderate hypergastrinaemia in patients treated with 
omeprazole. There were however no subsequent changes reported in the 
fasting serum gastrin concentrations in these patients during an 8-year 
follow up (Lamberts et al., 2001). Elevated fasting serum gastrin 
concentrations associated with PPI therapy take approximately one week 
to return to the normal range once the medication has been discontinued 
(Festen et al., 1984). 
 
1.4 Helicobacter  pylori and gastric adenocarcinoma 
It has been postulated for over a century that certain bacteria 
colonise the human stomach. Initially these bacteria were considered to be 
contaminants from ingested food rather than true colonizers of the human 
stomach. With the discovery and successful isolation of a spiral bacterium 
from the human stomach about 20 years ago by the Nobel Laureates 
Barry Marshall and Robin Warren, it has now been conclusively 
established that Helicobacter pylori organisms colonise the human 
stomach (Marshall and Warren, 1984). Helicobacter pylori is now 
implicated in the development of duodenal and gastric ulcers as well as in 
the development of gastric atrophy, gastric adenocarcinoma and Mucosa 
Associated Lymphoid Tissue (MALT) lymphoma.  
Helicobacter pylori belongs to the family Helicobacteraceae and the 
genus Helicobacter consists of over 20 recognised species with some still 
awaiting formal recognition (Fox, 2002). All members of this genus are 
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microaerophilic, most are catalase and oxidase positive and many are also 
urease positive. 
Helicobacter species can be divided into two major groups 
depending on the major organ of colonisation. Gastric and enterohepatic 
groups predominantly colonise the gastric or colonic and biliary systems 
respectively. They demonstrate a high level of organ specificity and are 
unable to colonise other sites (Solnick and Schauer, 2001). 
 
1.4.1 Enterohepatic Helicobacter species 
These bacteria, such as Helicobacter hepaticus, colonise the lower 
gastrointestinal tract (ileum and colon) and the biliary tree of humans and 
some other mammals. Infection has been reported to cause a chronic 
inflammatory reaction and may predispose to neoplastic lesions in the 
hepatobiliary tree (Solnick and Schauer, 2001; Verhoef et al., 2003; 
Avenaud et al., 2000). In addition, enterohepatic Helicobacter species 
have also been reported to be associated with the development of colitis in 
animal models. Fox and colleagues initially reported the possible 
association between Helicobacter hepaticus infection and intestinal 
inflammation in immunodeficient mice (Ward et al., 1996) and this has 
subsequently been confirmed in other studies (Kullberg et al., 2006). 
 
1.4.2 Gastric Helicobacter species 
Gastric Helicobacter tend to be motile with flagella and are all 
urease positive. The urease enzyme allows survival for a short time in the 
56 
 
acid milieu of the stomach. The spiral morphology and flagella related 
motility assist penetration into the viscous mucous layer of the stomach, 
where the more neutral pH allows growth. Hence both motility and urease 
production are required for gastric colonisation. 
H. pylori lacks clonality because it is genetically heterogeneous, 
suggesting that every H. pylori positive patient carries a distinct strain 
(Kansau et al., 1996). However organisms cultured from related family 
members are genetically similar. This heterogeneity may be the result of 
adaptation by H. pylori to survive the gastric conditions as well as the 
immune response of the host. The cagPAI described in section 1.4.4 is a 
striking example of this heterogeneity. 
 
1.4.3 Helicobacter  pylori 
1.4.3.1 Morphology 
H. pylori is a spiral shaped gram-negative bacterium measuring 2 to 
4 µm in length and 0.5 to 1 µm in width (Fig1-7). It can be seen in coccoid 
and rod shapes (usually after prolonged in vitro culture or antibiotic 
treatment) (Kusters et al., 1997). H. pylori is a fastidious organism and 
requires complex growth conditions. This explains why it was initially 
difficult to obtain cultures from gastric biopsies. It is microaerophilic and 
growth occurs at a pH range of 5.5 to 8.0 although it survives brief 
exposures to pH<4 (Scott et al., 2002). 
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Figure 1-7: Helicobacter  pylori  
(adapted from www.h pylori.com.au/h pylori-16.png) 
 
1.4.3.2 Epidemiology 
The prevalence of Helicobacter pylori shows large geographical 
variations throughout the world. More than 80% of the population in 
developing countries are Helicobacter pylori positive, whereas the 
prevalence in developed countries is approximately 40% (Pounder and Ng, 
1995). Prevalence is also rapidly declining as a result of eradication by use 
of antibiotics, improved hygiene and sanitation, less overcrowding and 
improved housing conditions. The incidence of new H. pylori infection in 
the Western world is less than approximately 0.5% per year (Roosendaal 
et al., 1997).  Hence the prevalence of H. pylori infection in industrialised 
countries currently increases markedly with age (Parsonnet, 1995). 
New infection occurs predominantly in childhood and unless treated 
usually lasts for life. Transmission is by direct person to person infection 
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usually from close family members. There is no evidence to suggest 
zoonotic transmission. 
 
1.4.3.3 Colonisation in the gastric lumen 
H. pylori is the main organism that survives and inhabits the normal 
human stomach (Blaser and Atherton, 2004). However, it remains 
susceptible to low pH. Elucidation of the H. pylori genome and post 
genomic techniques have demonstrated several factors that are important 
for successful gastric colonisation (Wen et al., 2003).  
Acid resistance is crucial and one of the many genes that determine 
acid resistance encodes the urease protein, which hydrolyses urea to 
ammonia and carbon dioxide (Weeks et al., 2000). This transiently buffers 
the acidic environment, lowering the pH to below 5.0 which allows survival 
for long enough for the bacteria to colonise the gastric mucosa (Marshall et 
al., 1990). This also forms the basis of two of the commonly used 
diagnostic tests for H. pylori – the invasive biopsy test (Rapid Urease test) 
and the non-invasive Urea breath test.  
However, the presence of urease is insufficient for long term 
survival and the bacteria have evolved other mechanisms to minimize 
exposure to a low pH, in particular they remain in very close proximity to 
the surface of the epithelium where the pH is near neutral. Their natural 
habitat is located below the gastric mucous layer, attached to the mucus 
secreting epithelial cells lining the stomach. Most H. pylori are free 
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swimming. They utilise their flagellar motility and chemotactic responses 
for colonisation.  
H. pylori inhabits only gastric type mucus and hence does not 
colonise duodenal or oesophageal mucosa unless these have undergone 
gastric metaplasia. Approximately 20% of H. pylori organisms in the 
stomach are found adherent to epithelial cells by means of adhesions 
(Hessey et al., 1990). This adhesion often shows a tropism for the 
intercellular junctions and to the expression of Trefoil factor 1 to which H. 
pylori binds strongly and specifically (Clyne et al., 2004). The best studied 
adhesins are the outer membrane proteins that bind to host cell 
glycoproteins. The three Hop (Hsp Organising Proteins) proteins are the 
best characterised and are detailed below. 
a) BabA (HopS): this is probably the best characterized H. pylori 
adhesion protein. It is a 78-KDa protein encoded by the babA gene. 
BabA mediates binding to the fucosylated Lewis b (Le b ) blood group 
antigen in human host cells (Ilver et al., 1998). Animal studies have 
suggested that for colonisation and pathogenesis of H. pylori, BabA 
mediated adhesion is essential (Rad et al., 2002). Some studies have 
suggested that BabA plays a role in H. pylori virulence due to the 
strong association demonstrated between the babA2 allele and gastric 
inflammation and adenocarcinoma (Gerhard et al., 1999). However 
other studies have not confirmed this association (Yamaoka et al., 
2002). It is possible that BabA may not be an independent marker, as 
the presence of the babA2 allele is linked to vacAs1 and cagA alleles. 
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b) Oip (HopH): Oip (proinflammatory outer membrane protein) was 
originally described as a proinflammatory response inducing protein. 
The gene encoding this protein is present in all H. pylori strains. It is 
believed to play a role in gastric inflammation (Yamaoka et al., 2002). 
c) SabA (HopP): this is thought to play a role in chronic inflammation and 
atrophic gastritis disease stages. It mediates binding to sialic acid 
containing glycoconjugates. It has been shown that H. pylori induced 
gastric inflammation and carcinogenesis is associated with the 
replacement of non sialylated Lewis antigens by sialylated antigens 
(Mahdavi et al. 573-78). This probably explains the role of SabA in 
gastric inflammation and carcinogenesis (Yamaoka et al., 2006). 
However no individual adhesin is essential for attachment to the gastric 
mucosa and the expression of adhesins is diverse between several strains 
and has also been found to be variable within the same strain over time(de 
et al., 2004). 
Three hypotheses have therefore been proposed to explain why H. 
pylori adhere to epithelial cells (Amieva and El-Omar, 2008). 
1. Cellular damage and inflammation induced by adhesion: 
This hypothesis suggests that H. pylori adhere to epithelial cells to 
cause damage, deliver toxins and induce inflammation. The delivery 
of the major H. pylori virulence factors (CagA and VacA) is also 
dependent on this adhesion. There also remains the possibility of H. 
pylori deriving nutrients from damaged cells. 
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2. Promotion of invasion and persistence and avoidance of clearance: 
Adhesion protects against mechanical clearance in the gastric lumen. 
3. Possible use of adhesion site for bacterial replication 
 
1.4.3.4 Clinical consequences of H. pylori infection: 
Helicobacter colonisation of the gastric mucosa is in itself not a 
disease, but a predisposing condition to various diseases of the stomach.  
Symptoms of childhood infection and its subsequent immediate 
effect on gastric acid secretion are unknown. In adults, when colonisation 
occurs for the first time, it can result in a gastritis associated with 
hypochlorhydria, dyspepsia and nausea (Graham et al., 1988; Morris and 
Nicholson, 1987). There is an estimated subsequent 10 to 20% lifetime 
risk of developing peptic ulcer disease and a 1 to 2% chance of developing 
gastric adenocarcinoma (Kuipers et al., 1995). 
 Chronic infection with Helicobacter pylori results in two different types 
of pathology depending upon the distribution of gastritis and resultant 
changes in acid secretion: 
If acid secretion remains intact, then H. pylori organisms are often 
confined to the gastric antrum resulting in an antral-predominant gastritis 
(type 1). On the other hand in patients with decreased acid secretion (such 
as those taking Proton Pump Inhibitor drugs), there is a more even 
distribution of the bacteria in the antrum and corpus resulting in pan-
gastritis (corpus-predominant). 
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Chronic antral-predominant gastritis can result in a rebound 
increase in acid secretion by direct stimulation of gastrin secreting G cells. 
This, as well as changes in the duodenal mucosa induced by excess acid 
may predispose to the development of duodenal ulcers. 
On the other hand, chronic corpus-predominant gastritis may result 
in the development of gastric atrophy and this may progress to intestinal 
metaplasia and dysplasia and eventually gastric adenocarcinoma (Fig1-8). 
Not all people with H. pylori infection however develop disease. 
Several bacterial and host factors influence disease development and 
progression including: 
a) Virulence factors of the infecting H. pylori (section 1.4.4) 
b) Host immune response to the infection (section 1.4.5) 
c) Environmental cofactors (section 1.5) 
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Figure 1-8: Clinical consequences of H. pylori infection 
 
1.4.4 Bacterial Virulence Factors 
The two best characterised H. pylori virulence factors are the 
cytotoxin associated gene A (cag) pathogenecity island (PAI) and the 
vacuolating cytotoxin gene (vacA).  These are described in detail below. 
Pathogenecity islands (PAIs) are large sections of DNA acquired by 
bacterial species over time that render them pathogenic.  
1.4.4.1 cagPAI 
Initial observations that some H. pylori infected patients developed 
symptoms whereas others did not led to the hypothesis that there might be 
differences in the virulence of the infecting H. pylori organisms. Further 
investigations showed that some H. pylori strains were more virulent and 
caused morphological changes, vacuolisation and degeneration of in vitro 
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cells. This activity was subsequently linked to the presence of a 140 kDa 
protein named cagA (cytotoxin associated gene A). This protein is 
encoded by the cagA gene and is present in about 50 to 70% of H. pylori 
strains. Studies using Mongolian gerbils have indicated that in the 
presence of a functioning cag PAI and cagA, there is a subsequent 
increased progression to atrophic gastritis (Rieder et al., 2005). H. pylori 
strains that carry the cagPAI (Pathogenecity Island) are referred to as 
cagA+ and those that lack it, either in its entirety or in parts, are referred to 
as cagA-. Those strains that are cagA+ are associated with a greater 
inflammatory response and more significant outcome such as peptic ulcer 
or gastric cancer. In a nested case-control study, Japanese–American 
men with gastric and duodenal ulcers and matched controls were tested 
for antibodies to H. pylori and for antibodies to cagA. Patients who tested 
positive for H. pylori had an odds ratio of 4.0 for the development of gastric 
ulcer and an odds ratio of 2.5 for duodenal ulcer. If seropositive for both H. 
pylori and cagA then the odds ratio for gastric ulcer was 4.4 and for 
duodenal ulcer was 5.8 suggesting that cagA positivity increases the risk 
of developing both gastric and duodenal ulcers above that of cag- strains 
(Nomura et al., 2002).  Using the same cohort, in a subsequent study the 
authors sought to assess the association between cagA+ and the risk of 
development of gastric adenocarcinoma. 103 patients with H. pylori 
positivity and gastric cancer were matched with 103 H. pylori positive 
subjects without gastric cancer (controls) and their sera were analysed for 
the presence of cagA antibodies. The odds ratio of developing gastric 
adenocarcinoma if patients had evidence of cagA positive H. pylori 
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infection was 1.9 and for the intestinal subtype this was 2.3. Interestingly, 
the authors also found that age < 72 years and advanced tumour stage at 
the time of diagnosis were also associated with cagA positivity (Blaser et 
al., 1995). 
The cag Pathogenecity Island comprises 30 genes and these 
encode proteins that comprise a type IV secretory system (T4SS) (Censini 
et al., 1996) (Fig1-10). H. pylori utilises this T4SS to translocate products 
into the host cell’s cytoplasm. This is often seen microscopically as a 
sheathed rigid needle linking H. pylori to the host cell (Tanaka et al., 2003). 
CagA protein is subsequently translocated into the gastric epithelial cell 
where it undergoes phosphorylation (Odenbreit et al., 2000). In the host 
cell this stimulates cell signalling pathways resulting in changes in cell 
morphology and shape. In vitro the most commonly seen changes are of 
cell elongation and the development of long processes – termed the 
‘hummingbird phenotype’ (Moese et al., 2004). 
CagA also stimulates the expression of transcription factors 
involved in cellular proliferation. Unregulated cagA signalling can also 
result in apoptosis. However activated cagA inhibits the SRC kinase that 
phosphorylates cagA in the first instance, thereby providing a negative 
feedback inhibition of further cagA expression (Moss et al., 2001). CagA is 
also thought to disrupt the apical junctional complexes between epithelial 
cells resulting in loss of barrier function (Amieva et al., 2003). This may 
also help the bacteria to derive nutrients from the host cell. 
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Figure 1-9: CagA is translocated into the cytoplasm of the gastric epithelial cell through 
the type IV secreting system following the attachment of the cagA+ H. pylori 
(www.nature.com; Nature Reviews Cancer 4, 688-694 [September 2004] doi: 
10.1038/nrc1433). 
 
1.4.4.2 VacA 
VacA is a pore forming cytotoxin initially discovered when cultured 
cells developed abnormal vacuolation following infection with H. pylori 
(Leunk et al., 1988). The vacuolating cytotoxin gene is present in all strains 
of H. pylori, although there is marked polymorphism.  
VacA is a 140 KDa polypeptide that is trimmed at both ends during 
secretion from the bacterial cell. The amino terminus contains the signal 
sequence ‘s’ region of the gene. Those strains harbouring the s1 types of 
VacA are associated with gastric cancer and ulcers. The middle region of 
the gene is classified as the ‘m’ region – this shows allelic variations 
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similar to the ‘s’ region; with the m1 subtype also being strongly associated 
with increased vacuolation (Atherton et al., 1995).  
 
 
Figure 1-10: VacA and its effects on gastric epithelial cells include increased cellular 
permeability, apoptosis and altered mitochondrial membrane permeability.  
It can also inhibit the activation of T-cell and its proliferation. (www.nature.com; Nature 
Reviews Microbiology 3, 320-332 [April 2005] doi: 10.1038/nrmicro1095) 
 
 
In humans, the VacA s2 type is rarely associated with disease and 
whereas the s1m1 type is commonly seen in association with gastric 
adenocarcinoma. In Japan, the s1m1 type is ubiquitous (Ito et al., 1998).  
Studies have shown that VacA is transferred into host cells by either 
secretion or by contact dependent transfer (Ilver et al., 2004). The pore 
forming effect of Vac A has been best studied in vitro and is thought to 
result from its effects on endosomal maturation. Other effects include 
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increased paracellular permeability, membrane channel formation, 
disruption of lysosomal and endosomal activity, immune modulation and 
induction of apoptosis through pore formation in mitochondrial membranes 
and also through activation of proapoptotic signal molecules (Papini et al., 
1998; Cover et al., 2003) (Fig1-10). VacA has also been found to be a 
powerful inhibitor of T cell activation in vitro (Gebert et al., 2003). VacA is 
therefore thought to play a major role in regulating susceptibility to peptic 
ulceration and gastric adenocarcinoma development.  
 
1.4.5 Host immune response  
The immune response of the host to H. pylori is an important 
feature that helps to determine susceptibility to the diseases associated 
with infection with this organism. The Th1 response (mainly cell-mediated) 
is the predominant immune response induced by H. pylori. 
The importance of this Th1 mediated response has been shown in 
various experiments. For example mice that are genetically prone [eg. 
C57B2/6 or IL 4-null mice (which have been manipulated to have a 
predominantly Th1 response)] develop more intense inflammation 
following infection with H. pylori (Smythies et al., 2000) than mice which 
develop a predominantly Th2 response (eg. Balb/c). However the Th1 
response is not strong enough to achieve bacterial eradication and hence 
bacterial persistence occurs. 
Many of the pathogenic effects of H. pylori result from chronic 
inflammation.  It has been shown that various genetic polymorphisms in 
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the host can lead to alterations in the levels of these inflammatory 
mediators. This eventually influences the outcome of infection. 
Proinflammatory genetic polymorphisms tend to increase the risk of 
development of pre-neoplastic changes, leading to the development of 
gastric adenocarcinoma. 
The best characterised of these host genetic polymorphisms is the 
IL-1 cytokine (El-Omar et al., 2001). The IL-1 cytokine is encoded by the 
gene cluster containing IL-1B, which encodes the IL-1β cytokine and IL-
RN, encoding the IL-1 receptor antagonist. IL-1β is the most potent 
inhibitor of gastric acid secretion and is also a powerful pro- inflammatory 
cytokine. The IL-1 gene has been found to have several polymorphisms, 
all leading to elevated levels of expression of IL-1β. This leads to 
significant acid suppression and hence to a corpus predominant gastritis 
following H. pylori infection. This pattern of gastritis has been shown to be 
associated with the development of atrophic gastritis and thus an 
increased risk of gastric cancer (Furuta et al., 2002; Rad et al., 2004). 
Studies using IL-1β transgenic mice have demonstrated the step wise 
progression to gastric adenocarcinoma through the stages of spontaneous 
inflammation, metaplasia, dysplasia and carcinoma (Tu et al., 2008). This 
effect was mediated by activation and recruitment into the stomach of 
myeloid-derived suppressor cells (MDSCs) following IL-1β activation of the 
IL-1 RI/NF-κB pathway. The progression to gastric atrophy and 
adenocarcinoma was greatly accelerated by co-infection with H. felis 
infection in IL-1β transgenic mice. Antagonism of IL-1β receptor 
suppressed MDSCs mobilisation and inhibited development of gastric 
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preneoplastic changes, confirming the important role played by IL-1β in 
gastric carcinogenesis (Tu et al., 2008).   
IL-8 has also been found to have effects on cellular proliferation, 
migration and angiogenesis and increases the risk of severe inflammation 
and pre-neoplastic changes (Troost et al., 2003). 
Similar polymorphisms in the TNF-α gene and in IL-10 have also 
been studied. TNF-α is also an inhibitor of acid secretion and is produced 
in the gastric mucosa in response to infection with H. pylori. IL-10 on the 
other hand down regulates IL-1β, TNF-α and other proinflammatory 
cytokines. Hence relative deficiencies of IL-10 may result in a greater 
proinflammatory response with subsequent greater mucosal damage (Rad 
et al., 2004).  
 
1.4.6 H. pylori and fasting serum gastrin concentrations 
There are two proposed mechanisms by which H. pylori infection 
can cause elevations in fasting serum gastrin concentrations, which are 
often modest. In antral predominant H. pylori infection, inhibition of 
somatostatin secretion results in uninhibited gastrin secretion and the 
subsequent increased acid secretion is often associated with the 
development of duodenal ulcers. 
Chronic corpus predominant H. pylori infection on the other hand 
sometimes results in gastric atrophy. The subsequent hypochlorhydria, 
due to the loss of acid secreting parietal cells, results in an appropriate G-
cell hyperplasia and hypergastrinaemia (Troost et al., 2003).  
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Eradication of H. pylori has been shown to be associated with a 
normalisation of serum gastrin concentration by 12-15 months (Ohkusa et 
al., 2004). In several studies, a gradual decrease and subsequent 
normalisation of serum gastrin concentrations was observed within about 6 
months following H. pylori eradication (El-Omar et al., 1997; Iijima et al., 
2000). An increase in serum gastrin concentrations has also been 
observed following reinfection with H. pylori (Chen et al., 1994).  
 
1.5 Distal gastric adenocarcinoma  
1.5.1 Epidemiology 
1.5.1.1 World statistics 
Adenocarcinoma is the most common tumour of the human 
stomach. It is the fourth most frequent cancer worldwide and accounts for 
7.8% of new cancer cases. It also remains the second most common 
cause of cancer related deaths worldwide (after lung and breast cancer)   
(http://globocan.iarc.fr/). 
988,000 new diagnoses of gastric cancer were made in 2008 and 
there were 736,000 worldwide deaths. The incidence is approximately 22 
per 100,000 in men and 10.3 per 100,000 in women, with associated 
mortality reaching 14.3 and 8.3 per 100,000 respectively. 
Gastric adenocarcinoma is currently the fourth most common 
cancer in males (after lung , prostate and colorectal cancers) and fifth in 
women (after breast, cervix, colorectal and lung) (Parkin et al., 2005). 
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The lowest global rates for gastric cancer are in North America and 
Western Europe and the highest rates occur in East Asia, South America 
and Eastern Europe. Japan and Korea have the highest incidence. In 
2006, 86,000 new cases were diagnosed in the EU (Cancer statistics 
registration, 2008). 
1.5.1.2 UK statistics 
In 2009, approximately 7500 cases of gastric adenocarcinoma were 
diagnosed in the UK with 5178 deaths (UK Mortality 2010). It is the 9th 
most common cause of cancer in men in the UK with 4900 new cases per 
year and 14th most common cancer in women with 2600 new cases a year.  
The incidence of gastric adenocarcinoma is approximately 12.3 per 
100,000 men and 5.1 per 100,000 women in England and Wales, of which 
more than 80% of cases occur in patients aged 65 years and over and less 
than 8% of cases occur below 55 years of age (Cancer statistics 
registration, 2008). 
There has also been a change in the anatomical site of gastric 
adenocarcinoma development over recent years. The incidence of 
tumours in the gastric cardia (proximal stomach) is increasing compared to 
the previously more commonly occurring distal gastric carcinoma (Cancer 
statistics registration, 2008).  
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1.5.2 Risk factors for the development of distal gastric 
adenocarcinoma 
There are several known risk factors for the development of gastric 
adenocarcinoma. These include: 
1.5.2.1 Gastritis  
Chronic atrophic gastritis is a recognised risk factor for the 
development of gastric adenocarcinoma. This may result from autoimmune 
conditions such as pernicious anaemia or be secondary to corpus 
predominant Helicobacter pylori infection. Atrophic gastritis stimulates 
metaplasia of the gastric epithelium to the intestinal type. Metaplastic 
glands have been shown to consistently surround the periphery of gastric 
adenocarcinomas in pathology specimens. Intestinal metaplasia itself is a 
dynamic process. Younger individuals often exhibit ‘small-intestinal type’ 
metaplasia whereas older patients exhibit dysplasia and patients at high 
risk of gastric cancer consistently show ‘colonic type’ metaplasia (Cancer 
statistics registration, 2008). Intestinal metaplasia is classified as either 
complete or incomplete (Jass and Filipe, 1980). The complete type of 
intestinal metaplasia (type 1) is characterised by the presence of Paneth 
cells, absorptive cells and mucin secreting goblet cells, resembling small 
intestinal epithelial cells. The incomplete type (type 2 and type 3) on the 
other hand is characterised by the presence of columnar cells and goblet 
cells. The other important feature associated with type 3 intestinal 
metaplasia is the distortion of columnar cells and absence of Paneth cells. 
Gastritis eventually progresses to gastric atrophy over years or decades in 
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some individuals (Cancer statistics registration, 2008). The presence of 
SPEM (spasmolytic polypeptide-expressing metaplasia) has recently been 
more strongly associated with the development of gastric adenocarcinoma 
than intestinal metaplasia and this entity may well be the precancerous 
lesion (Schmidt et al., 1999).  In addition newer studies have assessed the 
potential of gene expression profiling (Serial Analysis of Gene Expression, 
SAGE) of intestinal metaplasia and SPEM in identifying not only useful 
prognostic markers of early gastric cancer but also metaplasia biomarkers. 
Studies have also demonstrated that cumulative expressions of such 
metaplasia biomarkers provide a better prognostic marker rather than 
single individual markers (Suh et al., 2012).   
 
 
Figure 1-11: Progression from atrophic gastritis to adenocarcinoma (Correa Pathway). 
SPEM (spasmolytic polypeptide-expressing metaplasia) has been found to be more 
strongly associated with gastric cancer than intestinal metaplasia. 
 
Autoimmune  
Helicobacter  pylori 
Atrophic gastritis 
Intestinal Metaplasia and  
SPEM 
Dysplasia - Low grade/High grade 
Adenocarcinoma 
? Other factors 
75 
 
1.5.2.2 Pernicious anaemia  
Chronic atrophic gastritis and gastric polyps are commonly seen in 
pernicious anaemia (Schmidt et al., 1999). Screening by endoscopy has 
shown a high incidence of gastric epithelial dysplasia in this condition, 
hence pernicious anaemia is considered to be a precancerous condition. 
Some studies have shown up to a threefold increase in the risk of 
developing gastric adenocarcinoma (Siurala and Seppala, 1960; Schmidt 
et al., 1999) in affected subjects. 
 
1.5.2.3 Previous gastric resection  
Gastric stump carcinoma is defined as gastric adenocarcinoma 
developing in the remnant gastric stump at least 5 years following gastric 
resection for benign peptic ulcer disease (Helsingen and Hillestad, 1956; 
Safatle-Ribeiro et al., 1998). This risk increases with time since surgery, 
with lifetime risk exceeding that of the general population 15 years 
following gastric surgery(Helsingen and Hillestad, 1956). Several factors 
have been proposed to account for this increased susceptibility to 
carcinogenesis.  
a) Chronic duodenogastric reflux resulting from gastric resection and 
anastomosis. This may result in intestinal metaplasia, dysplasia and 
adenomatous changes in the gastric stump (Kondo, 2002; Lorusso et 
al., 2000; Mason et al., 1988; Miwa et al., 1995; Tanigawa et al., 
2002). 
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b) Bile acids in the refluxate may also exert a pro-carcinogenic effect. In 
animal models, nitrated bile acid derivatives – namely glycocholic and 
taurocholic acids have been shown to be carcinogenic in the stomach 
(Kondo, 2002; Tanigawa et al., 2002). 
c) The gastric stump is often associated with gastritis and atrophy 
resulting in chronic hypochlorhydria and possible increased bacterial 
growth. Some bacteria (especially anaerobes) may be associated with 
the production of carcinogens (Muscroft et al., 1981).  
d) Unrecognised Helicobacter pylori infection is another factor that 
predisposes to gastric atrophy and progression to adenocarcinoma. 
 
The risk seems to be higher in those patients who have undergone 
gastric resection for gastric ulcer rather than duodenal ulcer. This risk was 
3 fold within the first 20 years following surgery and 5.5 fold after this time 
period. In contrast, in patients with duodenal ulcer, the risk of gastric stump 
cancer was increased only 3 fold more than 20 years following surgery 
(Caygill et al., 1986). This could be explained by the observation that 
gastritis and gastric atrophy occur more frequently in patients with gastric 
ulcer disease, whereas duodenal ulcers are associated with antral 
predominant Helicobacter pylori infection and increased gastric acid 
production. 
Patients with Billroth–II reconstruction had a 4 fold increased risk of 
gastric stump cancer compared with patients who had undergone Billroth-I 
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surgery, further suggesting that duodenal reflux plays a role in the 
development of gastric stump cancer (Muscroft et al., 1981). 
Atrophy resulting from deficiency of gastrin following antrectomy 
has also been thought to play a role in the development of gastric stump 
cancer. This has also been suggested following vagotomy with the 
resultant loss of vagus mediated growth regulation (Kaminishi et al., 1995; 
Fisher et al., 1993).  
 
1.5.2.4 Diet  
There is evidence to suggest that reduced consumption of fresh fruit 
and vegetables is associated with an increased risk of developing gastric 
cancer.  Dietary antioxidants (seen in fruits and vegetables) may play an 
important role in cancer prevention as shown in the study by Munoz et al., 
where a diet enriched with vitamins C and E and carotene lowered the 
incidence of intestinal metaplasia in a susceptible population (Plummer et 
al., 2007).  
Increased consumption of salt and preserved food has also been 
postulated to increase the risk of gastric cancer (Hill, 1998). In a recent 
publication by the World Cancer Research Fund and the American 
Institute for Cancer Research, it has been suggested that there is a 
probable increased risk of stomach cancer with consumption of salt and 
salt-preserved food. There, is also a probable decreased risk associated 
with the consumption of non-starchy and allium vegetables (for example 
garlic and onions) and fruits (World Cancer Research Fund., 2007). 
78 
 
 
1.5.2.5 Alcohol 
There is no convincing evidence suggesting an increased risk of 
gastric cancer associated with alcohol consumption. In a recently 
published study based on the Netherlands Cohort Study (NLCS), there 
was no association seen between alcohol consumption (>30gms/day 
compared to abstaining) and gastric non-cardia, cardia or oesophageal 
adenocarcinoma (relative risk of 1, 0.9 and 1.04 respectively, compared to 
a relative risk of 4.61 for oesophageal squamous cell carcinoma) 
(Steevens et al., 2010). 
 
1.5.2.6 Smoking   
As with other cancers, there is an increased risk of developing 
gastric cancer in smokers, but this association is  not as strong as with 
lung cancer (Tredaniel et al., 1997).  In a recently published study, an 
increased risk of gastric cancer (relative risk of 1.6) was noted in current 
smokers, with risk being in proportion to the duration of smoking (gastric 
noncardia cancers only) (Steevens et al., 2010). 
 
1.5.2.7 Genetic predisposition  
Approximately 5 to 10% of gastric cancer cases have a familial 
association. This has been well documented for about 200 years. For 
example Napoleon Bonaparte died from stomach cancer and so did 
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several of his family members – father, grandfather, brother and three 
sisters (Kubba and Young, 1999). 
This familial risk is more common with the diffuse type of gastric 
adenocarcinoma than the intestinal variant, conferring  a 7-fold increased 
risk amongst relatives of patients with diffuse-type gastric cancer 
compared to a 1.4 fold increased risk in the relatives of patients with 
intestinal-type gastric adenocarcinoma (Lehtola, 1978). 
The term ‘Hereditary diffuse gastric cancer’ (HDGC) was coined to 
include patients who have an autosomal dominant inheritance pattern for a 
diffuse-type gastric cancer syndrome. The International Gastric Cancer 
Linkage Consortium (IGCLC) has established criteria to define HDGC as 
well as guidelines for the clinical management of such patients and their 
families (Park et al., 2000; Guilford et al., 1999). HDGC is an autosomal 
dominant inherited cancer syndrome characterised clinically by either  
(1) ≥ 2 documented diffuse gastric cancer cases in first or second 
degree relatives with at least one case being diagnosed before the age of 
50 years; or 
(2) ≥ 3 cases of documented diffuse gastric cancer in first or second 
degree relatives irrespective of age of onset (Park et al., 2000). 
E-cadherin gene mutations (CDH1 mutation) have been 
demonstrated  in about 30-50% of HDGC cases and the penetrance is 
about 75-80%, suggesting that carriers of the CDH1 mutation have a 75-
80% lifetime chance of developing gastric cancer by the age of 80 
(Pharoah et al., 2001). 
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The E-cadherin gene is located at chromosome 16q22.1. It is a 
type-1 cadherin found in all epithelial tissues. Type-1 cadherins are 
glycoproteins that medicate adhesion at junctions. In addition, it also plays 
a vital role in the regulation of cell division and inhibits both apoptosis and 
proliferation (Grunwald, 1993). Mutation therefore results in loss of cell 
adhesion, proliferation, invasion and metastasis (Pharoah et al., 2001; 
Becker et al., 1994; Norton et al., 2007). 
Genetic screening for HDGC is often reserved until patients are old 
enough to be able to give informed consent as the implication of the 
diagnosis is far reaching (Oliveira et al., 2003). There is currently no role 
for routine endoscopic screening. Prophylactic total gastrectomy 5 years 
before the youngest affected family member is advocated in relatives 
(Chun et al., 2001; Newman and Mulholland, 2006). Apart from breast 
cancer screening, routine screening for other cancers is not currently 
advocated in HDGC.  
 
1.5.2.8 Helicobacter  pylori 
With the discovery of Helicobacter pylori in 1983 by Warren et al., 
our understanding of gastric diseases has vastly improved (Marshall and 
Warren, 1984). Helicobacter  pylori  has been recognised as a type-1 
carcinogen and is associated with the development of gastric 
adenocarcinoma as well as mucosa associated lymphoma (MALT) (IARC 
Working Group on the Evaluation of Carcinogenic Risks to Humans, 1994) 
(see section 1.4). 
81 
 
 
1.5.3 Pathological classification of distal gastric adenocarcinoma 
Various different classification systems have been suggested for 
gastric adenocarcinoma including:   
a) Ming – which classifies the tumour border as being either infiltrative or 
expansile (Ming, 1977);  
b) WHO – based on histopathology (papillary, tubular, signet ring cell, 
mucinous and undifferentiated);  
c) Goseki – classifying tumours depending on whether tumours show 
evidence of good tubal formation and intracellular mucin (Goseki et 
al., 1992) 
 group I – tubular differentiation well, mucous in cytoplasm – 
poor;  
 group II – tubular differentiation well, mucous in cytoplasm – 
rich;  
 group III – tubular differentiation poor, mucous in cytoplasm – 
poor;  
 group IV – tubular differentiation poor, mucous in cytoplasm – 
rich   
d) Lauren classification – diffuse, intestinal or mixed types. The Lauren 
classification is currently the most widely used. 
 Intestinal-type: these tumours tend to be well differentiated with 
cells being arranged in tubular or glandular structures. The 
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terms tubular, papillary and mucinous are all within the 
spectrum of intestinal-type gastric cancer. 
 Diffuse-type:  the cells are undifferentiated and lack glandular 
structure. Clinically the diffuse type tends to infiltrate the gastric 
wall (linitis plastica).  
 Mixed-type: Features of both intestinal-type and diffuse-type 
cellular architecture are consistently seen. 
 
1.5.4 Clinical features associated with distal gastric 
adenocarcinoma 
Approximately 70% of patients with so called ‘early gastric cancer’ 
(confined to the mucosa or submucosa) have symptoms of uncomplicated 
dyspepsia (Hallissey et al., 1990; Eckardt et al., 1990).  
Patients with advanced gastric cancer often present with alarm 
symptoms including weight loss, anaemia, vomiting, haemetemesis and 
abdominal pain (Fuchs and Mayer, 1995; Bramble et al., 2000). The 
concurrent use of proton pump inhibitors has been thought to potentially 
mask and delay the diagnosis of gastric cancer and hence the use of these 
medications should be delayed in individuals ‘at risk’, prior to establishing 
a diagnosis (Allum et al., 2002). 
Currently in the UK the following are considered as alarm symptoms 
in patients of any age with dyspepsia. Such patients are advised to have 
an urgent upper GI endoscopy to rule out underlying gastric cancer (NICE 
Guidelines) (National Institute for Health and Clinical Excellence, 2004): 
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 Chronic gastrointestinal bleeding 
 Progressive unintentional  weight loss 
 Progressive swallowing difficulties 
 Iron deficiency anaemia 
 Persisting vomiting 
 Epigastric mass 
 Suspicious barium meal 
 
1.5.5 Diagnosis of distal gastric adenocarcinoma 
The diagnosis of gastric adenocarcinoma is usually made by 
examination of biopsy specimens obtained at gastroscopy (Fig1-12). 
Additional investigations to stage the disease include CT scan of the 
abdomen and Endoscopic ultrasound. There is currently no role for PET 
(Positron Emission Tomography) CT in the routine diagnosis of gastric 
cancer (Shoda et al., 2007), although there may be roles for this modality 
in the diagnosis of distant metastases (Rosenbaum et al., 2006) and in 
evaluating the response to chemotherapy (Sun et al., 2007). Staging of the 
disease is usually based on the TNM classification (table1-3).  
 
84 
 
 
Figure 1-12: Endoscopic appearance of distal gastric adenocarcinoma 
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Tumour staging Lymph node Involvement Metastasis 
T1 
Lamina propria, 
Submucosa 
 
N0 
No nodes 
M0 
No metastasis 
T2 
Muscularis propria, 
Subserosa 
 
N1 
1-6 nodes 
M1 
Distant metastasis 
T3 
Penetrates serosa 
 
N2 
7-15 nodes 
 
 
T4 
Adjacent 
structures 
N3 
>15 nodes 
 
 
Tumour staging 
 
Stage 1 
 
T1N1M0; T2NOMO 
 
 
Stage 2 
 
T1N2M0; T2N1M0; T3N0M0 
 
 
Stage 3 
 
T2N2M0; T3N1-2M0; T4N0-1M0 
 
 
Stage 4 
 
T4N2M0; T1-4N3 
 
 
  
Table 1-3: TNM classification of oesophageal and gastric cancer and staging  
   (Greene and Sobin 119-20). 
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1.5.6 Treatment of distal gastric adenocarcinoma 
Surgery (partial or total gastrectomy) is the treatment of choice for 
gastric cancer. The most important variable that determines tumour 
resectability and surgical outcome is the stage of disease at presentation. 
However multiple factors determine the outcome of curative surgery 
including a patient’s age, co-morbidities and fitness for operation in 
addition to the tumour stage at presentation. There is a higher post 
operative mortality with total gastrectomy than subtotal gastrectomy. 
Results from specialist units in the UK report an operative mortality of 
4.5% (The NHS Information Centre, 2010).  
The role of adjuvant chemotherapy has been addressed in several 
studies and meta-analyses and this modality has been shown to confer a 
survival advantage (Mari et al., 2000; Sakuramoto et al., 2007). In a recent 
trial (MAGIC Trial), pre and post-operative chemotherapy for localised 
disease using a combination of epirubicin, cisplatin and 5-FU 
demonstrated significantly improved 5-year survival rates (36.3%) 
compared to surgery alone (23%) (Cunningham et al., 2006). This strategy 
of peri-operative chemotherap for localised gastric cancer has increasingly 
become the standard of care in the UK and in some centres in Europe 
(Cunningham and Oliveira, 2008; Allum et al., 2011). 
Palliative chemotherapy is widely used in patients with inoperable 
and advanced disease. Several randomised studies have demonstrated 
survival benefits and improved quality of life with palliative chemotherapy 
(Pyrhonen et al., 1995; Glimelius et al., 1997; Assersohn et al., 2004). The 
drugs most commonly used are a combination of epirubicin, cisplatin and a 
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continuous intravenous infusion of 5-flurouracil which has a 65% response 
rate and a 11% complete response rate (Findlay et al., 1994). A recent 
Cochrane review has also highlighted the benefits of combination 
chemotherapy in a palliative setting (Wagner et al., 2005). 
 
1.5.7 Prognosis of distal gastric adenocarcinoma 
Most patients in the UK are diagnosed with stage 4 disease and 
their 5-year survival rate is less than 5%. On the contrary, patients with 
tumours measuring less than 5 cm in diameter, with no serosal invasion or 
lymph node metastasis, have a 5-year survival rate approaching 80% 
(Gatta et al., 2006; Bowles and Benjamin, 2001). In a retrospective study 
conducted in our centre the median survival for patients with gastric 
adenocarcinoma was 246  39 days. Patients presenting as an emergency 
were found to have more advanced tumour stage. Such patients not only 
had lower surgical resection rates but also had reduced survival rates 
compared to those patients whose diagnosis was made through non-
emergency routes (Sehgal et al., 2009). 
 
1.5.8 Cardia or Proximal Gastric Cancer 
There is increasing recognition of another distinct type of gastric 
cancer namely ‘proximal’ or ‘cardia’ cancer. This is considered to be an 
entirely different entity from distal gastric cancer, as tumours at this site 
differ in their epidemiology and pathogenesis. Two types of cardia cancers 
have been recognised –  
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 Type A - associated with atrophic gastritis and resembling the 
more common distal gastric cancer and  
 Type B - resembling oesophageal adenocarcinoma, occurring 
in people with an acid secreting stomach and possibly arising 
as a consequence of chronic gastro-oesophageal reflux. 
The gastric cardia is the most proximal part of the stomach 
adjoining the oesophagus and located below the gastro-oesophageal 
junction. The mucosa of the cardia is similar to that seen in the gastric 
antrum and is lined by columnar cells and contains branched mucous 
secreting cells with a relative absence of parietal and chief cells. There has 
been much debate regarding the origin of cardia type mucosa.  Analysis of 
autopsy samples suggests the presence of cardia-type mucosa in only 
about 50% of specimens. The presence and also the total length of cardia 
type mucosa increases with age. It has therefore been suggested that 
cardia-type mucosa may be acquired secondary to gastro-oesophageal 
reflux (Chandrasoma et al., 2000). However, a study of the histology of the 
gastro-oeosophageal junction in 21 neonates, found a short segment of 
the mucosa resembling cardia-type mucosa in all specimens, suggesting 
that this is part of the normal anatomy of the stomach (De et al., 2003). 
However, it still remains unclear as to whether the cardia-type mucosa 
seen in neonates represents true gastric type epithelium or a primitive 
developing mucosa, as it appears to be different from adult-type cardia 
mucosa. 
Various hypotheses have been proposed to explain the 
mechanisms responsible for cardia mucosa development. The 
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oesophageal squamous epithelium is unable to withstand acid reflux and 
hence in some cases undergoes metaplastic change to gastric columnar 
type epithelium upon persistent acid exposure. Hence cardia mucosa 
might arise from metaplasia of the very distal end of the oesophageal 
squamous epithelium. However this does not differentiate between true 
cardia-type mucosa and metaplastic squamous epithelium (Barrett’s). 
Another possible aetiology involves changes secondary to chronic H. 
pylori-induced gastric atrophy involving the oxyntic mucosa.  This can 
stimulate metaplasia in the atrophic oxyntic mucosa leading to the 
formation of cardia-type mucosa (Van Zanten et al., 1999). 
It is currently difficult to define adenocarcinoma of the cardia and 
the term cardia cancer is therefore applied to those tumours 
(adenocarcinomas) arising in the proximal portion of the stomach near to 
or involving the gastro-oesophageal junction. 80% of these tumours are of 
the intestinal type (Palli et al., 1992). There has been an increase in the 
incidence of cardia cancers worldwide, while the incidence of distal gastric 
adenocarcinomas has been decreasing (Botterweck et al., 2000; Neugut et 
al., 1996). This suggests that different pathophysiological mechanisms are 
involved. 
Gastro-oesophageal reflux is an important risk factor for oesophageal 
adenocarcinoma and hence type B cardia adenocarcinoma may have a 
similar aetiology and pathogenesis (Lagergren et al., 1999), involving 
exposure to both acid reflux and luminal carcinogens (McColl, 2006). 
There also appears to be a higher prevalance of cardia cancer in men, 
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similar to that observed in oesophageal adencarcinoma (Brewster et al., 
2000).  
H. pylori induced gastric atrophy has also been shown to be positively 
associated with cardia cancer in a case-controlled study. There was a 
significant association between H. pylori sero-positivity and the risk of 
developing cardia-type cancer if there was also associated gastric atrophy. 
H. pylori infection on its own however was negatively associated with the 
development of cardia cancer in this study (Hansen et al., 2007).  
 
1.6  Gastric Neuroendocrine tumours (NETs) 
Gastric neuroendocrine tumours (gastric carcinoid tumours) are rare 
tumours occurring in 1 to 2 per 1,000,000 persons per year and account 
for 8.7% of all gastrointestinal neuroendocrine tumours (Modlin et al., 
2003a). This tumour type was discussed initially in section 3.2.3. 
 
1.6.1 Classification of gastric NETs 
Clinically gastric carcinoid tumours are classified depending on the 
background gastric pathology as follows (Rindi et al., 1993) (table1-5): 
1. Type-1: associated with atrophic body gastritis  
2. Type-2: seen in Zollinger Ellison syndrome when associated 
with the MEN-1 syndrome and 
3. Type-3: sporadic tumours which develop in the absence of any 
specific gastric pathology 
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This clinical classification is important not only in detecting co-existing 
diseases such as atrophic gastritis and Zollinger Ellison syndrome, but 
also in predicting tumour growth and prognosis. 
Histological classification of these tumours (WHO classification – 
table 1-4) is based on tumour differentiation namely: 
1. Well-differentiated, which includes most type-1 and -2 gastric 
carcinoid tumours and 
2. Poorly-differentiated, which are usually type-3 gastric carcinoid 
tumours  
In addition, a third type namely ‘mixed endocrine-exocrine’ tumours 
has also been recognised (Rindi et al., 2000). Although type-3 tumours are 
often poorly-differentiated they can also occur as well-differentiated or as 
mixed tumours. 
Well-differentiated tumours develop from enterochromaffin-like cells 
(ECL-cells) which are located mainly in the fundus and the corpus of the 
stomach. Gastrin is considered to be the main stimulant for the 
development of type-1 and -2 tumours and the ECL-cell appears to be the 
main proliferative target for gastrin. Type-3 tumours on the other hand 
grow independently to extrinsic gastrin stimulation (‘gastrin-independent’). 
 
 
WHO 
classification 
Tumour 
type 
Metastases 
Invasion 
beyond 
submucosa 
Histological 
differentiation 
Tumour 
size, cm 
Vascular 
invasion  
Ki 67 % 
Group 1 
Benign 
(low risk) 
– – 
well-
differentiated 
≤ 1 – <2 
Benign or 
low-grade 
– – 
well-
differentiated 
> 1 ± <2 
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malignant 
Group 2 
Low-grade 
malignant 
+ + 
well-
differentiated 
> 2 + >2 
Group 3 
High-grade 
malignant 
+ + 
poorly 
differentiated 
any + >15 
 
Table 1-4:  WHO classification of gastric neuroendocrine tumours.  
Ki 67 is the prototypic nuclear protein that is expressed in all active phases of the cell 
cycle and hence expressed by proliferating cells and absent in resting cells. The Ki 67 
index is the ratio between the numbers of Ki 67 expressing cells to the total number of 
resting cells. The correlation between low Ki 67 index and low grade tumours is strong 
(Pelosi et al. 1124-34; Scholzen and Gerdes 311-22). 
 
1.6.1.1 Type-1 gastric NETs 
These are the most common form of gastric carcinoid and account 
for 70-80% of gastric NETs (Bordi, 1999). They are usually small (less 
than 1 to 2cms in size), often multiple, occur predominantly in the fundus 
and corpus of the stomach, are associated with atrophic body gastritis and 
are most frequently seen in women aged >50 years (Annibale et al., 
2001a) (fig 1-15).   
It has been proposed that persistent achlorhydria (resulting from 
complete loss of parietal cells or atrophic body gastritis secondary to 
autoimmune gastritis such as pernicious anaemia) and the subsequent 
loss of negative feedback inhibition of gastrin secretion stimulate G-cell 
hyperplasia. The resulting hypergastrinaemia promotes ECL-cell growth 
and carcinoid tumour formation (Annibale et al., 2001a) (Fig1-13). 
Approximately 5% of patients with autoimmune atrophic body gastritis will 
develop type-1 gastric carcinoid tumours (Fig1-14). These tumours are 
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associated with a good long term prognosis with 5 year survival rates 
quoted at 96% (Hosokawa et al., 2005). 
Type-1 gastric carcinoid tumours are fairly indolent and are often 
found incidentally at gastroscopy. There is associated hypergastrinaemia 
and an elevated gastric pH. These tumours are often polypoidal or 
intramucosal, are well differentiated and considered to be of low grade, as 
demonstrated by low numbers of mitotic cells (or absent mitosis) and a low 
Ki 67 index. Metastatic potential is low, with rates of ~5% observed in most 
studies and in most cases metastases have been found to be limited to 
local lymph nodes (Rindi et al., 1996; Rindi et al., 1999b). 
 
Carcinoid tumour
a
b c
 
Figure 1-13: Histological characteristics of gastric neuroendocrine tumours. (a) Atrophic 
gastritis; (b) Linear ECL-cell hyperplasia and (c) Nodular ECL-cell hyperplasia. 
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Type-1 gastric neuroendocrine tumours 
(NETs)  (70% of all gastric NETs )
Pernicious anaemia / Chronic atrophic gastritis
Enterochromaffin-like (ECL) cell hyperplasia (30%)
Gastric ECL-cell carcinoid tumours (5-10%)
 
Figure 1-14: Progression of atrophic gastritis to ECL-cell hyperplasia and carcinoid 
tumour formation. 
 
1.6.1.2  Type-2 gastric NETs 
Type-2 gastric carcinoid tumours account for approximately 5 to 6% 
of gastric NETs (Bordi, 1999) and tend to occur in Zollinger Ellison 
syndrome associated with MEN-1 syndrome. Patients with the ZES/MEN-1 
syndrome have a 29 to 34% risk of developing type-2 gastric carcinoid 
tumours in contrast with patients with sporadic ZES (not associated with 
MEN-1), who have a much lower risk at 0 to 1% (Gibril et al., 2004). 
Type-2 gastric carcinoid tumours, like the type-1 tumours, are 
usually small, often multiple and are most frequently located in the 
fundus/corpus of the stomach. However, tumours have also been reported 
to occur in the antrum (Bordi et al., 2001) and the rate of metastasis has 
been shown to be higher than that seen with type-1 tumours, occurring in 
about 10 to 30% of cases (Norton et al., 2004). Type-2 gastric carcinoid 
tumours are usually polypoidal and well-differentiated and there is 
associated hypergastrinaemia in the presence of an acidic gastric pH.  
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1.6.1.3 Type-3 gastric carcinoid tumours 
These tumours account for approximately 14 to 25% of gastric 
NETs and often develop in the absence of hypergastrinaemia or specific 
gastric pathology (Bordi, 1999). These tumours are often large (>2 cm), 
single, polypoidal or ulcerated at presentation and are more frequently 
seen in men aged > 50years. Metastasis at presentation is observed in 
approximately 50 to 70% of patients with well-differentiated tumours and in 
almost 100% of poorly-differentiated tumours (Rindi et al., 1996). Patients 
with type-3 carcinoid tumours have a relatively poorer prognosis due in 
part to the metastatic nature of the disease. Studies have shown 5-year 
survival rates at 30% (Borch et al., 2005; Rappel et al., 1995). 
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Features Type-1 Type-2 Type-3 
% of gastric 
NETs 
70-80% 5-6% 14-25% 
Associated 
gastric 
pathology 
Atrophic Body 
gastritis 
None None 
Associated 
diseases 
Autoimmune 
gastritis; 
Pernicious 
anaemia 
ZES and MEN-1 None 
Site of 
tumours 
Fundus 
Fundus (antrum 
occasionally) 
Antrum or 
fundus 
Typical size Usually <1cm <1cm >2 cms 
Numbers Multiple Multiple Solitary 
Serum gastrin 
concentration 
High High Normal 
pH of stomach 
juice 
Neutral Acidic Acidic 
Prognosis Good 
Mostly good 
(some 
aggressive) 
Poor 
Treatment 
options 
Endoscopic 
resection, 
antrectomy, 
surveillance 
Endoscopic 
resection, 
gastrinoma 
resection, 
somatostatin 
analogues 
Partial or 
total 
gastrectomy 
 
Table 1-5: Types of gastric carcinoid tumours 
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1.6.2 Management of gastric NETs 
Accurate clinical assessment and evaluation of the pathological 
features of gastric NETs are essential for the management of affected 
patients. Detecting the presence of associated conditions namely atrophic 
body gastritis and ZES/MEN-1 is crucial in classifying the tumours into the 
different clinical types and deciding upon the most appropriate treatment. 
 
1.6.2.1 Investigations to aid tumour classification 
In order to detect the presence of atrophic body gastritis and 
therefore to diagnose type-1 carcinoid tumours, all patients should 
undergo haematological and immunological assessment for the presence 
of autoimmune gastritis and pernicious anaemia. Investigations should 
include measurement of serum vitamin B12 levels and assessment for the 
presence of anti Gastric Parietal cell (anti-GPC) and anti Intrinsic factor 
(anti-IF) antibodies. Histological assessment should be made not only of 
the tumour and its surrounding gastric mucosa but also the antral mucosa 
for assessment of G-cell hyperplasia, the source of hypergastrinaemia in 
these patients. 
In patients with type-2 tumours, hypergastrinaemia should be 
confirmed by estimating fasting serum gastrin concentration and 
demonstrating the presence of an acidic gastric pH (pH<2 is confirmatory 
of ZES). Investigations to assess the presence of the other components of 
the MEN-1 syndrome (eg. evaluation of the pancreas, pituitary and 
98 
 
parathyroid glands) and mutations in the MENIN gene should also be 
performed. 
~ 20-30 nodules (~1cm)  in corpus
 
Figure 1-15: Endoscopic appearances of gastric type-1 carcinoid tumours in a 
background of atrophic gastritis.  
 
1.6.2.2 Estimation of disease extent and localisation of associated 
neuroendocrine tumours 
Given that metastatic gastric carcinoid tumours carry a worse 
prognosis, it is imperative to assess disease extent at presentation. 
Multislice CT (computerised tomography) scans help not only to identify 
metastatic disease, but can also locate type-2 gastric carcinoid tumours or 
other associated gastrinomas (Ba-Ssalamah et al., 2003). 
However, CT scans do not provide any indication of functionality of 
tumours. Diffuse lesions could therefore be missed if CT scans were used 
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as the only imaging modality. Approximately 85% of gastric carcinoid 
tumours express somatostatin receptors and hence in these cases 
somatostatin receptor scintigraphy (octreotide scan) can be a useful 
technique to assess disease extent (Gibril et al., 2000). Anatomic 
localisation of tumours using somatostatin receptor scintigraphy on the 
other hand can be difficult, especially for distinguishing pancreatic and 
gastric tumours (Gibril et al., 2000). 
Positron emission tomography scans (PET) may also help improve 
localisation of difficult lesions (Eriksson et al., 2000a). Using 11C-5-
hydroxytryptophan as a tracer rather than the conventional 18F-
fluorodeoxyglucose may be of more value in evaluating neuroendocrine 
tumours (Eriksson et al., 2005). Newer PET techniques using 68Ga-
DOTATOC have been shown to have a sensitivity of 97%, a specificity of 
92% and a greater overall diagnostic accuracy in the diagnosis of 
neuroendocrine tumours compared to somatostatin receptor scintigraphy 
and conventional CT scan (Gabriel et al., 2007). 
In combination, the three modalities namely CT scan, somatostatin 
receptor scintigraphy and 11C-5-hydroxytryptophan PET scan may help to 
localise tumours accurately (Orlefors et al., 2005). 
In patients with type-2 gastric carcinoid tumours, localisation of the 
gastrin secreting tumour is also essential for determining treatment 
strategies. Although gastroscopy may help to localise such tumours, 
particularly as they are often located in the duodenum, the combined use 
of CT, 68Ga-DOTATOC PET scans and somatostatin receptor scintigraphy 
often provides more valuable information. Gastrin secreting 
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neuroendocrine tumours are often also detected by endoscopic ultrasound 
(EUS) and a histological diagnosis can be achieved using EUS guided fine 
needle aspiration (FNA) in approximately 90% of cases (Vander, III et al., 
2004). On rare occasions, angiography and selective venous sampling 
may also be necessary to identify the location of gastrin producing tumours 
(Jackson, 2005). 
 
1.6.2.3 Confirming tumour dependency on gastrin 
As previously mentioned, both type-1 and -2 gastric carcinoid 
tumours are gastrin driven tumours. Removal of the source of 
hypergastrinaemia (eg. antrectomy in type-1 and gastrinoma resection in 
type-2 gastric carcinoid tumours) may well provide the treatment required 
to stop the growth of such tumours. It therefore becomes essential to 
confirm the dependency of these tumours on gastrin for their growth. This 
has been described in a single case study utilising the ‘octreotide 
suppression test’ (Higham et al., 1998). This will be described in more 
detail in chapter 8. 
 
1.6.2.4 Monitoring disease progression and tumour burden 
Since most gastric carcinoid tumours are functionally non-secretory, 
the usual method of measurement of secreted hormones in 
neuroendocrine tumours is replaced by alternative serological markers. 
Serum chromogranin A (CgA) is one such marker that has been studied in 
considerable detail (Giovanella et al., 1999). It is a protein produced by all 
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cells derived from the neural crest (Tomassetti et al., 2001) and is 
produced in large amounts by neuroendocrine tumour cells irrespective of 
their secretory status (Eriksson et al., 2000b). Serum concentrations of 
CgA have been shown to correlate with ECL-cell mass in type-1 gastric 
carcinoid tumours (Borch et al., 1997), hence CgA is considered to be 
useful in monitoring disease extent and tumour burden in patients with 
metastatic disease as suggested by the European Neuroendocrine 
Tumour Society (ENETS) guidelines (Delle et al., 2012). 
1.6.2.5 Treatment of gastric NETs 
Treatment approaches for gastric carcinoid tumours depend on the 
type of tumour. It is appropriate for small type-1 gastric carcinoid tumours, 
due to their low metastatic potential, to be monitored by regular 
surveillance as outlined in the ENETS guidelines (Plockinger et al., 2004). 
Those type-1 tumours not suitable for simple surveillance may benefit from 
endoscopic resection. Type-1 carcinoid tumours that are amenable to 
endoscopic resection are usually small (<1cm) and few in number (3-5) 
(Ichikawa et al., 2003). Alternatively, removal of the source of gastrin by 
antrectomy or distal partial gastrectomy has also been advocated (Higham 
et al., 1998; Dakin et al., 2006). By utilising the inhibitory effect of 
somatostatin on ECL-cell hyperplasia (mediated by its direct 
antiproliferative effect on the ECL-cell and indirectly through the inhibition 
of gastrin synthesis), long acting somatostatin analogues have also been 
shown to be useful in the treatment of type-1 gastric carcinoid tumours 
(Fykse et al., 2004; Grozinsky-Glasberg et al., 2008b). However, follow up 
studies on patients following cessation of long acting somatostatin 
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analogues have demonstrated regression of tumours, suggesting that long 
term continuation of such therapy may be required (Jianu et al., 2011). 
A similar approach of removing the source of hypergastrinaemia by 
gastrinoma resection may be used for type-2 gastric carcinoid tumours. In 
addition to endoscopic or surgical resection of type-2 gastric NETs, the 
somatostatin analogue, octreotide, has also been demonstrated to cause 
marked regression in tumour size and a decrease in serum gastrin 
concentrations (Tomassetti et al., 2000). This therefore is a potential 
strategy for the management of those type-2 gastric carcinoid tumours that 
are multiple and not suitable for surgical resection (Ramage et al., 2005a). 
Type-3 carcinoid tumours will require surgery if there is no evidence 
of metastatic disease. Surgery usually involves either a partial or total 
gastrectomy with lymph node dissection, not dissimilar to that offered for 
gastric adenocarcinoma (Ruszniewski et al., 2006). 
 
1.7 Tumour biomarkers 
Specific tumour markers are useful for assessing the presence or 
response to treatment of various tumour types. For example, CEA 
(carcino-embryonic antigen) is useful in colorectal cancer; CA19-9 in 
pancreatic cancer; AFP (alpha fetoprotein) in hepatocelluar carcinoma and 
seminomas and PSA (prostate specific antigen) in prostate cancer. 
However, although significantly elevated concentrations of such 
biomarkers may be associated with tumours, in most cases they are not 
particularly useful as diagnostic tools. Nonetheless they are sometimes 
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useful as markers for disease progression or recurrence following therapy 
(especially CEA in colorectal cancer and PSA in prostate cancer) and can 
aid in the detection of difficult to diagnose cases. No such markers have 
however been associated with gastric adenocarcinoma to date,  although 
serum pepsinogen concentrations (low serum pepsinogen and low 
pepsinogen I/pepsinogen II ratio [PGI/II] ) have been utilised as a non-
invasive tool for the diagnosis of gastric atrophy and in predicting the risk 
of development of gastric adenocarcinoma (Oishi et al., 2006; Ren et al., 
2009). Ideally biomarkers should not only be associated with the presence 
of a tumour itself, but ideally should also be elevated during the 
precancerous stages. This would permit risk stratification and thereafter 
appropriate surveillance. No such surveillance programmes are currently 
available for gastric adenocarcinoma even though gastric atrophy and 
intestinal metaplasia are recognised precancerous conditions. Even in 
Japan, where there is a very high prevalence of gastric cancer, mass 
screening for this cancer is performed using gastric fluoroscopy 
(Hamashima et al., 2008). Patients then subsequently undergo 
gastroscopy only when the screening fluoroscopy is abnormal. Although 
the evidence to support the routine use of endoscopy, serum pepsinogen 
or H. pylori antibody testing in gastric cancer screening is not strong, the 
possible role of endoscopic surveillance in the detection of early gastric 
cancers has been studied. In a prospective study conducted in the UK, it 
was observed that surveillance endoscopy of patients with atrophic 
gastritis and intestinal metaplasia enabled detection of early stage gastric 
cancers (Whiting et al., 2002). Such patients had a better outcome due to 
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the early detection of gastric cancer. However such endoscopic 
surveillance programmes are currently restricted only to those patients 
with a known high risk genetic disorder associated cancer (such as 
Hereditary non-polyposis colorectal cancer, Familial Adenomatous 
polyposis, MUTYH-associated polyposis, Juvenile polyposis and Peutz-
Jegher syndrome) (Cairns et al., 2010).  
The Liverpool NIHR-Biomedical Research Centre (BRC) funded 
project ‘Identification of genes and proteins involved in promoting gastric 
cancer development in patients with chronic Helicobacter pylori infection’ 
in which the author was involved, was designed to investigate specific 
biomarkers that may predict development or progression to gastric 
adenocarcinoma. The following are potential candidate biomarkers of 
gastric preneoplasia that are currently being assessed within that study 
(Table 1-6). 
 
1.7.1 IGF family 
The IGF (Insulin-like Growth Factor) family comprises the peptide 
hormones IGF-1 and IGF-2, their cell surface receptors namely IGFR1 and 
IGFR2 and the binding proteins IGFBP, of which IGFB1 to 6 have been 
identified. This family of proteins plays important roles in regulating cell 
growth and apoptosis.  
1.7.1.1 IGF-1 and 2 
These were initially characterised in 1970 (Rinderknecht and 
Humbel, 1978) and are homologous, small chain peptides of about 7.5kD 
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in size. The gene encoding IGF-1 is located on chromosome 12q22-q24.1 
and that encoding IGF-2 is located to the insulin gene at 11p15.5. IGF-1, a 
trophic factor, is present in high concentrations in the serum. The main 
source is the liver and its production is modulated by both growth hormone 
and insulin (Yu and Rohan, 2000).  
IGF-1 exerts its effects mainly by binding to the extracellular domain 
of the IGF receptor 1 and it also binds to the insulin receptor. IGF-1 has 
been shown to directly stimulate DNA synthesis. It also stimulates the 
expression of cyclin D1, which in turn accelerates the progression of the 
cell cycle from the G1 to the S phase. It also stimulates the expression of 
the Bcl-2 protein and suppresses the expression of Bax, thereby blocking 
the initiation of apoptosis (Sara and Hall, 1990). 
IGF-2 on the other hand binds with high affinity to the IGF-2 
receptor, with low affinity to the IGF-1 receptor and not at all to the insulin 
receptor. The expression of IGF-2 is increased in foetal tissue, where it is 
thought to play a major role in the regulation of growth as compared to the 
postnatal period. It is a regulatory peptide and most of its actions are 
mediated through IGFR1 (Yu and Rohan, 2000). 
Both IGF-1 and -2 are mitogens regulating cell proliferation, 
differentiation and apoptosis. These effects are mediated predominantly 
through stimulation of IGFR1. A pattern of autocrine stimulation of 
malignant cell division through stimulation of the IGFR1 receptor by both 
IGF-1and -2 has been shown in in vitro, in vivo and clinical studies. 
Increased secretion of IGF-2 has also been demonstrated in gastric cancer 
cells of both the diffuse and intestinal variants. A corresponding increased 
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expression of mRNA for IGF-2 and IGFR1 and a decreased expression of 
IGFR2 mRNA have been shown in gastric cancer cells (Pavelic et al., 
2003). 
 
1.7.1.2 IGFR 
As mentioned above, IGF-1 and IGF-2 bind to the IGFR1 receptor 
and most of the effects of IGF-2 are mediated through binding to this 
receptor. IGF binds to the extracellular part of IGFR1. This results in a 
cytoplasmic signal cascade and a conformational change in the receptor 
through stimulation of phosphorylation. The subsequent downstream 
signalling results in activation of cell proliferation, differentiation and 
migration, and also inhibition of apoptosis (Yu and Rohan, 2000). 
IGFR1 has been shown to be over expressed in some tumours and 
if this occurs independently of other peptides (such as associated over 
expression of IGF), it allows cells to develop a new phenotype of 
anchorage independent growth leading to tumour progression (Pavelic et 
al., 2003). 
 
1.7.1.3 IGF B proteins and proteases 
IGF Binding proteins (IGFBPs) 1 to 6 are six multifunctional proteins 
that were originally thought to be passive circulatory transport proteins for 
the IGFs. However, there is now sufficient evidence to suggest that they 
play major roles in the regulation of cell activity (Firth and Baxter, 2002). 
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IGFBP-3 is the most abundant circulatory IGFBP and acts as a 
carrier for over 70% of circulating IGF-1 and 2. The IGFBPs act via both 
autocrine and paracrine pathways. They modulate activation of IGFR1 by 
IGFs. They therefore influence cell motility and adhesion, apoptosis and 
cell survival as well as cell cycle progression. The expression of IGFBP-4 
and 5 is regulated by IGF-1 in vascular smooth muscle cells and 
conversely IGFBP-4 inhibits IGF-1 and IGFBP-5 stimulates IGF-1. IGFBP-
1 can either inhibit or stimulate IGF depending on the phosphorylation 
state of IGFBP-1 (when dephosphorylated the affinity of IGFBP-1 for IGF-1 
is decreased six fold). IGFBP-2 on the other hand, by virtue of its 
increased affinity, often inhibits IGF-2. There is also evidence to suggest 
that the actions of IGFBPs may be independent of IGF binding (Firth and 
Baxter, 2002). 
 
1.7.1.4 IGF and cancer 
Several case studies and epidemiological studies have 
demonstrated associations between IGF and cancers of the lung, breast, 
colon and pancreas (Yu et al., 1999; Sugumar et al., 2004; Nomura et al., 
2003; Lin et al., 2004). Increased concentrations of IGFs have been 
consistently seen in these cancers and elevated IGFBP-3 concentration 
has also been associated with a decreased cancer risk (Renehan et al., 
2004; Yu and Rohan, 2000). However such an association has not been 
consistently established for stomach cancer. 
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Yatsuya et al., followed up 210 gastric cancer patients and 410 
controls and determined the efficacy of IGF-1,-2, IGFBP-3, TGFβ-1, sFAS 
and SOD as potential biomarkers. Of the 6 biomarkers tested, only sFAS 
was found to be significantly elevated in cancer patients (and only in 
females) and none of the other biomarkers were consistently elevated 
(Yatsuya et al., 2005). However in a study including 97 patients, Zhang et 
al. found that IGFBP-2 was significantly elevated in patients with gastric 
cancer and this positively correlated with cancer progression (Zhang et al., 
2007). 
In patients with H. pylori  infection, increased serum concentrations 
of IGFBP-2 and decreased concentrations of IGFBP-3 have been 
demonstrated (Baricevic et al., 2004). In a study from the UK, serum 
IGFBP-3 concentrations were found to be decreased in patients with 
gastric intestinal metaplasia, suggesting a potential role of IGFBP-3 in 
preventing the development of intestinal metaplasia and adenocarcinoma 
(Zhang et al., 2004). However conflicting results were seen in a study by 
Francois et al. in which serum samples from 26 patients with gastric 
cancer were analysed for concentrations of IGF-1 and IGFBP-3 before and 
after (15th day) surgery. Significantly higher concentrations of IGF-1 were 
seen in patients with gastric cancer compared to controls and in all cancer 
patients the concentration of IGF-1 was above that of baseline normal. 
Following surgery, there was a significant decrease in IGF-1 
concentrations, but no such change was seen with IGFBP-3, whose 
concentration was also higher at baseline compared to normal controls. 
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IGF-1 concentrations were not related to tumour extension or nodal 
involvement (Franciosi et al., 2003). 
In addition, Pham et al. found no significant association of IGF-1/-2 
with gastric cancer in a nested case control study. Although increased 
concentrations of IGFBP-3 were seen in patients with a lower risk of 
stomach cancer and decreased concentrations of IGFBP-3 were found in 
patients with stomach cancer, both of these associations were not 
statistically significant (Pham et al., 2007).  
 
1.7.2 uPA (Urokinase Plasminogen Activator) system 
The response of tissues to injury or inflammation often involves 
activation of the uPA system which includes uPA, its receptor (uPAR) and 
the plasminogen activator inhibitors (PAI-1,-2 and -3). 
 
1.7.2.1 Urokinase Plasminogen Activator 
uPA is one of several serine proteinases that are central to 
pericellular proteolysis through the conversion of plasminogen to plasmin. 
The uPA system comprises a single chain polypeptide (sc-uPA) 
consisting of 411 amino acids. Plasmin confers proteolytic activity to sc-
uPA after cleavage at the 157 site and plasmin is regarded as the most 
efficient method for converting the uPA to its active form. Other proteases 
including cathepsins, plasma kallikrien, nerve growth factor and mast cell 
tryptase can also activate uPA. Once activated enzymatically, the active 
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high molecular weight two chain form (HMWuPA) then converts 
plasminogen to plasmin. Plasmin is then able to amplify its own production 
by converting other sc-uPA into active HMWuPA (Dass et al., 2008). 
 
1.7.2.2 Urokinase Plasminogen Activator Receptor (uPAR) 
uPAR is a glycoprotein that binds to UPA through its growth factor 
like domain. It was first described as a receptor on human monocytes. 
uPAR is not  a transmembrane protein and binds to both the single 
chained and double chained forms of uPA (Blasi and Carmeliet, 2002). 
This binding greatly increases the activation of plasminogen by uPA. uPAR 
can also bind to uPA which has been inactivated by PAI-1. This forms the 
uPA-uPAR-PAI complex, which is then rapidly endocytosed and the uPAR 
is recycled and delivered to a different site on the cell surface. This 
process is said to be directional and important for cell migration (Nykjaer et 
al., 1997) 
1.7.2.3 Plasminogen Activator Inhibitors (PAI) 
uPA mediated conversion of plasminogen to plasmin is regulated by 
two plasminogen activator inhibitors, PAI-1 and PAI-2. They exert their 
inhibitory effects by either binding to uPA in solution or to the uPA-uPAR 
complex present on the cell surface (Andreasen et al., 1990).  
PAI-1 appears to be the more dominant inhibitor and is produced by 
platelets, endothelial cells and tumour cells (Schmitt et al., 1997). PAI-2 on 
the other hand is produced by phagocytic cells, trophoblasta and tumour 
cells (Schmitt et al., 1997). 
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Binding to the uPA-uPAR system, PAI-1 internalises the complex by 
stimulating endocytosis, resulting in subsequent degradation of the 
complex and recycling of uPAR to the cell surface at a different site 
(Conese et al., 1995). 
The uPA system once activated following the binding of  uPA to the 
uPAR may elicit several events linked to the conversion of plasminogen to 
plasmin. This probably includes extravascular fibrinolysis, activation of 
growth factors and matrix remodelling. These processes are integral to 
angiogenesis and metastasis, which are characteristic processes in 
malignant tissues. The uPA system is primarily associated with the 
degradation and regeneration of the basement membrane and the 
extracellular matrix and this therefore plays a major role in regulating 
metastasis, whereas its role as an anti-thrombolytic agent stimulates 
angiogenesis in tumour cells. 
 
1.7.2.4 uPA and cancer 
The various individual components of the uPA/uPAR system have 
been demonstrated to be differentially expressed in various cancer tissues 
compared to normal tissues. For example, in normal oesophageal tissue, 
uPA, uPAR and PAI-2 are not seen. uPAR was demonstrated in the border 
of oesophageal squamous carcinomas and uPA and PAI-2 were 
demonstrated throughout all the cancer cells (other than stromal cells) 
(Shiomi et al., 2000). Tumours expressing higher concentrations of uPA 
were associated with a higher rate of metastasis, whereas tumours with 
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higher PAI-2 concentrations were associated with lower degrees of 
metastasis. In colorectal cancers, greater concentrations of uPAR were 
associated with increased cancer related mortality (Stephens et al., 1999). 
1.7.2.5 Gastric cancers 
In a study by Ji et.al, 67 gastric tumour samples were analysed for 
the abundance of uPA and uPAR RNA by Northern Blot. Gastric cancer 
tissue expressed both UPA and uPAR in abundance and the presence of 
these proteins was associated with higher mortality and poorer prognosis 
(Ji et al., 2005). In another study of 105 gastric cancer specimens, 
increased expression of uPA and uPAR mRNA was seen in association 
with increased tumour invasion into the muscular and peritoneal layers. 
This was again associated with lower patient survival rates (Zhang et al., 
2006). 
uPAR, uPA and PAI-1 have all been shown to be associated with 
adverse outcomes in gastric cancer. Heis et al. noted an inverse 
correlation of levels of uPA, uPAR and PAI-1, but not PAI-2 with survival 
time. In their study, 203 consecutive patients with gastric cancer were 
recruited and the resection specimens were analysed by 
immunohistochemistry for the presence of uPA, uPAR and PAI-1 and –2. 
Expression was correlated with disease free and overall survival (Heiss et 
al., 1995). In another study, Ito et al. analysed specimens from 125 
patients with gastric cancer by immunohistochemistry for uPA, PAI-1 and -
2. uPA positive patients had more lymph node metastases, tumour 
infiltration and peritoneal dissemination and had a poorer prognosis. The 
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PAI-1 negative group were also more likely to have liver metastases and 
poorer prognosis. No significant associations were noted with PAI-2 
expression (Ito et al., 1996).  
 
1.7.2.6 uPA and gastric preneoplasia: 
In a study of 104 patients, Beyer et al. studied the expression of the 
uPA system in biopsy specimens of gastric carcinoma and also gastric 
intestinal metaplasia (Beyer et al., 2006). Increased expression of uPAR 
and PAI-1 was seen by immunohistochemistry in specimens with intestinal 
metaplasia and this was significantly associated with more advanced 
tumour stage and lymph node involvement. This suggests that uPAR and 
PAI-1 may potentially be useful as predictors of disease staging. 
In another study, Farinati et al. analysed specimens from 92 
patients - 12 with gastric adenocarcinoma, 33 with chronic atrophic 
gastritis (all exhibiting intestinal metaplasia and 12 with dysplasia) and 47 
controls for the expression of uPA, PAI-1, CATB and CATL (Farinati et al., 
1996). There was significantly greater expression of uPA, PAI-1, 
cathepsins B (CATB) and cathepsin L (CATL) in patients with chronic 
atrophic gastritis than controls and a similar difference was seen in 
patients with cancer. CATB and uPA were significantly increased in 
patients with chronic atrophic gastritis and dysplasia compared to those 
with chronic atrophic gastritis without dysplasia. This suggests that the 
uPA system may play a significant role not only in cancer invasion, but 
also in the progression of the preneoplastic changes to cancer. 
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H. pylori infection itself also results in the stimulation of the uPA 
system in the gastric corpus (Kenny et al., 2008). In this study, uPA 
induced hyperproliferation of gastric epithelial cells was demonstrated to 
be inhibited by PAI-1. PAI-2 has also been shown to be directly induced by 
H. pylori infection and the inhibitory effect of PAI-2 on cell invasion and 
apoptosis increases the risk of progression to gastric adenocarcinoma 
(Varro et al., 2004). 
 
1.7.3 Matrix Metalloproteinases (MMPs) 
1.7.3.1 MMP family 
MMPs are a family of zinc-dependent enzymes that are secreted as 
pro-enzymes prior to activation by cleavage of the propeptide. 
Approximately 25 MMPs have been identified and they are classified 
according to their substrate specificity into the following groups: 
 Collagenases: MMP-1, 8 and 13. These cleave interstitial 
collagen and breakdown several extracellular matrix (ECM) 
related molecules. 
 Gelatinases: MMP-2 and 9. These as the name suggests 
digest and degrade denatured collagen and gelatin. 
 Stromelysins: MMP-3 and 10. These activate a number of the 
MMPs and also digest several ECM components. 
 Matrilysins: MMP-7 and 26. These are involved in processing 
cell surface molecules. 
115 
 
 Membrane type (MT): MMP-14, 15, 16, 17, 24, 25. These 
activate pro-MMP-2 and digest ECM-molecules. 
 Uncategorised: these are said to process a variety of non-
matrix substrates and are involved in the cleavage of numerous 
growth and angiogenic factors and also are involved in 
controlling cell migration. 
 
1.7.3.2 Role played by MMPs in cancers 
The breakdown of the extracellular matrix (ECM) in a timely manner 
is essential for embryogenesis, tissue resorption and remodelling. The 
matrix metalloproteinases (MMP) or matrixins play major roles in the 
regulation of these processes. Liotta et al identified proteolysis as an 
important step in tumour invasion and described the role of type IV 
collagenase in melanoma invasion and metastasis (Liotta et al., 1980). It 
was initially assumed that the MMPs were produced by tumour cells, 
however there is now more evidence to suggest that stromal cells respond 
to tumour cells by induction of MMPs and this concept of stromal 
production of MMPs was brought to the forefront by identification of 
stromelysin-3 as a stromal MMP in association with breast cancer (Basset 
et al., 1990). In situ hybridisation techniques have further confirmed the 
stromal origin of several of the MMPs and this is generally now though to 
be more common than tumourous origin. There is a general correlation 
between the level of MMP expression and tumour stage – the higher the 
MMP expression, the more advanced and invasive is the associated 
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tumour. Malignant tumours have been found to not only have increased 
expression of MMPs, but also to express a wider variety of MMPs 
compared to more benign tumours. For example, in colonic 
adenocarcinoma the expressions of stromelysin -1,-3, matrilysin and 
gelatinase A are all increased, whereas in adenomatous colonic polyps, 
matrilysin (MMP-7) was the only MMP that was found to be elevated 
(Newell et al., 1994). 
It has also been shown that MMPs could have roles in tumour 
prognosis or diagnosis. For example, some MMPs such as stromelysin-3 
are expressed only in breast adenocarcinomas and not by the normal 
breast or by fibroadenomas. 
 
1.7.3.3 MMP-7 (Matrilysin) 
MMP-7 belongs to the group of matrilysins and is unusual in that it 
is secreted by epithelial cells (malignant or normal) rather than stromal 
cells. MMP-7 is secreted as a 28-kD proenzyme and is enzymatically 
activated by endoproteinases, trypsin and plasmin (Wilson and Matrisian, 
1996). Increased MMP-7 expression has been described in several 
malignancies. 
 
1.7.3.4 MMP-7 and Gastric cancer 
In a study of 47 gastric cancer patients, Honda et al. measured 
MMP-7 mRNA expression in tumour vs. normal tissues (Honda et al., 
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1996). They demonstrated increased MMP-7 mRNA expression in 87% of 
tumour samples compared to corresponding normal tissues. Also, a 
tumour/normal MMP-7 expression ratio of more than 2:1 was associated 
with deeper invasion and more frequent lymphatic or vascular invasion 
than a tumour/normal ratio of less than 2:1. Subsequent 
immunohistochemistry confirmed that MMP-7 expression was  localised in  
cancer cells, with only  weak expression being observed in normal 
epithelial cells and no expression was seen in surrounding stromal tissue, 
confirming that the predominant source of MMP-7 is from epithelial cells (in 
this instance the malignant cells). This suggests that over expression of 
MMP-7 may play an important role in tumour progression in gastric cancer 
and also suggests that it may be an important marker for predicting the 
behaviour of tumours. 
MMP-7 has also been demonstrated as being an epithelial derived 
signal for IGF-II, which in turn stimulates proliferation of both stromal and 
epithelial cells in the stomach (McCaig et al., 2006). MMP-7 is upregulated 
in H. pylori infection and therefore plays an important role in the 
hyperproliferation induced by the presence of this bacterium. 
 
1.7.3.5 MMP-2 
Also called gelatinase A and collagenase IV, MMP-2 is a 72-kD 
member of the MMP family which is capable of degrading gelatin and type 
IV collagen. This suggests that it probably plays a role in tumour invasion 
and metastasis. MMP-2, like other MMPs is secreted as an inactive 
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proenzyme and is activated by proteolytic cleavage. The activity of MMP-2 
is regulated by transcriptional factors as well as by the tissue inhibitors of 
MMPs (TIMPs). 
However, in contrast to other MMPs, MMP-2 is expressed by a 
large number of cell types and is also over expressed in a wide variety of 
tumour cells. 
1.7.3.6 MMP-2 and gastric cancer 
Following on from an earlier study of MMPs and gastric cancer, 
Kubben et al.  highlighted the association between MMP-2 and gastric 
cancer (Kubben et al., 2006). In this study involving 81 gastric cancer 
patients, the investigators assessed expression of MMP-2, MMP-9, MMP-
7, MMP-8, TIMP-1 and -2. All MMPs studied were found to be significantly 
increased in gastric cancer tissues compared to normal gastric mucosa. 
Increased MMP-2 levels were significantly associated with survival rates, 
whereas no correlation was seen with clinical and pathological parameters 
including the TNM stage of disease and Lauren/WHO classification of the 
tumour. However the other MMPs (-7,-8,-9) and the TIMPs (-1 and -2) 
showed some correlation with clinical and pathological parameters, but not 
with patient survival. 
  In another study of 74 gastric cancer specimens, Murray et al. 
demonstrated that MMP-2 was consistently over expressed by tumour 
cells, but was not detected in the adjacent normal gastric epithelium. This 
study therefore demonstrated the important role played by MMP-2 in 
gastric cancer invasion and metastasis (Murray et al., 1998). 
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In a recent study of 116 gastric adenocarcinoma specimens, Alakus 
et al. demonstrated that increased expression of MMP-2 was significantly 
association with more advanced tumour stage and poorer survival (Alakus 
et al., 2008).  
MMP-2 has thus been shown in several studies to be of prognostic 
value – higher levels of expression seem to be associated with a poorer 
prognosis in keeping with the protein’s role in regulating cancer invasion 
and metastasis. 
In a study by Bergin et. al, increased MMP-2 expression was also 
observed in patients with H. pylori infection compared to controls. MMP-9 
expression was also shown to be significantly elevated, suggesting that 
several members of the MMP family are involved in regulating H. pylori 
associated gastric inflammation (Bergin et al., 2004). 
 
1.7.4 Tissue Inhibitors of matrix metalloproteinases (TIMPs) 
TIMPS are the natural inhibitors of MMPs. TIMPS 1-4 have been 
identified and are secreted proteins which form complexes with MMPs and 
thereby regulate their activation and activity. The expression of TIMPs, like 
MMPs, is also regulated during tissue remodelling.  
TIMP-1 is a general inhibitor of MMPs whereas TIMP-2 is usually 
associated with MMP-2. TIMPs have also been found to influence 
apoptosis and proliferation by mechanisms other than regulation of MMPs. 
TIMP-3 has been shown to have unique features – it is the only 
TIMP that binds firmly to ECM and is associated with a specific disease - 
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Sorsby fundus dystrophy, characterised by early blindness due to 
excessive accumulation of TIMP-3 in Bruch’s membrane. This occurs due 
to mutations of cysteine residues to serine (Felbor et al., 1995). TIMP-3 
has been also shown to initiate apoptosis whereas TIMPs-1and -2 inhibits 
apoptosis. 
TIMP-4 is the latest TIMP to be identified and is the largest. It 
shares many similarities with other TIMPs, in particular with TIMP-2. It 
does not activate, but inhibits MMP-2. TIMP-4 expression has been shown 
to be increased in tumours of the breast, ovary, cervix, endometrium, 
prostate, colon and papillary renal tumours and to be down regulated in 
pancreatic and some renal tumours (Bister et al., 2007; Lizarraga et al., 
2005).  
Bodger et al. demonstrated significantly elevated concentrations of 
specific TIMPs (TIMP-1, 3 and 4) in the glandular corpus mucosa of H. 
pylori infected humans compared to uninfected controls (Bodger et al., 
2008). This suggests that TIMPs may play an important role in regulating 
the gastric inflammation associated that is associated with H. pylori 
infection. 
Increased expression of TIMP-2 was also observed more frequently 
in gastric adenocarcinoma and this was associated with a poorer overall 
survival (Kubben et al., 2006). In a study of 74 gastric adenocarcinoma 
patients, increased expression of TIMP-1 and -2 was demonstrated in the 
tumour tissue (no expression in normal gastric tissue) and this was 
associated with advanced tumour stage (Murray et al., 1998). 
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Potential 
biomarker 
Family 
group 
Expression in 
Hp Gastric 
preneoplasia 
Gastric 
adenocarcinoma  
Other 
cancers 
IGF-1 IGF ↓ ↑  ↑  ↑  
IGF-2 IGF ↓ ↑ ↑ ↑ 
IGFBP-2 IGF ↑ ↑ ↑  ↑ 
IGFBP-3 IGF ↓ ↓  ↓  NK 
uPA uPA ↑ ↑ ↑ ↑ 
uPAR uPA ↑ ↑ ↑ ↑ 
PAI-1 uPA ↑ ↑ ↑ ↑ 
PAI-2 uPA ↑ ↓ ↓ NK 
MMP-2 MMP ↑ ↑ ↑ ↑ 
MMP-7 MMP ↑ ↑ ↑ ↑ 
TIMP 1,3,4 TIMP ↑ NK ↑ ↑ 
 
Table 1-6: Summary of potential gastric tumour biomarkers and their relation to H.  pylori 
infection, the presence of gastric preneoplastic pathology and gastric cancer. (NK=not 
known). 
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1.8 Aims and Objectives: 
 
1. To determine in a population undergoing diagnostic 
gastroscopy, factors associated with the presence of gastric 
pre-neoplastic and neoplastic changes following Helicobacter 
pylori infection.  
2. To evaluate the association between gastrin and gastric pre-
neoplastic changes and the association between cagA status of 
infecting Helicobacter pylori and gastric cancer development. 
3. To determine the association between factors and the 
presence of type-1 gastric carcinoid tumours in patients with 
autoimmune atrophic body gastritis. 
4. To assess the role of the ‘octreotide suppression test’ in 
predicting whether patients with type-1 gastric carcinoid 
tumours benefit from antrectomy. 
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Chapter 2 
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2 Materials and Methods 
 
2.1 Study design 
A cross-sectional study (described in chapters 3 to 6) recruiting 
symptomatic patients attending for diagnostic gastropscopy at a single 
University Hospital funded by and funded by the National Institute of 
Health Research (NIHR) Biomedical Research Centre in Microbial 
diseases at Royal Liverpool and Broadgreen University Hospitals NHS 
Trust, Liverpool, UK.  
 
2.2 Patient recruitment 
Local adult ethics committee approval and informed patient consent 
was obtained from participating patients who were attending for a 
diagnostic gastroscopy for clinical indications. The study was sponsored 
by Royal Liverpool and Broadgreen University Hospitals NHS Trust (R&D 
Number 3592) and the University of Liverpool.  REC reference number 
08/H1005/37).  
Exclusions to recruitment into this study included: 
 patients with a bleeding diathesis or on anticoagulants 
 hepatits B or C infection, HIV infection 
 pregnancy 
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 active bleeding or hemodynamic instability at the time of 
gastroscopy  
 inability to obtain/give informed consent.  
Patients with known Barrett’s oesophagus attending for gastroscopy 
as part of a Barrett's or oesophageal adenocarcinoma surveillance were 
also excluded, although some patients who were found to have a new 
diagnosis of Barrett’s were recruited. 
All patients were interviewed and consented by Senthil Murugesan 
and their height and weight were recorded. A clinical questionnaire was 
completed for each patient (see appendix 1). Symptoms resulting in 
referral for gastroscopy, history of previous gastric surgery, relevant family 
history and other co-existing illnesses were documented. Smoking status, 
alcohol consumption and drug treatment, in particular the dosage of PPIs 
and the time elapsed since the last doses of PPI were recorded. Previous 
H. pylori status and eradication therapies were also recorded in the clinical 
questionnaire. 
 
2.3 Samples 
 20mls of blood was obtained by venepuncture (fasting) at the time 
of recruitment prior to gastroscopy. 5mls were stored at -20◦C in an EDTA 
containing vacuette for future DNA analysis for various genetic 
polymorphisms (of which 1 ml was also stored on protein saver cards). 
10mls of blood was centrifuged and the serum obtained was subsequently 
stored at -20◦C. This was utilised to analyse fasting serum gastrin 
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concentrations and the cagA status of the infecting Helicobacter pylori. A 
further 5 mls was used for serological analysis for Helicobacter infection 
(anti-IgG antibodies to Helicobacter pylori; performed by the Microbiology 
department at the Royal Liverpool and Broadgreen University Hospital 
NHS Trust). 
At gastroscopy, two biopsies (each ~ 2mm size) were obtained from 
the antrum and two from the corpus using standard biopsy forceps. These 
were formalin fixed and paraffin embedded for subsequent histological 
analysis by a GI histopathologist, Dr. Laszlo Tiszlavicz, University of 
Szeged. The histological analysis was performed following staining with 
Giemsa, immunohistochemistry, H&E (haematoxin and eosin) and PAS 
(Periodic Acid Shiff). The gastric biopsy report (see appendix 2) included 
the Modified Sydney classification for inflammation (Dixon et al., 1996), the 
Padova (Rugge et al., 2000) and the modified Vienna classifications for 
dysplasia scoring (Schlemper et al., 2000) and also the presence of 
Helicobacter pylori. A rapid urease test (PRONTO Dry®, MIC France) was 
also performed using two gastric biopsies (two biopsies from the antrum in 
those patients not on concurrent PPI therapy or one biopsy each from the 
antrum and corpus from those on concurrent PPI) in all patients in order to 
obtain a rapid diagnosis of Helicobacter  pylori infection. In this study, a 
diagnois of current Helicobacter  pylori infection was made in the presence 
of a  positive histology for this organism  (with or without positive 
serology/rapid urease test) in keeping with currently accepted ‘gold 
standard’ method for the diagnosis of this organism (Malfertheiner et al., 
2012).  8 additional corpus biopsies were obtained and stored in RNA-
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Later® at 4˚C for RNA extraction and subsequent analysis of mRNA 
abundance of various potential biomarkers of gastric carcinogenesis. 
 
2.4 Gastrin analysis by Radioimmunoassay  
The technique of radioimmunoassay for the measurement of serum 
concentrations of hormones was first described by Berson and Yalow 
(Yalow and Berson, 1960). This is based on the principle that unlabelled 
hormone (in serum) competitively binds to a specific antibody and thus 
inhibits the binding of labelled hormone. Therefore as the concentration of 
unlabelled hormone increases, the ratio of bound to free labelled hormone 
decreases. The concentration of the hormone can therefore be measured 
by comparing the inhibition observed with that produced by standard 
solutions containing known concentrations of the hormone being 
measured (Berson and Yalow, 2006). 
The antibody utilised in this technique (L2 antibody) of 
radioimmunoassay was directed against the α-amidated C-terminal portion 
of gastrin molecules, therefore binding all bioactive gastrins irrespective of 
N-terminal peptide length and degree of sulfation. This antibody however 
does not bind to the immediate precursors of amidated gastrin namely 
progastrin or glycine extended peptides (Dockray, 1980; Varro and Ardill, 
2003; Rehfeld, 2007). There are currently no assays that reliably measure  
total gastrin concentrations. 
Serum gastrin concentrations were measured for all the patients 
recruited to the study by radioimmunoassay. Very high concentrations 
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were subsequently analysed by serial dilutions. Quality controls (Qc; serum 
containing known concentrations of serum gastrin) were used in each 
assay to detect inter assay variations. 
 
2.5 Determination of cagA status of infecting Helicobacter  pylori by 
Enzyme Linked Immunoabsorbant Assay (ELISA) 
As described in section 4.4.1, the presence of the cagA gene has 
been found to be associated with increased pathogenicity of H. pylori 
(leading to an increased incidence of peptic ulcer disease and gastric 
adenocarcinoma). Infection with cagA+ve H. pylori strains results in a 
serological response from the host to the cagA subunit (cagA antibodies). 
The cagA status of the Helicobacter pylori in our study population 
was determined using a commercially available Enzyme Linked 
Immunosorbant Assay (ELISA) (Genesis Diagnostics Ltd, Product code 
GD33, cagA IgG ELISA) kit. This technique is based on the following 
principle. 
Serum samples (diluted) were incubated in microtitre wells with 
recombinant cagA protein (immobilised on the titre wells). Rabbit anti-
human IgG conjugated to horseradish peroxidase was subsequently 
added to the wells after washing out the unbound serum. This IgG 
antibody bound to the surface bound antibodies during the second 
incubation. Unbound conjugate was removed by washing and a solution 
containing 3, 3’, 5, 5’- tetramethylbenzidine (TMB) and enzyme substrate 
was added to trace specific antibody binding. The reaction was terminated 
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by the addition of STOP solution (0.25M sulphuric acid), which provided 
the appropriate pH for the development of colour. The optical densities of 
the standards, controls and samples were then read at 450nm using a 
microplate reader. Optical density (OD) was directly proportional to the 
antibody activity in the sample. The use of quality controls (positive and 
negative controls and water blanks) in every assay helped to monitor for 
any reagent failure. 
Sera obtained from all those patients in our cohort who were 
deemed H. pylori positive were analysed for the presence of cagA 
antibodies using the ELISA technique. Each assay included positive and 
negative controls and water blanks to assess inter-assay variation. All the 
samples were analysed in duplicate and the mean optical density was 
measured. The calculated mean optical densities for the standards were 
plotted against their known concentrations on a graph and the values of 
the samples (unknowns) were determined from this curve. 
The sensitivity and specificity of this assay (compared to Western 
Blot assay) is reported to be 96% and 97% with a <12% interassay 
coefficient of variation. The interassay variation was however found to be 
<10% in our analyses.  
 
 
130 
 
Interassay Variation
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
0.4
0.45
0.5
Assay
P
o
s
it
iv
e
 c
o
n
tr
o
l 
O
D assay1
assay2
assay3
assay4
assay5
assay6
assay7
Mean of assays
 
 
Figure 2-1: Mean optical density for positive controls per assay and 
the overall mean OD. 
 
2.6 Determination of cagA status of infecting Helicobacter pylori by 
polymerase chain reaction (PCR) 
In order to determine accurately and validate the ELISA technique for 
determination of the cagA status of the infecting Helicobacter pylori, we 
developed a specific PCR technique using primer sets (two sets for cagA 
and atp A) based on the Hp 700392 genome with the following 
sequences: 
cagA set A: 198F + 470 R 
cagA set B: 13F + 397R 
atpA set C: 166F + 603R 
atpA set D 759F + 1153R 
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and used as a positive control, Hp 700392 genomic DNA, at a 
concentration of 10ng/ml. 
The initial development of this technique was performed by Prof. 
Rod Dimaline. Subsequent optimisation of the technique and performance 
of PCR of biopsy samples was performed by Senthil Murugesan. 
Optimisation of the PCR technique was performed to identify: 
1. the minimum required concentration of genomic DNA  
2. template concentration 
3. optimal annealing temperature 
4. optimal magnesium concentration 
5. optimal required quantity of Taq polymerase enzyme 
The final total reaction volume used in the PCR assay was 25µl 
(master mix of 23µl and 1µl each of template i.e. sample or genomic Hp 
DNA). The master mix contained 3.5mM magnesium, 0.25µl of Taq 
polymerase enzyme, 2.5 µl STD Neb 10x buffer, 10mM dNTPs and 
15.75µl distilled water. The reaction was performed using an annealing 
temperature of 55˚C.  
Following optimisation of the technique, initial PCR reactions were 
performed on gastric corpus biopsy samples that were known to be H. 
pylori positive. Agarose gel electrophoresis of the PCR products was 
however unsuccessful in identifying H. pylori or cagA. This was felt to be 
secondary to the low prevailing concentrations of H. pylori DNA that was 
available in the gastric biopsy samples for the PCR technique to amplify. 
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Due to the consistency of the ELISA technique and its low inter-assay 
variation, the PCR technique was therefore not pursued further. 
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3 Demographics, co-morbidities and endoscopic findings of study 
patients  
3.1 Cohort demographics 
A total of 1017 patients were recruited to the study. 576 (56.6%) 
were female with a median age of 59 years (interquartile range 47-69). 
99.3% (1010 patients) were Caucasian reflecting the ethnic distribution of 
the local population. Of the remaining 7 patients, 4 were Asian, 1 Chinese, 
1 African and 1 Middle Eastern in origin. The median BMI (Body Mass 
Index) of the cohort was 26.8 (range 13.5-54.8) with more than half the 
cohort (651 patients, 64.5%) exceeding a BMI of 25.  
The BMI status of patients recruited to our current study is listed in 
table 3-1. BMI was not calculated in 8 patients and the reason for these 
included patients who were unable to stand/weight bear or who had had 
bilateral lower limb amputations. 
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BMI range Definition Total no. of patients (%) 
<18.5 Underweight 21 (2%) 
18.5 to <25 Normal 337 (33.4%) 
25 to <30 Overweight 368 (36.5%) 
30 to <40 Obese 257 (25.5%) 
>40 Morbidly obese 26 (2.5%) 
  
Table 3-1: BMI range and total number of patients.  
 
 
3.2 Co-morbidities and other illnesses 
A total of 527 (51.8%) patients reported the following co-morbidities 
listed in table 3-2. 
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Co-Existing Medical Illness Total no. of patients (%) 
Single comorbidity 
Diabetes mellitus 
(types-1 & 2) 
35 (3.4%) 
Ischaemic heart disease 20 (2.0%) 
Cerebrovascular disease 9 (0.9%) 
COPD 26 (2.6%) 
Asthma 57 (5.6%) 
Hypertension 93 (9.1%) 
Coeliac disease 2 (0.2%) 
Autoimmune thyroid disease 
(hypothyroidism/hyperthyroidism) 
11 (1.0%) 
Arthritis 
(osteoarthritis/rheumatoid/ psoriatic) 
17 (1.7%) 
Inflammatory bowel disease 13 (1.3%) 
Hypercholestrolemia 10 (1%) 
Liver and pancreatic diseases 6 (0.6%) 
Multiple sclerosis 2 (0.2%) 
Nephrotic syndrome 2 (0.2%) 
Systemic lupus erythematosus 3 (0.3%) 
Epilepsy 4 (0.4%) 
Osteoporosis 4 (0.4%) 
Multiple co-morbidities 213 (21%) 
 
Table 3-2: Comorbidities and total patient numbers 
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213 (21%) patients had more than one comorbidity and the remaining 485 
(47.7%) of the 1017 patients recruited had no significant co-existing 
medical illness. 5 (0.5%) patients had Familial Adenomatous Polyposis 
(FAP). 
Some patients were known to have co-existing cancer or had 
received previous cancer treatment and this is summarised in table 3-3. 
 
Type of previous cancer Number of patients 
Oesophageal cancer 2 (past) 
Gastric cancer 3 (past) 
Breast cancer 15 (past) 
Lung cancer 2 (1 past, 1 current) 
Prostate cancer 5 (current) 
Colorectal cancer 10 (past) 
Throat cancer 1 (past) 
Renal cancer 1(past) 
Bladder cancer 1 (past) 
Thyroid cancer 1 (past) 
Non-hodgkins lymphoma 1 (past) 
Nasopharyngeal MALTOMA 1(past) 
 
Table 3-3: Previous cancer and number of patients 
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3.3 Concurrent drug therapy 
482 patients (47.4%) were on a PPI at the time of recruitment, 28 
(2.7%) on a H2-receptor antagonist (H2RA) and 5 (0.5%) on both PPI and 
H2RA. Patients who had discontinued PPI therapy at least 2 weeks prior to 
recruitment were considered to be ‘off PPI’. 193 (18.9%) patients were on 
antiplatelet agents (172 on aspirin and 21 on clopidogrel) and 45 (4.4%) 
were taking a non-steroidal anti-inflammatory drug (NSAID) at the time of 
recruitment. 
 
3.4 Smoking and alcohol history 
484 (47.6%) of patients had never smoked, 276 (27.1%) were ex-
smokers (those who had stopped smoking at the time of recruitment to the 
study) and 257 (25.3%) were current smokers. A total of 565 (55.7%) 
patients consumed alcohol, of whom 40 female patients and 50 male 
patients drank alcohol above the current recommended weekly upper limit 
(>14 units for women and >21 units for men; 
http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/Publication
sPolicyAndGuidance/DH_075218). However these data may not reflect the 
true prevalence of excess alcohol intake in this cohort due to the high 
prevalence of underreporting and underestimation of alcohol intake by 
patients (Feunekes et al., 1999; Stockwell et al., 2004). Hence in the final 
analysis patients were classified as either consumers or non-consumers of 
alcohol. 
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3.5 Previous H. pylori eradication 
118 (11.6%) patients reported receiving previous eradication 
treatment for H. pylori with varying intervals between receiving eradication 
therapy and recruitment into the study. 
 
3.6 Indications for referral for gastroscopy 
The following table (table 3-4) summarises the indication and 
symptoms prompting referral for gastroscopy. Row 1 includes patients with 
a single presenting symptom and row 2 those with multiple symptoms.
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Symptoms 
Total no. of 
patients 
Reflux/ 
heartburn 
Indigestion 
Abdominal 
pain 
Vomiting 
Weight 
loss 
Anaemia Dysphagia 
Haemetemesis/ 
malaena 
Follow 
up 
gastric 
ulcer 
One 
symptom 
588 95 123 118 20 21 86 106 19 0 
Mixed 
symptoms 
429 154 179 143 54 76 63 80 23 14 
 
Table 3-4: Indications for gastroscopy 
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3.6.1 Routes of referral for gastroscopy 
386 patients (37.9%) were referred via the ‘2-week rule’, 158 
(15.8%) via GP open access endoscopy and 473 (46.5%) by a hospital 
clinician referral (outpatient clinics and inpatient referrals). The ‘2-week 
rule’ referral, as stipulated by the Department of Health (DOH), is the 
chosen pathway for General Practitioners (GPs) to refer those patients 
with symptoms suggestive of cancer for urgent specialist management 
(http://www.dh.gov.uk/en/Publicationsandstatistics/Lettersandcirculars/Hea
lthservicecirculars/DH_4004253). 
 
3.7 Significant past upper gastrointestinal tract surgical history 
Of the 1017 patients recruited, 54 (5.3%) had undergone previous 
gastric or oesophageal surgery (table 3-5) and an additional 14 (1.4%) had 
a history of previous peptic ulcer disease but without surgery.    
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Type of previous 
gastric surgery 
Total number of 
patients 
Antrectomy 3 
Gastroenterostomy 7 
Vagotomy 3 
Partial and or distal 
gastrectomy 
9 
Billroth II 
gastrectomy 
4 
Oesophago partial 
gastrectomy 
6 
Oesophageal 
resection for 
cancer 
4 
Heller’s 
cardiomyotomy for 
achalasia 
1 
Fundoplication 9 
Details unknown 
(for symptoms of 
peptic ulcer 
disease) 
7 
Gastric banding 1 
 
Table 3-5: Types of previous gastric or oesophageal surgery and 
total patient numbers 
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3.8 Family history of gastric cancer and peptic ulcer disease 
5.5% (55) of patients reported a first degree relative with a history of 
gastric cancer and a further 2% (20) reported a second degree relative 
with a history of gastric cancer. 12.5% (125) also reported a family history 
of peptic ulcer disease (gastric or duodenal ulcer) (table 3-6).  
 
 
Family history of gastric cancer 
 
Family history of 
peptic ulcer disease 
(%) Total 
number 
(%) 
Affected first 
degree relative 
(%) 
Affected second 
degree relative 
(%) 
75 (7.4%) 55 (5.4%) 20 (2%) 125 (12.3%) 
 
Table 3-6: Total number of patients with a reported family history of gastric cancer (first 
degree or second degree relatives) and peptic ulcer disease (PUD) 
 
3.9 Endoscopic diagnosis at gastroscopy 
Table 3-7 is a summary of the most significant diagnosis made at 
gastroscopy. When more than one endoscopic diagnosis was observed 
(such as gastritis and gastric ulcer), the more significant pathology was 
taken into consideration (for example gastric ulcer would be recorded 
instead of any associated gastritis). 
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Diagnosis 
Total number of 
patients (%) 
Normal 246 (24.2%) 
Hiatus hernia   80 (7.9%) 
Post surgical 32 (3.1%) 
Oesophageal dysmotility 12 (1.2%) 
Vascular malformations 6 (0.6%) 
Oesophagitis 
 
49 (4.8%) 
Gastritis and/or Duodenitis 477 (46.9%) 
Peptic ulcer disease 
(Gastric and duodenal ulcer) 
30 (3%) 
Gastric polyps 45 (4.4%) 
Gastric cancer 7 (0.7%) 
Barrett's oesophagus 26 (2.5%) 
Oesophageal cancer 7 (0.7%) 
 
Table 3-7: Endoscopic diagnosis 
 
3.10 Discussion 
Several previous studies have addressed some of the individual risk 
factors that influence the development of gastric adenocarcinoma (detailed 
in section 1.5.2). However none of these studies have evaluated the 
interactions between environmental, bacterial and host factors in the 
development of gastric preneoplastic pathology and the subsequent 
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progression to gastric adenocarcinoma. This present study aims to 
evaluate the roles played by the above mentioned factors and the 
interactions between these factors during the development of gastric 
preneoplastic pathology.  
There are several strengths to the current study.  Patients have 
been recruited prospectively and the cohort reflects the local population 
being referred for endoscopy. The cohort if predominantly white Caucasian 
population which is unqiue compared with other studies. Patients with 
incomplete data sets have been excluded from the final analysis (n=13). 
Demographics and clinical details of all the recruited patients have been 
extensively recorded. H. pylori status of patients has been defined by 
stringent criteria and patients with previous eradication of this organism 
have also been clearly identified. Gastric biopsies have been reported 
based on internationally accepted classifications including the modified 
Sydney system, Vienna and Padova classification by a dedicated GI 
Histopathologist who was blinded to the endoscopy findings (section 2.2).  
One of the main limitations of this study is that only those patients 
with symptoms have been recruited. Hence those patients who may have 
gastric preneoplastic pathology but who are otherwise asymptomatic and 
those who have not been referred for an endoscopy have not been 
represented in this study. Patients with previous or current known cancers 
have been included in this cohort and those patients with the known 
familial cancer syndrome ‘Familial Adenomatosis Polyposis’ (FAP) have 
not been excluded. The dosage and duration of therapy with proton pump 
inhibitors has not been reported in this study. 
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Patients with history of previous gastric surgery have not been 
excluded from the current study. Although previous gastric surgery 
(vagotomy etc.) maybe associated with increased fasting serum gastrin 
concentrations, this is usually modest (~100pM) (Murugesan et al., 2009). 
This group of patients were therefore not excluded from the study.  
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4 Factors that determine the sensitivity of the rapid urease test (RUT) 
for the detection of Helicobacter pylori infection in adult patients 
 
4.1 Introduction 
H. pylori infection is not only a recognised cause of gastric and 
duodenal ulceration but also an important factor in the development of 
gastric adenocarcinoma as detailed in sections 1.4 and 1.5.2. It is also 
implicated in the development of gastric Mucosa Associated Lymphoid 
Tissue (MALT) lymphomas. Hence accurate diagnosis of the presence of 
this organism is essential for the optimal management of patients with 
dyspeptic symptoms (including the test and treat strategy (Chiba et al., 
2002), peptic ulcer disease and gastric MALT lymphoma (Fischbach et al., 
2004). Eradication of this organism has been associated with a reduction 
in the risk of developing gastric adenocarcinoma (Malfertheiner et al., 
2005). Several methods have been developed to diagnose the presence of 
this organism and these include demonstration of the bacteria on 
histological samples (by conventional and or immunohistochemical 
staining), rapid urease testing, 13C-urea breath testing, serology and stool 
antigen testing. Although histological examination of gastric biopsies 
currently remains the gold standard diagnostic test, none of the methods 
has a consistently high diagnostic accuracy (Malfertheiner et al., 2007).  
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Rapid urease tests (RUT) are currently routinely utilised to diagnose 
H. pylori infection as they are quick, cost effective and have been reported 
to have comparable sensitivity and specificity with histology, PCR and 
culture.  As H. pylori prevalence is decreasing in Western countries, we 
hypothesised that the sensitivity of the rapid urease test may be impairing 
diagnosis and we have therefore evaluated whether the RUT is still useful 
in current clinical practice and have investigated the roles of various host, 
drug and bacterial factors which may affect the accuracy of RUT for 
detecting H. pylori infection. 
4.2 Methods   
RUT was performed using the commercially available PRONTO 
DRY® test as per protocol, using two biopsies from the antrum in patients 
who were not using acid suppressing drugs and one antral and one corpus 
biopsy if patients were taking a proton pump inhibitor (PPI). There was no 
defined unit policy regarding RUT testing on those patients on a 
concurrent H2 receptor antagonist and hence the RUT was performed 
using antral biopsies in such patients. The PRONTO test was considered 
positive for H. pylori if the reagent turned colour from yellow to red/pink 
after an hour’s incubation as shown in figure 4-1. 
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Figure 4-1: Rapid urease test – PRONTO Dry. Top negative result and bottom positive 
with change in colour of the reagent well. 
 
Gastric antral and corpus biopsies were analysed for the presence of 
H. pylori and any preneoplastic changes (atrophic gastritis, intestinal 
metaplasia or dysplasia) by a single experienced GI pathologist using 
haematoxylin and eosin (H&E) stained sections and Giemsa stains 
(section 2.2). H. pylori and cagA serology were determined by enzyme 
linked immunoassay (as described in detail in sections 2.2 and 2.4 
respectively). 
4.3 Results 
 Of the 1017 patients recruited, 985 patients (55.2% female; mean 
age 56.9 years) were included in this analysis in whom RUT and histology 
had both been performed. 469 (47.6%) were taking PPIs at the time of 
enrolment, 23 patients (2.3%) were on a H2 receptor antagonist (H2RA; 22 
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on ranitidine 150mg twice daily dose and one patient on famotidine 20mg 
once daily dose) and 5 were on both PPI and H2RA (one patient having 
discontinued both PPI and H2RA 7 days prior to endoscopy). 
Table 4-1 shows the most significant pathology observed at gastroscopy in 
these 985 patients. 
Diagnosis 
Total number of 
patients (%) 
Normal 237 (24.1%) 
Hiatus hernia  80 (8.3%) 
Post surgical 27 (2.5%) 
Dysmotility 12 (1.2%) 
Vascular malformations 5 (0.5%) 
Oesophagitis 49 (4.9%) 
Inflammatory  
(Gastritis, Duodenitis) 
463 (47%) 
Ulcer disease 
(Gastric and duodenal ulcer) 
29 (2.9%) 
Gastric polyps 44 (4.5%) 
Gastric cancer 7 (0.7%) 
Barrett's oesophagus 25 (2.5%) 
Oesophageal cancer 7 (0.7%) 
 
Table 4-1: Most significant pathology observed at gastroscopy 
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4.3.1 Sensitivity and specificity of RUT 
218 (21.4%) patients showed histological evidence of H. pylori 
infection of whom 153 (15.1%) also had a positive RUT. 10 (1%) patients 
had a false positive RUT with no histological evidence of infection seen 
(but only 3 of these patients were seropositive for H. pylori; one patient 
had received previous H. pylori eradication therapy). 757 (74.4%) patients 
were negative for H. pylori infection by RUT and histology and 65 (6.4%) 
patients had a false negative RUT. The specificity of the RUT was 
therefore 98.9% and sensitivity 70% compared to histology. The probability 
of the presence of H. pylori infection with a positive RUT [positive 
predictive value (PPV) for the rapid urease test] was 90.5% and 
conversely the negative predictive value (NPV) was calculated to be 
65.4% (Bayes’ equation).  
114 (11.2%) patients had received previous H. pylori eradication 
therapy. However 21 of this group of patients (18.4%) had histological 
evidence of persisting H. pylori infection (15 of whom were also RUT 
positive and 20 were serology positive; one patient did not have serology 
performed) suggesting failure of eradication therapy in these patients. Of 
the remaining 93 patients who had received previous H. pylori eradication 
therapy with no evidence of current H. pylori infection at histology, 48 had 
a positive H. pylori serology test and all had a negative RUT. 
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Figure 4-2: Rapid urease test vs. histology 
 
4.3.2 The outcome of Rapid Urease Testing and the effect of 
concomitant PPI use, H. pylori serology, cagA status and 
gastric preneoplastic pathology 
 
Of the 65 patients with a false negative RUT, 56 (86.2%) also had 
positive H. pylori serology (7 were negative and in 2 cases serology was 
not performed). 20 (30.8%) of the patients with a false negative RUT 
showed histological evidence of H. pylori infection in the gastric corpus 
only compared to only 2.6% of those patients who had a true positive RUT 
(χ2 p<0.0001).   
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A false negative RUT was also associated with concurrent PPI use 
(50.8% of patients with a false negative RUT were taking PPIs compared 
to only 23% of those with a true positive RUT (χ2 p<0.0001)).  
CagA negative H. pylori serology was detected in 78.4% of the 
patients with a false negative RUT compared to 53.9% of those with a true 
positive RUT (χ2 p<0.001).  
The presence of preneoplastic gastric pathology (atrophic gastritis, 
intestinal metaplasia or dysplasia) (43% in patients with a false negative 
RUT vs. 36.6% in those patients with a true positive RUT) did not appear 
to affect the sensitivity of the RUT in this cohort of patients (table 4-2). 
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False –ve RUT vs. True +ve RUT 
 
False –ve 
(%) 
True +ve 
(%) 
p values (χ2) 
Total 
Number 
65  153  - 
Concurrent 
PPI use 
32 (49.2%) 35 (22.9%)  p<0.0001 
Corpus only 
H.pylori 
infection 
20 (30.8%) 4 (2.6%)  p<0.0001 
cagA -ve 
H.pylori 
serology 
46 (70.8%) 83 (54.2%) p<0.001 
Preneoplastic 
pathology 
28 (43.1%) 56 (36.6%) 0.481 
  
Table 4-2: False negative RUT vs. True Positive RUT.
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4.4 Discussion 
Helicobacter pylori infection of the stomach can be detected by 
several invasive and non-invasive methods as outlined in table 4-3. These 
methods have been reported to have varying sensitivities and specificities 
for the detection of H. pylori infection and it is known that some are 
influenced by factors including concurrent PPI therapy and the number of 
H. pylori bacteria in the biopsy samples. Low sensitivity and specificity has 
also been reported in patients with upper gastrointestinal tract bleeding 
and therefore rapid urease testing has not been recommended in this 
clinical setting (Schilling et al., 2003). False negative tests can also occur 
in patients with achlorhydria and in those on a concurrent PPI. It is thought 
that the high luminal pH resulting from the above two conditions can result 
in the destruction of the infecting H. pylori due to the action of its own 
urease enzyme (Basset et al., 2004; Schilling et al., 2003). 
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Diagnostic 
method 
Sensitivity Specificity References 
Invasive methods 
Histology  93% 99% (Cutler et al., 1995) 
Rapid Urease 
Test 
85-95% 95-100% (Tseng et al., 2005) 
Culture of 
biopsy sample 
80-90% 100% (Ricci et al., 2007) 
Serological 
testing 
90-97% 50-96% (Ekesbo et al., 2006) 
Polymerase 
Chain Reaction 
(PCR) 
85-96% 90-100% (Li et al., 1996; 
Ashton-Key et al., 
1996) 
In-situ 
hybridisation 
95% 100% (Ruzsovics et al., 
2004) 
Non-invasive methods 
Urea Breath 
Test 
90-98% 92-100% (Goddard and Logan, 
1997) 
Stool antigen 
test 
91% 93% (Vaira et al., 2000) 
 
Table 4-3:  Various tests and their diagnostic accuracy for the 
detection of H. pylori infection. 
 
RUT is routinely used for the immediate (rapid) diagnosis of H. pylori 
infection at gastroscopy. It is based on the ability of the urease enzyme 
produced by H. pylori to split the urea test reagent to form ammonia as 
discussed in section 1.4.3.3. This increases the pH which is detected by 
the indicator - phenol red. Commensal bacteria in the oral cavity also 
produce urease, however, the weaker enzyme produced by these bacteria 
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is rapidly denatured by the acidic pH of the stomach and therefore this is 
less likely to be associated with a false positive urease test. 
Several different types of RUT have been developed and some of 
these are described in table (4-4).  
 
Rapid 
Urease 
Test 
Type Sensitivity Specificity 
Time of  
assessment 
References 
CLO test Gel-based 98% 97% 24 hours 
(Weston et 
al., 1997) 
Hp Fast Gel-based 97.7% 87.7% 24 hours 
(Laine et al., 
1996; Yousfi 
et al., 1996) 
PyloriTEK 
Paper-
based 
urea 
membrane 
test 
96% 97% 
One hour 
(positive and 
negative 
controls 
included) 
(Laine et al., 
1996) 
ProntoDry 
Paper-
based 
86.8% 97% One hour 
(Said et al., 
2004) 
 
Table 4-4: Rapid urease tests in the diagnosis of H. pylori infection – diagnostic accuracy 
and rapidity of test results.  
 
It has previously been shown that the diagnostic accuracy of the 
various RUTs is decreased when the test is performed in patients on 
concurrent PPI therapy. We have established a similar significant 
association between false negative RUT and concurrent PPI use. This was 
in spite of obtaining samples for RUT from both the antrum and corpus in 
those patients who were on concurrent PPI therapy. Sampling error alone 
therefore cannot explain this association. It has been described that in the 
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presence of hypo or achlorhydria, such as that seen with PPI therapy, the 
usually antral predominant H. pylori infection colonises the corpus 
preferentially, however this  cannot be the only explanation for a false 
positive RUT in those on a PPI. Other possible explanations include an 
associated decrease in the density of H. pylori infection, inactivation of the 
urease enzyme or indeed destruction of the bacteria above a certain 
gastric mucosal pH. A significantly greater proportion of patients with a 
false negative RUT also had histological evidence of infection in the gastric 
corpus only compared to those with a true positive RUT. 
It has not previously been established whether other host factors 
(such as the presence of preneoplastic pathology) and the presence of 
bacterial virulence factors (cagA) also influence the diagnostic accuracy of 
the RUT in the diagnosis of H. pylori infection. In our analysis, cagA 
positive H. pylori infection was associated with a lower incidence of a false 
negative RUT. It is well known that the bacterial virulence factor, cagA, is 
associated with greater pathogenicity of the infecting bacteria. Hence this 
bacterial virulence factor should be considered as an important 
determinant influencing the rapid urease test result. 
 
4.5 Conclusions 
This analysis has shown that concomitant PPI use, corpus 
predominant H. pylori infection and less virulent (cagA negative) strains of 
H. pylori are more likely to lead to false negative RUT results. The RUT 
should therefore be used with caution as the sole determinant of H. pylori 
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infection in these settings, especially in areas of the world in which H. 
pylori prevalence is now decreasing. 
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5 The associations between host, environmental and bacterial factors 
and the presence of gastric preneoplastic pathology 
 
5.1 Introduction 
As already discussed, H.pylori is a recognised gastric carcinogen 
(section 1.5.2.8). Several host factors such as age and sex, environmental 
factors such as smoking and alcohol consumption and bacterial virulence 
factors such as presence of the cagA gene have previously been 
suggested to increase the risk of developing gastric adenocarcinoma 
(detailed in section 1.5.2). However, it is not known how these factors 
interact to influence the development and progression of gastric 
preneoplastic pathology. Also it remains unclear whether factors such as 
Body Mass Index (BMI) and proton pump inhibitor therapy influence the 
development of gastric preneoplastic pathology. We have therefore 
investigated to what extent these factors are associated with the presence 
of gastric preneoplastic pathology (atrophic gastritis, intestinal metaplasia 
or dysplasia) in a large cohort of adult patients. 
5.2 Methods  
Patients enrolled in the study (described in section 2.1) funded by the 
National Institute of Health Research (NIHR) Biomedical Research centre 
in Microbial diseases at Royal Liverpool and Broadgreen University 
Hospitals NHS Trust, Liverpool, UK, were recruited in this analysis. 
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Clinical data recorded at recruitment, estimation of H. pylori and 
cagA serology, gastric antral and corpus biopsy analysis, measurements 
of fasting serum gastrin concentration are already discussed in detail in 
sections 2.1 to 2.3.   
5.3 Statistical analysis 
Statistical analysis was performed on those cases with no missing data 
(table 5.1 and table 5.2). Statistical analysis was performed using 
statistical software SAS v9.2 by statisticians Mr. Girvan Burnside (Lecturer 
in Medical Statistics, Department of Biostatistics, University of Liverpool) 
and Mr. Andrew McKay (Research Assistant, Clinical Trials Research 
Centre, University of Liverpool) working in liaison with the Biomedical 
Research Centre and the University of Liverpool. Power calculation for this 
study was realistically not possible due to the cross-sectional nature of the 
study. For some of the univariate analysis post hoc sample size 
estimations suggest that the sample size was adequate in detecting a true 
difference. For example a total of 199 patients (H. pylori positive with 
gastric preneoplastic pathology vs. H. pylori negative cases) would have 
been required in each group for a study powered at 80%, allowing for a 
type-1 error rate of  5%  to demonstrate a 20% difference (background 
prevalance of gastric preneoplastic pathology estimated at 10%). However 
there does exist the possibility of type-2 error in some of the sub-grup 
analysis due to smaller sample size.  
164 
 
5.3.1 Univariate analysis 
For each of the pathology outcomes, namely presence of 
preneoplastic pathology (atrophy, intestinal metaplasia, low grade/ high 
grade dysplasia or a combination of these pathologies), the relationship 
with individual variables including clinical and demographic features was 
assessed using univariate analysis (unadjusted association) without taking 
into account the influence of other factors. The associations are presented 
as odds ratios (compared to the reference category with an odds ratio of 
1.0). 
However for calculating the relationship between fasting serum 
gastrin concentrations and clinical and demographic features, a 
generalised logistic regression analysis was performed by calculating two 
odds ratios for each predictor, one ratio comparing serum gastrin 
concentrations between 40-100pM to serum gastrin concentration <40pM 
(upper limit of normal concentration) and the second odds ratio comparing 
serum gastrin concentrations >100pM to serum gastrin concentration of 
<40pM. 
 
5.3.2 Multiple logistic regression analysis 
In order to analyse the influence of more than one variable on the 
development of gastric preneoplastic pathology, multiple logistic 
regression analysis was performed. The odds ratio calculated has been 
adjusted for other variables in order to assess the effect of such individual 
variables on the outcomes.  
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5.4 Results 
5.4.1 Demographics 
As previously stated, a total of 1017 patients were recruited to the 
study. 576 (56.6%) were female with a median age of 59 years 
(interquartile range 47-69). The patient demographics for this cohort were 
described in detail in chapter 3. 
 
5.4.2 Preneoplastic pathology 
The following table is the summary statistic for the prevalence of 
gastric preneoplastic pathology and gastric adenocarcinoma in this cohort 
of patients (table 5-1). Although 1017 patients were recruited, a complete 
set of data was available in 1014 patients and these were therefore 
included in the final analysis. 
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Preneoplastic 
pathology 
Total 
number of 
patients 
analysed 
Total 
number (%) 
Any gastric 
preneoplastic 
pathology 
1014 246 (24.3%) 
Atrophy (A) 1014 109 (10.7%) 
Atrophy alone 
(without IM) 
1014 43 (4.2%) 
Intestinal Metaplasia 
(IM) 
1014 187 (18.4%) 
Intestinal Metaplasia 
alone (without 
atrophy) 
1014 121 (11.9%) 
IM + A 1014 66 (6.5%) 
Low grade dysplasia 
(LGD) 
1014 12 (0.2%) 
High grade 
dysplasia (HGD) 
1014 4 (0.4%) 
Gastric 
adenocarcinoma 
1014 8 (0.8%) 
 
Table 5-1: Total number of preneoplastic pathology and gastric adenocarcinoma reported. 
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5.4.3 Summary of factors that are associated with the development 
of gastric preneoplastic pathology 
The following table (5-2) summarises the key bacterial, 
environmental and host factors that are thought to be associated with  
the presence of gastric preneoplastic pathology.  
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Factors 
Total number of 
patients analysed 
Total number (%) 
BACTERIAL FACTORS 
H. pylori infection 
Total positive 1017 421 (41.4%) 
Current positive (Histology +ve or RUT 
+serology positive) 
1017 225 (22.1%) 
Past positive (serology +ve) 1017 196 (19.3%) 
Negative 1017 596 (58.6%) 
cagA status of H. pylori infection 
Current H. pylori infection 1008 94 (9.3%) 
Past H. pylori infection 1008 60 (6.0%) 
Overall cagA +ve H. pylori infection  154 (15.3%) 
ENVIRONMENTAL FACTORS 
Acid suppression medication use 
Proton pump inhibitor use 1017 482 (47.4%) 
H2RA use 1017 30 (2.9%) 
Smoking status (ever smoked) 1015 533 (52.5%) 
Alcohol consumers 1014 565 (55.7%) 
HOST FACTORS 
Serum gastrin concentration (pM) categories 
Median serum gastrin concentration (pM): 32 (IQR: 19.2, 74). 
<40 1002 586 (58.5%) 
40-100 1002 253 (25.2%) 
>100 1002 163 (16.3%) 
BMI   
<18.5 
1009 
21 (2.1%) 
18.5-24.9 337 (33.4%) 
25-29.9 368 (36.5%) 
30-39.9 257 (25.5) 
≥40 26 (2.5) 
Family history of gastric cancer 1017 75 (7.4%) 
 Table 5-2: Bacterial, environmental and host factors – key summary. 
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5.4.4 Prevalence of H. pylori infection 
A total of 421 (51.4%) patients had evidence of H. pylori infection. In 
this group, 225 (22.1%) patients had evidence of current infection with this 
organism as evidenced by the presence of H. pylori on histological 
analysis of either gastric antral or corpus biopsies or both rapid urease test 
and serology positive even if there was no histological evidence of this 
organism. 196 (19.3%) patients had evidence of previous infection with 
this organism (H. pylori serology only positive; histology negative) (table 5-
2).  
118 (11.6%) patients reported previous eradication treatment for H. 
pylori with varying intervals between receiving eradication therapy and 
recruitment into the study. However 22 (18.6%) of these patients had 
evidence of current H. pylori infection suggesting failure of previous 
eradication therapy. Of the 22 patients with previous failed eradication 
therapy, 21 were H. pylori serology positive and 16 had a positive rapid 
urease test. Of the remaining 96 patients who had received eradication 
therapy with no current evidence of H. pylori infection, 50 (42.4%) patients 
were H. pylori serology positive and only one patient had a positive rapid 
urease test at the time of recruitment into the study. 
 
5.4.5 Prevalence of cagA positive H. pylori infection  
Of the 421 patients who had evidence of infection with H. pylori (past 
or current infection), 154 (36.6%) were positive for cagA. In this group, 94 
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(22.3%) patients with current H. pylori infection and 60 (14.3%) patients 
with past H. pylori infection were positive for cagA (table 5-2). 
 
5.4.6 Univariate associations between demographic and host 
characteristics and presence of preneoplastic pathology 
 
The association between individual demographic variables namely 
gender, age and BMI and the presence of gastric preneoplastic pathology 
was assessed. This has been expressed as odds ratio with 95% 
confidence interval in table 5-3. Similarly the associations between 
environmental factors (such as smoking and alcohol consumption) and a 
family history of gastric cancer and the presence of preneoplastic gastric 
pathology are expressed as odds ratios with 95% confidence interval in 
table 5-4. 
Univariate analysis therefore suggested that there was no increased 
incidence of preneoplastic pathology in male patients. However increasing 
age was significantly associated with the presence of gastric preneoplastic 
pathology (table 5-3).  
Smoking was not associated with an increased incidence of gastric 
preneoplastic pathology in this cohort (table 5-5). Alcohol consumption on 
the other hand was associated with a lower incidence of gastric 
preneoplastic pathology (table 5-5). In the presence of a positive family 
history of gastric cancer, there was an associated significant incidence of 
gastric atrophy and intestinal metaplasia although no such association was 
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observed for all degrees of preneoplastic change combined (tables 5-5 
and 5-6).  
As there were insufficient numbers for a robust analysis in the low 
grade dysplasia, high grade dysplasia and gastric adenocarcinoma 
groups, odds ratios were not calculated for these pathology outcomes in 
any of the variables in tables 5-3 and 5-4. 
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Table 5-3: Relationship between the presence of gastric preneoplastic pathology and demographic variables – univariate analysis.  
Demographic 
variable 
Atrophy Atrophy (without IM) IM (%) IM (without atrophy) A+IM (%) 
 n (%) OR 
(95% 
CI) 
n (%) OR 
(95% 
CI) 
n (%) OR 
(95% 
CI) 
n (%) OR 
(95% 
CI) 
n (%) OR 
(95% 
CI) 
Gender 
Male 
41 
(9.3) 
1.0 - 
12 
(2.7) 
1.0 - 
89 
(20.2) 
1.0 - 
60 
(13.6) 
1.0 - 
29 
(6.6%) 
1.0 - 
Female 
68 
(11.9) 
1.31 
(0.87-
1.97) 
31 
(5.4) 
2.04 
(1.03-
4.01) 
98 
(17.1) 
0.81 
(0.59-
1.12) 
61 
(10.6) 
0.75 
(0.51-
1.10) 
37 
(6.5%) 
0.98 
(0.59-
1.61) 
Age 
< 50 
15 
(4.9) 
1.0 - 
10 
(3.2) 
1.0 - 
34 
(11.0) 
1.0 - 
29 
(9.4) 
1.0 - 5 (1.6) 1.0 - 
50-70 
59 
(12.2) 
2.71 
(1.51-
4.88) 
21 
(4.3) 
1.35 
(0.63-
2.91) 
86 
(17.7) 
1.74 
(1.14-
2.67) 
48 
(9.9) 
1.06 
(0.65-
1.72) 
38 
(7.8%) 
5.17 
(2.01-
13.28) 
>70 
35 
(15.9) 
3.71 
(1.97-
6.98) 
12 
(5.5) 
1.73 
(0.73-
4.07) 
67 
(30.5) 
3.54 
(2.24-
5.6) 
44 
(20.0) 
2.41 
(1.46-
4.00) 
23 
(10.5%) 
7.1 
(2.65-
18.98) 
BMI 
<18 
43 
(12.8) 
1.0 
- 17 
(5.0) 
1.0 - 
61 
(18.1) 
1.0 - 
35 
(10.4) 
1.0 
- 26 (7.7) 1.0 - 
18 -<25 
3 
(14.3) 
1.14 
(0.32-
4.03) 1 
(4.8) 
0.94 
(0.12-
7.44) 
6 
(28.6) 
1.81 
(0.68-
4.85) 
4 
(19.1) 
2.03 
(0.67-
6.37) 
2 (9.5) 1.26 
(0.28-
5.71) 
25 - <30 
37 
(10.1) 
0.77 
(0.48-
3.78) 16 
(4.4) 
0.86 
(0.43-
1.73) 
71 
(19.4) 
1.09 
(0.74-
1.59) 
50 
(13.6) 
1.36 
(0.86-
2.16) 
21 (5.7) 0.73 
(0.40-
1.32) 
30 - <40 
21 
(8.2) 
0.61 
(0.48-
1.22) 8 
(3.1) 
0.61 
(0.26-
1.44) 
39 
(15.3) 
0.82 
(0.53-
1.27) 
 
26 
(10.2) 
0.98 
(0.57-
1.67) 
 
13 (5.1) 0.64 
(0.32-
1.28) 
>40 
4 
(15.4) 
1.24 
(0.41-
3.78) 1 
(3.9) 
0.75 
(0.10-
5.89) 
8 
(30.8) 
2.01 
(0.84-
4.84) 
5 
(19.2) 
2.05 
(0.73-
5.79) 
3 (11.5) 
1.56 
 
(0.44-
5.54) 
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Demographic 
variable 
LGD 
(%) 
HGD 
(%) 
All preneoplastic pathology 
(%) 
Adenocarcinoma 
(%) 
 n (%) n (%) n (%) OR 
(95% 
CI) 
n (%) 
Gender 
Male 
7 
(1.6%) 
2 
(0.5%) 
104 
(23.6%) 
1.0 - 5 (1.1%) 
Female 
5 
(0.9%) 
2 
(0.4%) 
127 
(22.1%) 
0.92 
(0.69-
1.24) 
3 (0.5%) 
Age 
< 50 
0 
(0.0%) 
0 
45 
(14.5%) 
1.0 - 0 
50-70 
1 
(0.2%) 
1 
(0.2%) 
107 
(22.15) 
1.67 
(1.14-
2.45) 
3 (0.6%) 
       >70 
3 
(1.4%) 
3 
(1.4%) 
79 
(35.8%) 
3.28 
(2.16-
4.98) 
5 (2.3%) 
BMI 
<18 
5 (1.5) 2 (0.6) 77 
(22.9) 
1.0 - 3 (0.9) 
18 -<25 1 (4.8) 0 (0.0) 8 (38.1) 2.07 
(0.83-
5.18) 
 
0 (0.0) 
25 - <30 2 (0.5) 1 (0.3) 
88 
(24.0) 
1.06 
(0.74-
1.51) 
 
2 (0.5) 
30 - <40 3 (1.2) 1 (0.4) 
47 
(18.3) 
0.75 
(0.50-
1.13) 
 
3 (1.2) 
>40 1 (3.9) 0 (0.0) 9 (34.6) 1.78 
(0.76-
4.15) 
 
0 (0.0) 
 
Table 5-4:  Relationship between the presence of gastric preneoplastic pathology and 
demographic variables – univariate analysis.  
(NB: Bold text indicates significant changes) 
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Demographic 
variable 
Atrophy 
Atrophy 
(without IM) 
IM (%) 
IM 
 (without atrophy) 
A+IM (%) 
 n (%) OR 
(95% 
CI) 
n 
(%) 
OR 
(95% 
CI) 
n (%) OR 
(95% 
CI) 
n (%) OR 
(95% 
CI) 
n (%) OR 
(95% 
CI) 
Smoking status 
Never smoked 
52 
(10.8) 
1.0 
- 
20 
(4.2) 
1.0 
- 
77 
(16.0) 
1.0 - 45 
(9.4) 
1.0 - 32 
(6.7%) 
1.0 - 
Ever smoked 
57 
(10.7) 
0.99 
(0.66-
1.47) 
23 
(4.3) 
1.04 
(0.56-
1.92) 
110 
(20.7) 
1.36 (0.989 
-1.88) 
76 
(14.3) 
1.61 (1.09-
2.38) 
34 
(6.4%) 
0.96 
(0.58-
1.58) 
Alcohol consumption 
No 
62 
(13.8) 1.0 - 
26 
(5.8) 
1.0 
- 
95 
(21.2) 
1.0 - 59 
(13.2) 
1.0 - 36 
(8.0%) 
1.0 - 
Yes 
47 
(8.4) 0.57 
(0.38-
0.85) 
17 
(3.0) 
0.51 
(0.27-
0.94) 
92 
(16.3) 
0.73 (0.53- 
0.998) 
62 
(11.0) 
0.82 (0.56-
1.19) 
30 
(5.3%) 
0.64 
(0.39-
1.06) 
Family history of gastric cancer 
No 
96 
(10.3) 
1.0 
- 
41 
(4.4) 
1.0 - 167 
(17.9) 
1.0 - 112 
(12.0) 
1.0 - 55 
(5.9%) 
1.0 - 
Yes 
13 
(16.3) 
1.69 (0.90-
3.17) 
2 
(2.5) 
0.56 (0.13-
2.53) 
20 
(25.0) 
1.53 (0.90-
2.60) 
9 
(11.3) 
0.93 (0.45-
1.91) 
11 
(13.8%) 
2.54 
(1.27-
5.08) 
 
Table 5-5: Relationship between the presence of gastric preneoplastic pathology and environmental factors such as smoking and 
alcohol consumption and also family history of gastric cancer – univariate analysis. 
(NB: Bold text indicates significant changes) 
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Demographi
c variable 
LGD 
(%) 
HGD 
(%) 
All preneoplastic pathology 
(%) 
Adenocarcinom
a (%) 
 n (%) n (%) n (%) OR 
(95% 
CI) 
n (%) 
Smoking status 
Never 
smoked 
4 
(0.8%
) 
2 
(0.4%
) 
97 
(20.2%) 
1.0 - 3 (0.6%) 
Ever smoked 
8 
(1.5%
) 
2 
(0.4%
) 
134 
(25.2%) 
1.3
3 
(0.991
-1.79) 
5 (0.9%) 
Alcohol consumption 
No 
6 
(1.3%
) 
4 
(0.9%
) 
121 
(27.1%) 
1.0 - 7 (1.6%) 
Yes 
6 
(1.1%
) 
0 
110 
(19.5%) 
0.6
5 
(0.49-
0.88) 
1 (0.2%) 
Family history of gastric cancer 
No 
9 
(1.0%
) 
3 
(0.3%
) 
210 
(22.5%) 
1.0 - 8 (0.9%) 
Yes 
3 
(3.8%
) 
1 
(1.3%
) 
21 
(26.6%
0 
1.2
5 
(0.74-
2.10) 
0 
 
Table 5-6: Relationship between the presence of gastric preneoplastic pathology and 
environmental factors such as smoking and alcohol consumption and also family history 
of gastric cancer – univariate analysis.  
(NB: Bold text indicates significant changes) 
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5.4.7 Univariate associations between bacterial virulence factors, 
concomitant PPI therapy and presence of preneoplastic 
pathology 
 
H. pylori infection (past or current) was significantly associated with 
the presence of gastric preneoplastic pathology in this cohort (Table 5-7). 
Presence of atrophy, intestinal metaplasia and concurrent atrophy and 
intestinal metaplasia (A + IM) were associated with both past and current 
infection with this organism.  
CagA positive H. pylori infection was also significantly associated 
with the presence of gastric preneoplastic pathology. Past and current 
infection with cagA positive H. pylori strain was significantly associated 
with the presence of atrophy, intestinal metaplasia and concurrent atrophy 
and intestinal metaplasia (A + IM).  
Fasting serum gastrin concentrations greater than 100pM were also 
significantly associated with the presence of gastric preneoplastic 
pathology (especially the presence of both atrophy and intestinal 
metaplasia) whereas fasting serum gastrin concentrations of less than 
100pM showed no such association. 
Concurrent PPI therapy was not found to be associated with the 
presence of gastric preneoplastic pathology in this cohort. 
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Variable Atrophy 
Atrophy 
(without IM) 
IM (%) 
IM 
(without atrophy) 
A+IM (%) 
 n (%) OR 
(95% 
CI) 
n (%) OR 
(95% 
CI) 
n (%) OR 
(95% 
CI) 
n (%) OR 
(95% 
CI) 
n (%) OR 
(95% 
CI) 
H. pylori infection 
Negative 
34 
(5.7) 
1.0 
- 
12 
(2.0) 
1.0 
- 
64 
(10.8) 
1.0 
- 
42 
(7.1) 
1.0 - 22 
(3.7%) 
1.0 - 
Past 
30 
(15.3) 
2.97 (1.77-
5.00) 
5 (2.6) 1.27 (0.44-
3.64) 
61 
(31.1) 
1.32 (2.51-
5.56) 
36 
(18.4) 
2.95 (1.83-
4.76) 
25 
(12.8%) 
3.80 
(2.09-
6.90) 
Current 
45 
(20.0) 
4.11 (2.55-
6.61) 
26 
(11.6) 
6.33 (3.13-
12.77) 
62 
(27.6) 
1.15 (2.13-
4.65) 
43 
(19.1) 
3.10 (1.96-
4.90) 
19 
(8.4%0 
2.39 
(1.27-
4.51) 
cagA status 
Negative for H. 
pylori 
72 
(8.5) 
1.0 
- 
27 
(3.2) 
1.0 
- 
128 
(15.0) 
1.0 
- 
83 
(9.8) 
1.0 - 45 
(5.3%0 
1.0 - 
Past 
13 
(21.7) 
2.99 (1.55-
5.79) 
3 (5.0) 1.61 (0.47-
5.46) 
23 
(38.3) 
3.51 (2.02-
6.11) 
13 
(21.7) 
2.56 (1.33-
4.93) 
10 
(16.7%0 
3.58 
(1.71-
7.53) 
Current 
23 
(24.5) 
3.51 (2.07-
5.95) 
13 
(13.8) 
4.90 (2.43-
9.86) 
32 
(34.0) 
2.92 (1.83-
4.65) 
22 
(23.4) 
2.83 (1.67-
4.80) 
10 
910.6%) 
2.13 
(1.04-
4.39) 
Concurrent PPI therapy 
No 
61 
(11.5) 
1.0 
- 
26 
(4.9) 
1.0 - 94 
(17.7) 
1.0 - 
59 
(11.1) 
1.0 - 
35(6.6) 1.0 - 
Yes 
48 
(10.0) 
0.85 (0.57-
1.27) 
17 
(3.5) 
0.71 (0.38-
1.33) 
93 
(19.3) 
1.14 
(0.81-
1.53) 
62 
(12.9) 
1.18 (0.81-
1.73) 
31(6.4) 0.98 
(0.59-
1.61) 
Serum gastrin concentration (pM) 
<40 
47 
(8.1) 
1.0 
- 
22 
(3.8) 
1.0 - 87 
(14.9) 
1.0 
- 
62 
(10.6) 
1.0 - 
25 (4.3) 1.0 - 
40-100 
29 
(11.5) 
1.48 (0.91-
2.41) 
11 
(4.4) 
1.16 (0.55-
2.43) 
48 
(19.0) 
1.34 (0.91-
1.97) 
30 
(11.9) 
1.13 (0.71-
1.80) 
18 (7.1) 1.71 
(0.92-
3.2) 
>100 
28 
(17.3) 
2.39 (1.44-
3.96) 
8 (4.9) 1.33 (0.58-
3.04) 
46 
(28.4) 
2.27 (1.50-
3.42) 
26 
(16.1) 
1.61 (0.98-
2.64) 
20 (12.4) 3.15 
(1.70-
5.83) 
Table 5-7: Relationship between the presence of gastric preneoplastic pathology and presence of H. pylori infection, cagA status of H. pylori, concurrent 
PPI therapy and fasting serum gastrin concentrations – univariate analysis.  
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Variable 
LGD 
(%) 
HGD 
(%) 
All preneoplastic 
pathology (%) 
Adenocarcinoma 
(%) 
 
n 
(%) 
n 
(%) 
n (%) OR 
(95% 
CI) 
n (%) 
H. pylori infection 
Negative 
6 
(1.1%) 
2 
(0.3%) 
76 
(12.8%) 
1.0 - 5 (0.8%) 
Past 
6 
(3.1%) 
2 
(1.0%) 
67 
(34.2%) 
3.54 
(2.52-
5.18) 
1 (0.5%) 
Current 0 0 
88 
(39.1%) 
4.38 
(3.05-
6.28) 
2 (0.9%) 
cagA status 
Negative for H. 
pylori 
10 
(1.2%) 
3 
(0.4%) 
156 
(18.3%) 
1.0 - 6 (0.7%) 
Past 
2 
(3.3%) 
1 
(1.7%) 
26 
(43.3%) 
3.41 
(1.99-
5.85) 
0 
Current 0 0 
45 
(47.9%) 
4.1 
(2.64-
6.36) 
2 (2.1%) 
Concurrent PPI therapy 
No 4 (0.8) 1 (0.2) 120(22.5) 1.0 - 2 (0.4) 
Yes 8(1.7) 3 (0.6) 111(23.1) 1.04 
(0.77-
1.39) 
6 (1.2) 
Serum gastrin concentration (pM) 
<40 9 (1.5) 3(0.5) 111(18.9) 1.0 - 3 (0.5) 
40-100 2 (0.8) 1(0.4) 59(23.3) 1.30 
(0.91-
1.86) 
2 (0.8) 
>100 1 (0.6) 0 55(33.7) 2.18 
(1.48-
3.20) 
3 (1.9) 
 
Table 5-8: Relationship between the presence of gastric preneoplastic pathology and 
presence of H. pylori infection, cagA status of H. pylori, concurrent PPI therapy and 
fasting serum gastrin concentrations – univariate analysis.  
(NB: Bold text indicates significant changes). 
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5.4.8 Multiple logistic regression analysis for the presence of 
preneoplastic pathology 
 
H. pylori infection (past and current) was also observed to be 
significantly associated with the presence of gastric preneoplastic 
pathology by multivariate analysis (table 5-9). Similarly cagA positive H. 
pylori infection was significantly associated with the presence of gastric 
preneoplastic pathology in this cohort, as was a fasting serum gastrin 
concentration greater that 100pM. However concurrent PPI therapy was 
not observed to be associated with the presence of gastric preneoplastic 
pathology. 
Advancing age was associated with the presence of gastric 
preneoplastic pathology by multivariate analysis with no differences 
observed between the sexes. A positive family history of gastric cancer 
was also associated with the presence of gastric atrophy and intestinal 
metaplasia (Table 5-10). However smoking and alcohol consumption 
appeared to have no significant association with the presence of gastric 
preneoplastic pathology in this cohort by multivariate analysis. Results 
summarised in figure 5-3. 
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Variable Atrophy 
Atrophy 
(without IM) 
IM (%) 
IM 
(without atrophy) 
A+IM (%) 
All preneoplastic 
pathology (%) 
 OR 
(95% 
CI) 
OR (95% CI) OR 
(95% 
CI) 
OR (95% CI) OR 
(95% 
CI) 
OR (95% CI) 
H. pylori infection 
Negative 1.0 - 1.0 - 1.0 - 1.0 - 1.0 - 1.0 - 
Past 1.94 
(1.02-
3.67) 
1.28 (0.44-3.69) 2.71 
(1.67-
4.41) 
2.85 (1.74-4.69) 3.22 
(1.71-
6.07) 
2.48 
(1.55-
3.97) 
Current 3.57 
(1.95-
6.54) 
6.90 (3.39-14.04) 2.52 
(1.49-
4.24) 
3.29 (2.05-5.29) 2.71 
(1.38-
5.33) 
3.60 
(2.25-
5.77) 
cagA status 
Negative for H. pylori 1.0 - - - 1.0 - - - - - 1.0 - 
Past 2.25 
(0.98-
5.15) 
- - 1.82 
(0.93-
3.57) 
- - - - 2.16 
(1.11-
3.87) 
Current 1.79 
(0.90-
3.57) 
- - 2.08 
(1.11-
3.89) 
- - - - 2.2 
(1.24-
3.91) 
Concurrent PPI 
therapy 
(Current therapy vs. 
None) 
- - - - - - - - - - - - 
Serum gastrin concentration (pM) 
<40 1.0 - - - 1.0 - - - 1.0 - 1.0 - 
40-100 1.24 
(0.74-
2.08) 
- - 1.10 
(0.72-
1.68) 
- - 1.33 
(0.69-
2.54) 
1.13 
(0.75-
1.68) 
>100 1.99 
(1.17-
3.40) 
- - 1.81 
(1.16-
2.82) 
-  2.3 
(1.21-
4.39) 
1.96 
(1.27-
3.01) 
Table 5-9: Multiple regression analysis: association between bacterial pathogenicity factors, fasting serum gastrin concentrations, PPI therapy and the 
presence of gastric preneoplastic pathology.
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Demographic 
variable 
Atrophy 
 
Atrophy 
(without IM) 
IM 
IM 
(without atrophy) 
A+IM All preneoplastic pathology 
 OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) 
Gender 
Female vs. Male 
- - 
2.17 
 
(1.07, 4.39) 
 
- -   - - - - 
Age             
< 50 1.0 - 1.0 - 1.0 - 1.0 - 1.0 - 1.0 - 
50-70 2.34 (1.26-4.33) 1.28 (0.44-3.69) 1.31 
(0.83-
2.08) 
2.85 (1.74-4.69) 3.71 (1.41, 9.79) 1.30 (0.85, 1.98) 
>70 3.45 (1.77-6.73) 6.90 
(3.39-
14.04) 
2.68 
(1.60-
4.51) 
3.29 (2.05-5.29) 4.91 (1.75,13.78) 2.74 (1.68, 4.48) 
BMI             
18-<25 - - - -   - -   1.0 - 
<18   - -   - -   1.72 (0.62-4.75) 
25 - <30   - -   - -   1.17 (0.79-1.72) 
30 - <40   - -   - -   0.71 (0.45-1.12) 
>40   - -   - -   1.68 (0.65-4.37) 
Smoking status 
Ever compared to never 
- - - - - - - - - - - - 
Alcohol 
consumption 
Any compared to 
none 
0.65 (0.43-1.01) 0.59 (0.31, 1.13) - - - - - - 0.78 (0.56, 1.08) 
Family history 
of gastric cancer 
Positive history 
compared to none 
2.24 (1.14-4.41) - - 1.82 
(1.01-
3.29) 
- - 2.90 (1.34, 6.25) - - 
Table 5-10: Multiple regression analysis: Effects of host, environmental and genetic factors (family history of gastric cancer) on 
the presence of gastric preneoplastic pathology. (NB: Bold text indicates significant changes). 
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Discussion 
Helicobacter pylori is a well recognised gastric carcinogen. Previous 
studies have established that cagA positive strains of H. pylori are more 
likely to be associated with the development of gastric adenocarcinoma 
(as discussed in section 1.4). However only a minority of patients infected 
with this organism develop gastric preneoplastic pathology and progress to 
gastric adenocarcinoma. Therefore several other factors are thought to 
influence the development of gastric preneoplastic pathology and the 
subsequent progression to gastric adenocarcinoma. In the present study, 
the effects of several host (age, gender, BMI, fasting serum gastrin 
concentration and genetic factors), environmental (smoking, alcohol 
consumption and PPI therapy) and bacterial factors (presence of H. pylori 
infection and cagA status of infecting H. pylori) on the development of 
gastric preneoplastic pathology have been analysed using a large cohort 
of adult patients undergoing gastroscopy.  
 
5.4.9 Host factors 
Advancing age was observed to be significantly associated with the 
presence of gastric preneoplastic pathology. This observation is in keeping 
with previous studies (and national statistics) in which gastric 
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adenocarcinoma has been reported to be more prevalent in older people 
(> 65 years of age) (Cancer statistics registration, 2008). However, in the 
present study, the presence of gastric preneoplastic pathology (or gastric 
adenocarcinoma) was not particularly observed to be more prevalent in 
older men as previously described. Female patients on the other hand 
were observed to have a significantly greater prevalence of gastric 
atrophy. It is therefore possible that some of these patients had 
autoimmune rather than H. pylori associated atrophic gastritis. 
A positive family history of gastric cancer (first or second degree 
relative with gastric cancer) was also significantly associated with the 
presence of gastric preneoplastic pathology in the current study. This 
raises the issue of possible genetic factors that may predispose patients to 
the development of gastric adenocarcinoma. None of the patients in this 
cohort with a positive family history of gastric adenocarcinoma had 
features to suggest Hereditary Diffuse Gastric Cancer syndrome, hence 
alternative genetic factors are likely to be involved. 
Elevated BMI (>35) has also been reported in several 
epidemiological studies to be associated with an increased risk of gastric 
cardia adenocarcinoma (and oesophageal adenocarcinoma) (Abnet et al., 
2008; O'Doherty et al., 2011). However no such increased risk has been 
demonstrated with distal or non cardia gastric adenocarcinoma in previous 
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studies. Similarly in this cohort of patients, elevated BMI was not found to 
be significantly associated with the presence of gastric preneoplastic 
pathology, although 64.5% of the cohort had an elevated BMI (>25). 
 
5.4.10 Environmental factors 
Smoking was not found to be associated with the presence of 
gastric preneoplastic pathology in this cohort, contrary to previous studies 
(Tredaniel et al., 1997).  Among the group of patients who had ever 
smoked, distinction between current smokers and ex-smokers has not 
however been made during this analysis.  
Previous studies assessing the effects of alcohol consumption have 
found no significant association between this habit and the development of 
gastric adenocarcinoma (Steevens et al., 2010). However in the present 
study, univariate analysis suggested that alcohol consumption may have a 
small beneficial effect (OR = 0.65; 95% CI = 0.49-0.88). No such effect 
was however demonstrated following multivariate analysis. One of the 
shortcomings of the current study is that data regarding self reporting of 
alcohol consumption may not be a true reflection of actual consumption 
(as has been discussed in chapter 3). Furthermore distinction between 
those who consumed alcohol within recommended limits and those who 
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consumed amounts above such limits has not been made. Differences in 
the various types of alcohol consumed (for example beer vs. wine vs. 
spirits) have also not been addressed.  
Other factors such as diet including the consumption of fatty and 
highly processed foods and intake of fresh fruits and red meat have not 
been addressed in the current study. There is already some evidence to 
suggest that diet influences the development of gastric adenocarcinoma 
especially in susceptible individuals and this has been discussed in detail 
in section 1.5.2. Specific diets, especially adherence to a ‘Mediterranean 
Diet’ has been suggested in some studies to be beneficial in protecting 
against the development of gastric adenocarcinoma (Buckland et al., 
2010). Processed meat, red meat and total meat intake have also been 
previously linked to an increased risk of developing gastric 
adenocarcinoma (Gonzalez et al., 2006; Ngoan et al., 2002).  
 
5.4.11 Gastrin 
The role of gastrin in the development of gastric adenocarcinoma 
has been described in several studies. Its influence on the progression of 
gastric preneoplastic pathology through its effects on angiogenesis, gastric 
epithelial cell mitosis, proliferation and migration has been previously 
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discussed (section 1.3.2.2). In the present study, elevated fasting serum 
gastrin concentrations (>100 pM) were significantly associated with the 
presence of gastric preneoplastic pathology (both atrophy and intestinal 
metaplasia). It has also been previously demonstrated in humans that 
moderate hypergastrinaemia (fasting serum gastric concentration >150pM) 
was associated with increased apoptosis of gastric epithelial cells in the 
presence of infection with H. pylori (Przemeck et al., 2008).  
 
5.4.12 Proton pump inhibitors (PPI) 
Concerns have previously been raised regarding the possible role 
played by acid suppressing drug therapy, especially proton pump inhibitors 
(PPI), in the development of gastric adenocarcinoma. It has been 
suggested that the increased fasting serum gastrin concentrations 
resulting from the achlorhydria or hypochlorhydria which are associated 
with PPI therapy could potentially increase the risk of developing gastric 
preneoplastic changes. However epidemiological studies have failed to 
demonstrate this association (Bateman et al., 2003; Garcia Rodriguez et 
al., 2006; Poulsen et al., 2009). Although both univariate and multivariate 
analyses found no significant association between the presence of gastric 
preneoplastic pathology and concurrent PPI therapy there are certain 
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limitations in this study. The effects of the dosage or the duration of 
treatment with proton pump inhibitors on gastric preneoplastic pathology 
was not analysed. Previous studies have reported an increased incidence 
of atrophic gastritis in patients treated with proton pump inhibitors in the 
presence of current H. pylori infection (Kuipers et al., 1996). Long term 
exposure to proton pump inhibitors (6 months) has been demonstrated to 
worsen atrophic gastritis leading to gastric adenocarcinoma development 
in Mongolian gerbils infected with H. pylori (Hagiwara et al., 2011).  
Although at the time of recruitment to the study it was possible to ascertain 
whether patients were on a current proton pump inhibitor therapy, further 
details regarding dose, duration of treatment (including change of proton 
pump inhibitor therapy due to perceived lack of efficacy) and compliance 
with therapy was not recorded.  
5.4.13 H. pylori and cagA positive H. pylori infection 
 This study has confirmed the well described association between 
H. pylori infection and presence of gastric preneoplastic pathology. What 
this study also demonstrates is that this effect persists even after 
eradication or disappearance of this organism. 
Similarly cagA positive H. pylori infection was observed to be 
significantly associated with the presence of gastric preneoplastic 
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pathology. Animal studies have previously demonstrated an association 
between infection with this strain of H. pylori and the occurrence of gastric 
atrophy (in Mongolian gerbils) (Rieder et al., 2005). Other studies in 
humans have demonstrated that the odds ratio of developing gastric 
adenocarcinoma was significantly higher in those patients with cagA 
positive H. pylori infection as compared with those with cagA negative H. 
pylori infection and especially in those patients presenting at a younger 
age and with more advanced disease (Blaser et al., 1995) as previously 
discussed in section 1.4.4. 
 
5.5 Conclusions 
This study has therefore confirmed the known association between 
H. pylori infection and the presence of gastric preneoplastic pathology. 
Host factors such as advancing age, bacterial virulence factor namely 
cagA and elevated fasting serum gastrin concentrations (>100pM) were 
also significantly associated with the presence of gastric preneoplastic 
pathology. Concurrent PPI therapy was not however associated with the 
presence of gastric preneoplastic pathology. Although no effects were 
observed with smoking, alcohol consumption may have a small beneficial 
effect. Further studies are therefore warranted to address the effects of 
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these exogenous factors on the development and progression of gastric 
preneoplastic pathology. 
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Chapter 6 
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6 Determinants of human fasting serum gastrin concentration – 
interaction between H. pylori infection, gastric preneoplastic 
pathology and proton pump inhibitor use 
 
6.1 Introduction 
The hormone gastrin plays an important role not only in the regulation 
of gastric acid secretion but also through its effects on cell proliferation, 
apoptosis and angiogenesis, it regulates gastric epithelial and ECL-cell 
growth. Long standing hypergastrinaemia in the setting of autoimmune 
atrophic gastritis results in ECL-cell hyperplasia and in some patients this 
can progress to type-1 gastric neuroendocrine tumours. 
Hypergastrinaemia can develop due to several factors and this has been 
previously discussed in detail in section 1.3. Fasting serum gastrin 
concentrations are often measured during the investigation of suspected 
gastrin secreting tumours such as Zollinger Ellison syndrome as well as 
during assessment of gastric neuroendocrine tumours. However 
interpretation of a fasting serum gastrin concentration is complicated 
because factors such as Helicobacter pylori infection, presence of gastric 
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preneoplastic pathology (especially atrophic gastritis) and concurrent 
proton pump inhibitor (PPI) therapy can all influence this parameter. 
Advancing age was previously considered to be associated with elevated 
fasting serum gastrin concentrations, but subsequent studies have 
demonstrated that this association was observed only in the presence of 
H. pylori  infection or gastric atrophy (Katelaris et al., 1993; Jassel et al., 
1999). Additionally it is also not known to what extent other factors such as 
gender, BMI and family history of gastric cancer influence fasting serum 
gastrin concentrations. Environmental factors including smoking and 
alcohol consumption may also have an additional effect on fasting serum 
gastrin concentrations. As the interactions between these various factors 
remain poorly understood, we have investigated how they influence fasting 
serum gastrin concentrations in our previously described cohort of 
prospectively recruited patients (described in section 2.1). 
 
6.2 Methods 
Patients enrolled in the study (described in section 2.1) funded by the 
National Institute of Health Research (NIHR) Biomedical Research Centre 
in Microbial diseases at Royal Liverpool and Broadgreen University 
Hospitals NHS Trust, Liverpool, UK, were recruited in this analysis. 
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Clinical data recorded at recruitment, estimation of H. pylori and 
cagA serology, gastric antral and corpus biopsy analysis, measurements 
of fasting serum gastrin concentration are already discussed in detail in 
sections 2.1 to 2.3.   
6.3 Statistical analysis 
Statistical analysis was performed on cases with no missing data for 
the variables that were being assessed. Statistical analysis was performed 
using statistical software SAS v9.2 by statisticians Mr. Girvan Burnside 
(Lecturer in Medical Statistics, Department of Biostatistics, University of 
Liverpool) and Mr. Andrew McKay (Research Assistant, Clinical Trials 
Research Centre, University of Liverpool) working in liaison with the 
Biomedical Research Centre and the University of Liverpool 
6.4 Results:  
Of the 1017 patients recruited to the study, 2 patients with an 
established diagnosis of pernicious anaemia and a further 13 patients who 
did not have complete data sets were excluded from the final analysis. Of 
the 1002 patients included in the analysis, 564 (56.3%) were female and 
476 (47.5%) were on a concurrent proton pump inhibitor. 223 (22.3%) 
patients had evidence of current infection with H. pylori infection (as 
evidenced by the presence of this organism on histological analysis of 
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gastric antral and corpus biopsies or by the presence of a positive rapid 
urease test and positive serology) and 196 (19.6%) had evidence of 
previous infection with this organism (as evidenced by  positive serology). 
225 (22.4%) patients had evidence of preneoplastic pathology on 
histological examination of gastric biopsy samples (defined as the 
presence of one or more of atrophy, intestinal metaplasia and dysplasia). 
Figure 6-1 shows the distribution of fasting serum gastrin 
concentrations in this cohort. 586 (58.5%) patients had fasting serum 
gastrin concentrations <40pM; 253 (25.2%) had fasting serum gastrin 
concentrations between 40 and 100pM, 145 (14.5%) had fasting serum 
gastrin concentrations between 100 and 400pM and the remaining 18 
(1.8%) had serum fasting gastrin concentrations >400pM. 
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Figure 6-1: Graph depicting the percentage distribution of fasting serum 
gastrin concentrations in the cohort. 
 
6.4.1 Fasting serum gastrin concentrations in patients without H. 
pylori infection, not on a concurrent PPI, with a normal 
gastroscopy and with no evidence of gastric preneoplastic 
pathology  
In this cohort, 207 (20.6%) patients had a normal gastroscopy 
without evidence of current or past evidence of H. pylori infection (H. pylori 
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negative) and with no evidence of gastric preneoplastic pathology on 
histological analysis of gastric antral and corpus biopsies. This group of 
patients were not on concurrent proton pump inhibitors or H2 receptor 
antagonist therapy. The median fasting serum gastrin concentration in this 
group of patients was 19.9 pM (IQR 14.8, 29). The mean fasting serum 
gastrin concentration in this cohort was 38.4 pM (95% CI; 38.0-38.8) and 
this probably reflects the ‘normal’ range for fasting serum gastrin 
concentration in this cohort. 
 
6.4.2 Does H. pylori infection influence fasting serum gastrin 
concentration? 
In this cohort, 583 (58.2%) patients were negative for H. pylori 
infection, 223 (22.2%) had evidence of current infection and 196 (19.6%) 
had evidence of past infection with this organism (table: 6-1). Patients with 
H. pylori infection as a group (combining current and past infection) had 
significantly higher fasting serum gastrin concentrations (p<0.001, Kruskal 
Wallis analysis) compared to patients who had no evidence of infection 
with this organism. Patients with current evidence of H. pylori infection and 
with past only infection with this organism also had significantly elevated 
fasting serum gastrin concentrations (p<0.001, Kruskal Wallis analysis). 
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6.4.2.1 Does cagA positive H. pylori infection influence fasting serum 
gastrin concentration? 
154 (36.7%) patients with evidence of H. pylori infection had infection 
with the cagA strain of H. pylori (94 patients had evidence of current 
infection and 60 patients had evidence of previous infection with this 
organism). Infection with a cagA positive strain of H. pylori was not found 
to be associated with significantly elevated fasting serum concentrations 
compared to infection with a cagA negative strain of H. pylori infection 
(table 6-2). 
 
6.4.3 Does concurrent acid suppression affect serum gastrin 
concentration? 
476 (47.5%) patients were on concurrent PPI therapy (table: 6-1). 
Patients on concurrent PPI therapy had significantly elevated fasting 
serum gastrin concentrations (p<0.001, Mann-Whitney test) compared to 
those not on PPI therapy. 
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6.4.4 Does the presence of gastric preneoplastic changes 
influence fasting serum gastrin concentration? 
225 (22.4%) patients had evidence of gastric preneoplastic 
pathology (table: 6-1). Presence of gastric preneoplastic pathology was 
significantly associated with elevated fasting serum gastrin concentrations 
compared to patients with no evidence of gastric preneoplastic pathology 
(p<0.001, Mann-Whitney test).  
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Variable Level 
Total 
number 
of 
patients  
Median 
fasting serum 
gastrin  
concentration  
(pM) 
IQR Range p-value 
H. pylori 
Negative 583 30 (18,62) 
1.2 to 
900 
<0.001 
(Kruskal 
Wallis 
test) 
Current 
positive 
223 30 (20,66) 
3 to 
795.8 
Past 
positive 
196 49 (22,120) 
5.8 to 
1256.6 
PPI 
No 526 22.7 (16,38) 
1.2 to 
1256.6 <0.001     
(Mann-
Whitney 
test) Current 476 50.5 (28,96) 
5.8 to 
680 
Preneoplastic 
pathology 
No 777 30 (18,64) 
1.2 to 
1256.6 <0.001     
(Mann-
Whitney 
test) Yes 225 40 (22,96) 
6.4 to 
680 
 
Table 6-1: The effect of H. pylori infection, concurrent PPI therapy 
and presence of gastric preneoplastic pathology on fasting serum gastrin 
concentrations. 
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cagA status Fasting serum gastrin concentrations (pM) 
‘<40’ 
n (%) 
‘40-100’ 
n (%) 
‘>100’ 
n (%) 
odds of ‘<40’ -> ‘40-100’ odds of ‘<40’ -> ‘>100’ 
OR1 (95% CI) OR2 (95% CI) 
Overall cagA status 
cagA  -ve infection 137 (32.7%) 69 (16.5%) 56 (13.4%) 1.0 - 1.0 - 
cagA +ve infection 84 (20%) 41(9.8%) 29 (6.9%) 0.96 (0.60 - 1.55) 0.84 (0.50-1.42) 
Current H. pylori  infection 
cagA  -ve infection 81 (19.3%) 25 (5.9%) 20 (4.8%) 1.0  - 1.0 - 
cagA +ve infection 57 (13.6%) 26 (6.2%) 11 (2.6%) 1.47 (0.77 - 2.81) 0.78 (0.34 - 1.75) 
Past H. pylori  infection 
cagA -ve infection 56 (13.4%) 44 (10.5%) 36 (8.6%) 1.0 - 1.0 - 
cagA  +ve infection 27 (6.4%) 15 (3.6%) 18 (4.3%) 0.70 (0.33 - 1.48) 1.03 (0.50 - 2.14) 
 
Table 6-2: The effect of cagA positive H. pylori infection on fasting serum gastrin concentrations.
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6.4.5 How do H. pylori infection, concurrent proton pump inhibitor 
therapy and the presence of gastric preneoplastic pathology 
interact to influence fasting serum gastrin concentrations? 
We analysed interactions of the three main factors namely presence 
of H. pylori infection, concurrent PPI therapy and presence of gastric 
preneoplastic pathology on fasting serum gastrin concentrations. Patients 
were differentiated into 12 different categories depending on the presence 
or absence of gastric preneoplastic pathology, concurrent PPI therapy and 
whether there was evidence of current or past H. pylori infection (as 
outlined in table 6-2). 
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 Categories Number 
of 
patients 
Median fasting 
serum gastrin 
concentration 
(pM) 
IQR Range 
 All 1002 32 (19.2, 
74) 
1.2 to 
1256.7 
A H. pylori negative / current PPI / 
preneoplastic pathology 
39 54 (33, 
120) 
11.2 to 
628 
B H. pylori negative / current PPI / No 
preneoplastic pathology 
255 46 (30, 84) 8.8 to 680 
C H. pylori negative / No PPI / 
preneoplastic pathology 
33 30 (19.6, 
160) 
7.6 to 680 
D H. pylori negative / No PPI / No 
preneoplastic pathology 
256 19.9 (14.8, 
29) 
1.2 to 900 
E H. pylori current positive / current PPI / 
preneoplastic pathology 
33 66 (32, 
120) 
11.2 to 
520 
F H. pylori current positive / current PPI / 
No preneoplastic pathology 
35 51 (28, 
108) 
11.6 to 
172 
G H. pylori current positive / No PPI / 
preneoplastic pathology 
53 28 (19.2, 
64) 
10 to 629 
H H. pylori current positive / No PPI / No 
preneoplastic pathology 
102 26 (19.8, 
40) 
3 to 795.8 
I H. pylori past positive / current PPI / 
preneoplastic pathology 
37 40 (26, 86) 6.4 to 
449.2 
J H. pylori past positive / current PPI / 
No preneoplastic pathology 
77 68 (32, 
136) 
5.8 to 400 
K H. pylori past positive / No PPI / 
preneoplastic pathology 
30 47 (24, 
220) 
13.6 564.2 
L H. pylori past positive / No PPI / No 
preneoplastic pathology 
52 25 (16.2, 
86) 
7.4 1256.7 
Table 6-3: Pairwise differences in fasting serum gastrin concentrations 
between groups (Mann-Whitney U-tests). The pairs of interest were 
specified in advance (23 pairs), and the p-values were adjusted using a 
Bonferroni correction to account for the multiple comparisons. 
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In H. pylori negative patients, concurrent PPI therapy and the 
presence of gastric preneoplastic pathology were both individually 
associated with significantly elevated fasting serum gastrin concentrations 
(groups D vs. C; B vs. C – table 6-3). In the presence of both these factors 
(concurrent PPI therapy and presence of gastric preneoplastic pathology), 
H. pylori negative patients also had significantly elevated fasting serum 
gastrin concentrations compared to those without either of these factors 
(group A vs. D; table 6-3). In H. pylori negative patients on concurrent PPI 
therapy, the additional presence of gastric preneoplastic pathology did not 
significantly alter fasting serum gastrin concentrations (figure 6-2).  
Current H. pylori infection caused significantly elevated fasting serum 
gastrin concentrations compared to H. pylori negative patients (in the 
absence of PPI use or preneoplastic pathology; group H vs. D) (figure 6-3). 
In those patients with current H. pylori infection compared to H. pylori 
negative patients, concurrent PPI therapy or presence of gastric 
preneoplastic pathology did not significantly alter fasting serum gastrin 
concentrations. 
In patients with current H. pylori infection, concurrent PPI therapy 
was associated with significantly elevated fasting serum gastrin 
concentrations irrespective of the presence or absence of gastric 
preneoplastic pathology (groups E vs. H and F vs. H; table 6-3). 
Preneoplastic pathology however had no significant effect on fasting 
serum gastrin concentrations in the presence of current H. pylori infection 
(group G vs. H; table 6-3). 
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Past H. pylori infection was not associated with significantly elevated 
fasting serum gastrin concentrations compared to H. pylori negative 
patients (in the absence of preneoplastic pathology and in patients not on 
concurrent PPI;  group L vs. D; table 6-3).). Preneoplastic pathology was 
also not associated with significantly elevated fasting serum gastrin 
concentrations in this group. However in those patients with evidence of 
past H. pylori infection, concurrent PPI therapy was again associated with 
significantly elevated fasting serum gastrin concentrations but only in the 
absence of preneoplastic pathology (p=0.034) ( group J vs. L; table 6-3 
and figure 6-4). 
 
 
 
 
 
 
. 
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 A B C D E F G H I J K L 
A  1.000 1.000 <0.001 1.000    1.000    
B    <0.001  1.000    0.156   
C    0.033   1.000    1.000  
D        0.001    0.371 
E      1.000 0.035 0.001     
F        0.001     
G        1.000     
H             
I          1.000 1.000 1.000 
J            0.034 
K            0.772 
L             
Table 6-4: p-values from pre-specified pairwise comparisons of categories (Mann-Whitney U-test) adjusted using 
Bonferroni’s method. Statistically significant differences (p<0.05) are shown in bold.  
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In addition to the above factors we also analysed the effect of host 
and environmental factors on fasting serum gastrin concentrations as 
detailed below. 
 
6.4.6 Effect of age and gender of patients on fasting serum gastrin 
concentrations 
Univariate analysis suggested that increasing age was associated 
with increased fasting serum gastrin concentrations (40-100pM and 
>100pM) (table 6-4), but patient gender did not appear to influence fasting 
serum gastrin concentrations in this cohort.  
However, in the subgroup of those patients who were negative for 
infection with H. pylori, who did not demonstrate gastric preneoplastic 
pathology and were not on a concurrent PPI therapy, age did not influence 
fasting serum gastrin concentrations (table 6-5). Thus age is likely to be an 
indirect factor by its association with H. pylori infection and presence of 
preneoplastic pathology. 
 
6.4.7 Effect of body mass index on fasting serum gastrin 
concentrations 
Univariate analysis demonstrated a significant association between 
BMI of patients and increased fasting serum gastrin concentrations only at 
the extreme ends of the BMI spectrum (table 6-4). Patients who were 
underweight (BMI<18.5) and those who were morbidly obese (BMI>40) 
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were both found to have a significantly greater prevalance of fasting serum 
gastrin concentrations >100pM. 
 
6.4.8 Effects of smoking and alcohol consumption on fasting 
serum gastrin concentrations 
Smoking was associated with a greater frequency of mildly 
increased fasting serum gastrin concentration (40-100pM) in this cohort of 
patients by univariate analysis (table 6-5). Alcohol consumption was 
however found to be associated with lower frequencies of more markedly 
elevated fasting serum gastrin concentrations (>100pM).  
 
6.4.9 Associations between positive family history of gastric 
cancer and fasting serum gastrin concentrations 
Univariate analysis showed no significant association between 
fasting serum gastrin concentrations and a positive family history of gastric 
cancer (table 6-5). 
 
6.4.10 Multiple logistic regression 
Generalised multiple logistic regression analysis demonstrated 
increased prevalance of elevated fasting serum gastrin concentrations only 
in older patients and a decreased prevalance in those subjects who 
consumed alcohol. No effects were demonstrated with BMI, smoking, 
gender or a positive family history of gastric cancer (table 6-5). 
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Host factors Fasting serum gastrin concentrations (pM) 
‘<40’ 
n (%) 
‘40-100’ 
n (%) 
‘>100’ 
n (%) 
odds of ‘<40’ -> ‘40-100’ odds of ‘<40’ -> ‘>100’ 
OR1 (95% CI) OR2 (95% CI) 
Gender 
Male 267 (61.0) 108 (24.7) 63 (14.4) 1.0 - 1.0 - 
Female 319 (56.6) 145 (25.7) 100 (17.7) 1.12 (0.84-1.51) 1.33 (0.93-1.89) 
Age at baseline 
<50 225 (73.3) 52 (16.9) 30 (9.8) 1.0 - 1.0 - 
50-70 251 (52.7) 140 (29.4) 85 (17.9) 2.41 (1.67-3.48) 2.54 (1.61-4.00) 
>70 110 (50.2) 61 (27.9) 48 (21.9) 2.40 (1.55-3.71) 3.27 (1.97-5.45) 
Body Mass Index (BMI): n (%) 
18.5-24.9: Normal (ref. cat.) 207 (62.5) 76 (23.0) 48 (14.5) 1.0 - 1.0 - 
16.0-18.4: Underweight 10 (47.6) 4 (19.1) 7 (33.3) 1.09 (0.33-3.58) 3.02 (1.09-8.33) 
25.0-29.9: Overweight 214 (58.8) 98 (26.9) 52 (14.3) 1.25 (0.87-1.78) 1.05 (0.68-1.62) 
30.0-39.9: Obese 138 (54.6) 67 (26.5) 48 (19.0) 1.32 (0.89-1.96) 1.50 (0.95-2.36) 
>=40.0: Morbidly obese 11 (44.0) 7 (28.0) 7 (28.0) 1.73 (0.65-4.63) 2.74 (1.01-7.45) 
 
Table 6-5 Univariate associations between fasting serum gastrin concentrations and host factors 
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Host factors Fasting serum gastrin concentrations (pM) 
‘<40’ 
n (%) 
‘40-100’ 
n (%) 
‘>100’ 
n (%) 
odds of ‘<40’ -> ‘40-100’ odds of ‘<40’ -> ‘>100’ 
OR1 (95% CI) OR2 (95% CI) 
Age at baseline 
<50 92 (36.5) 8 (3.2) 4 (1.6) 1.0 - 1.0 - 
50-70 90 (35.7) 9 (3.6) 5 (1.9) 1.15 (0.42-3.11) 1.27 (0.33-4.91) 
>70 38 (15.1) 4 (1.6) 2 (0.8) 1.21 (0.34-4.26) 1.21 (0.21-6.88) 
 
Table 6-6 Univariate association between age and fasting serum gastrin concentrations in H. pylori negative patients 
without   gastric preneoplastic pathology and who were not on concurrent PPI therapy. 
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Environmental factors and family history Fasting serum gastrin concentration (pM) 
 
‘<40’  
n (%) 
 
’40-100’  
n (%) 
 
‘>100’  
n (%) 
odds of ‘<40’ -> ‘40-100’ odds of ‘<40’ -> ‘>100’ 
OR1 (95% CI) OR2 (95% CI) 
Smoking status at baseline 
Never 298 (63.3) 104 (22.1) 69 (14.7) 1.0 - 1.0 - 
Ever 287 (54.3) 149 (28.2) 93 (17.6) 1.49 (1.10-2.01) 1.40 (0.985-1.99) 
Alcohol consumption 
None 238 (54.0) 113 (24.9) 90 (20.4) 1.0 - 1.0 - 
Any 346 (62.0) 139 (24.9) 73 (13.1) 0.85 (0.63-1.14) 0.56 (0.39-0.79) 
Family History of Gastric Cancer  
No 541 (58.7) 232 (25.2) 149 (16.2) 1.0 - 1.0 - 
Yes 44 (56.4) 20 (25.6) 14 (18.0) 1.06 (0.61-1.84) 1.16 (0.62-2.17) 
 
Table 6-7: Univariate associations between fasting serum gastrin concentrations and environmental factors and family 
history of gastric cancer
211 
 
 
 
Demographic  
variable 
Fasting serum gastrin concentration (pM) 
Odds of ‘<40’; 40-100 Odds of <40; >100 
OR1 (95% CI) OR2 (95%CI) 
Gender 
Female compared 
to male 
- - - - 
Age at baseline 
< 50 1.0 - 1.0 - 
50-70 2.13 (1.43-3.18) 1.99 (1.23-3.23) 
>70 2.20 (1.36-3.58) 2.17 (1.24-3.82) 
BMI 
<18     
18 -<25     
25 - <30     
30 - <40     
>40     
Smoking status at 
baseline: ever – 
compared to never 
    
Drinking alcohol: 
any – compared to 
none 
0.95 (0.69-1.32) 0.59 (0.40-0.86) 
Family History of 
Gastric Cancer – 
compared to none 
 
 
  
 
Table 6-8: Generalised multiple logistic regression analysis for fasting 
serum gastrin concentrations with demographic variables. 
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6.5 Discussion 
Several factors have been demonstrated in previous studies to 
influence fasting serum gastrin concentrations in humans. These include 
 Host factors such as age and the presence of gastric 
preneoplastic changes 
 Bacterial factors, namely H. pylori infection 
 Environmental factors including PPI therapy 
However studies that have analysed the interactions between the 
above three factors and their effects on fasting serum gastrin 
concentrations have not been published to date. We have demonstrated in 
the current study several interactions between these factors and their 
effects on fasting serum gastrin concentrations.  
H. pylori infection can cause mild to moderate elevations in fasting 
serum gastrin concentrations by two potential mechanisms. Firstly, antral 
predominant infection results in inhibition of somatostatin release which in 
turn causes hypergastrinaemia. The second mechanism involves the 
development of G-cell hyperplasia and hypergastrinaemia as result of 
achlorhydria due to chronic atrophic gastritis resulting from corpus 
predominant H. pylori infection (Murugesan et al., 2009). cagA positive H. 
pylori infection has been shown to be associated with a significantly higher 
incidence of peptic ulcers and gastric adenocarcinoma. This has been 
attributed to the higher inflammatory response evoked secondary to 
infection with this strain of H. pylori. It would therefore appear that similar 
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mechanisms may stimulate gastrin secretion. However studies have 
shown variable effects of cagA positive H. pylori infection on fasting serum 
gastrin concentrations. In a study of cagA positive H. pylori infection  in 
children no significant changes in fasting serum gastrin concentrations 
were observed (Fukuda et al., 2003).  Similarly, in the present study of 
adult patients, cagA positive H. pylori infection was not found to be 
significantly associated with elevated fasting serum gastrin concentrations. 
PPI therapy has also been associated with  mild to moderate 
hypergastrinaemia secondary to hypochlorhydria and G-cell hyperplasia 
(Murugesan et al., 2009). 
In the present study, H. pylori infection, concurrent PPI therapy and 
presence of gastric preneoplastic pathology were all individually found to 
be associated with significant elevations in fasting serum gastrin 
concentrations. 
Previous studies have also demonstrated the effect of concurrent 
PPI therapy in causing more pronounced elevation of fasting serum gastrin 
concentrations in patients with current H. pylori infection than that was 
observed with H. pylori infection alone (El-Nujumi et al., 1998; El-Omar et 
al., 1993).  A similar interaction between current H. pylori infection and 
concurrent PPI therapy was observed in the present study. Moreover this 
effect was seen irrespective of the presence or absence of gastric 
preneoplastic pathology.   
However in patients with past rather than current evidence of H. 
pylori infection, concurrent PPI therapy was significantly associated with 
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elevated fasting serum gastrin concentrations only in the absence of 
gastric preneoplastic pathology suggesting that this effect may be 
mediated mainly through PPI induced hypochlorhydria. 
Older subjects have previously been reported to have higher fasting 
serum gastrin concentrations compared to younger subjects. However 
concentrations are often still within the normal range in the absence of 
other factors such as H. pylori infection or presence of gastric 
autoantibodies (Jassel et al., 1999). In the current study, we found a 
similar association between advancing age and elevated fasting serum 
gastrin concentrations. This is likely to be partly attributable to PPI use, H. 
pylori infection and gastric atrophy since no significant difference in fasting 
serum gastrin concentrations was observed with advancing age in the 
group of H. pylori negative patients who had no gastric preneoplastic 
pathology and were not on concurrent PPI therapy. 
In addition, other host factors such as BMI have also been shown to 
influence fasting serum gastrin concentrations. Body mass index at either 
ends of the spectrum (BMI <18.5 and >40) were also found to be 
significantly associated with fasting serum gastrin concentrations >100pM 
in the current study. A positive association between elevated fasting serum 
gastrin concentrations and elevated BMI has been described in a previous 
human study (Lindstedt et al., 1985b) and in animal studies where 
hypergastrinaemia was demonstrated to be secondary to low overall 
gastric acid output (Morton et al., 1985).  However an association between 
low BMI and elevated fasting serum gastrin concentrations has not been 
previously reported.  
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In the current study, cigarette smoking was found to be associated 
with elevated fasting serum gastrin concentrations during univariate 
analysis. Cigarette smoking has been demonstrated to be a significant risk 
factor for the development of gastric adenocarcinoma (Steevens et al., 
2010). However the exact mechanisms that are involved are not entirely 
understood. Results from the current study suggest that smoking may 
possibly increase the risk of gastric adenocarcinoma through its effects on 
fasting serum gastrin concentrations.  
Alcohol consumption on the other hand was found in this cohort to 
be associated with significantly lower fasting serum gastrin concentrations. 
Recent studies have found no significant associations between alcohol 
consumption and risk of developing gastric cancer (Steevens et al., 2010). 
However one of the limitations of the current study is that the differentiation 
between various amounts of alcohol consumed was not determined. 
Hence further studies are required to address the role played by alcohol in 
influencing fasting serum gastrin concentrations.  
 
6.6 Conclusions 
There are complex interactions between H. pylori infection, PPI use 
and the presence of gastric preneoplastic pathology in determining fasting 
serum gastrin concentrations. In addition, other host and environmental 
factors also appear to influence fasting serum gastrin concentrations. For 
example PPI use only appears to cause hypergastrinaemia in the absence 
of gastric preneoplastic pathology in patients with previous H. pylori 
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infection. With concurrent PPI therapy, current H. pylori infection is 
associated with significantly elevated fasting serum gastrin concentrations 
unrelated to the presence of absence of gastric preneoplastic pathology. 
Concurrent PPI therapy and the presence of gastric preneoplastic 
pathology (in those patients without evidence of H. pylori infection) were 
both significantly associated with elevated fasting serum gastrin 
concentrations.  These factors should therefore be taken into consideration 
when interpreting fasting serum gastrin concentrations in individual 
patients. 
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Chapter 7 
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7 Investigation of factors that influence the progression of type-1 
gastric neuroendocrine (NET) tumours 
 
7.1 Introduction 
Type-1 gastric neuroendocrine (carcinoid) tumours (NETs) are the 
most common gastric neuroendocrine tumours (Bordi, 1999). Achlorhydria, 
caused by loss of acid secreting parietal cells resulting from autoimmune 
atrophic body gastritis (pernicious anaemia) results in antral G cell 
hyperplasia and unopposed gastrin secretion (due to loss of negative 
feedback inhibition). The resulting hypergastrinaemia stimulates ECL-cell 
hyperplasia and in some patients type-1 gastric carcinoid tumour formation 
(Annibale et al., 2001a). This has been discussed in detail in sections 
1.3.2.3 and 1.6. However not all patients with autoimmune atrophic 
gastritis develop type-1 gastric carcinoid tumours, with only about 5% of 
patients developing such tumours. Therefore factors in addition to 
achlorhydria and hypergastrinaemia are likely to influence the 
development of type-1 gastric carcinoid tumours in individual patients. 
Such factors however currently remain poorly understood. We therefore 
hypothesised that the following factors may influence the development of 
type-1 gastric carcinoid tumours in susceptible patients with autoimmune 
gastric atrophy:  
1. The extent and characteristics of gastric atrophy as determined 
by the severity of the associated hypergastrinaemia, whether 
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there was  associated vitamin B12 and/ or iron deficiency and 
the presence of autoantibodies namely anti-intrinsic factor and 
anti-gastric parietal cell antibodies 
2. Evidence of previous or co-existent H. pylori infection 
3. Presence of other autoimmune diseases such as 
hypothyroidism 
We therefore analysed the importance of the above factors by assessing 
patients with chronic atrophic gastritis and varying degrees of ECL-cell 
hyperplasia and others with type-1 gastric NETs. 
 
7.2 Methods   
Local adult ethics committee approval and informed patient consent 
was obtained from participating patients who were attending for a 
diagnostic gastroscopy at the Royal Liverpool and Broadgreen University 
Hospital (RLBUHT) for clinical indications. Patients with histologically 
confirmed atrophic corpus gastritis and ECL-cell abnormalities were 
included in this study. Clinical and demographic data including age, sex, 
and concurrent drug use were recorded.  
 At gastroscopy the total number of visible carcinoid polyps/nodules 
was counted for each individual patient and the maximum diameter of 
polyps was measured by comparison with the open jaws of standard 
biopsy forceps which measures approximately 8mm. Two biopsies were 
taken from the gastric antrum and corpus. Patients were deemed to have 
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current H. pylori infection if this organism was seen by histological analysis 
of either antral or corpus biopsies.  
Gastric corpus biopsies taken at the time of gastroscopy were 
assessed (by a Consultant Gastrointestinal Histopathologist at RLBUHT) 
for  
 The presence of gastric atrophy 
 Degree and extent of ECL-cell hyperplasia following 
chromogranin and or synaptophysin immunohistochemistry and 
 Presence of H. pylori infection 
Gastric corpus biopsies were analysed for the presence of ECL-cell 
hyperplasia and the extent of this hyperplasia was classified by an 
experienced GI histopathologist based on well defined criteria (Delle et al., 
2005; Solcia et al., 1988) as:  
 Simple (diffuse) ECL-cell hyperplasia (increase in number of 
ECL-cells by over 2 standard deviations over normal values) 
 Linear ECL-cell hyperplasia (consisting of linear sequences of 
a minimum of 5 ECL-cells lying inside the basement 
membrane and at least two such chains seen per millimetre of 
the gastric mucosa) 
 Micronodular ECL-cell hyperplasia (clusters of 5 or more cells 
of around 30-150 µm diameter in the lamina propria or within 
glands and at least one micronodule per millimetre of the 
gastric mucosa)  
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 Dysplastic ECL-cells (lesions between 150-500 µm located 
deep in the oxyntic mucosa with no evidence of deeper 
infiltration) 
 Carcinoid tumours (greater than 0.5 mm diameter and confined 
to the mucosa and submucosa with neighbouring endocrine 
cells showing hyperplasia or dysplasia.  
 
Fasting blood obtained at the time of gastroscopy was analysed for 
serum gastrin concentration by radioimmunoassay at the Physiological 
laboratory, University of Liverpool, as detailed in section 2.3. In some 
patients, fasting serum gastrin concentrations were measured using an in-
house RIA method (using a rabbit polyclonal antibody) at the Royal 
Hammersmith Hospital, London instead. Serum concentrations of vitamin 
B12 and ferritin, presence of gastric parietal cell and intrinsic factor 
antibodies and thyroid function tests were also measured at the 
biochemistry and immunology laboratories at RLBUHT as part of standard 
clinical assessment. Serological analysis for Helicobacter pylori infection 
(using anti-IgG antibodies to Helicobacter pylori) was performed by the 
microbiology department at the Royal Liverpool and Broadgreen University 
Hospital NHS Trust. 
Serum ferritin concentration was used as a marker of iron stores in 
the body and hence a low serum ferritin (below the lower limit of normal) or 
history of pre-existing iron deficiency anaemia was taken as a marker of 
iron deficiency anaemia and the presence of low serum vitamin B12 
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concentrations (or a history of vitamin B12 deficiency) as a marker of 
vitamin B12 deficiency in this cohort. Patients with a known history of 
hypothyroidism or with low serum total T4 concentration associated with 
an elevated thyroid stimulating hormone (TSH) concentration were 
considered to be hypothyroid. The biochemical reference ranges for the 
various parameters are described in table 7-1. 
 
Parameter Normal Range (units) 
Vitamin B12 191-663 ng/L 
Serum 
ferritin 
30-400µg/L in males 
and 13-150 µg/L in 
females  
TSH 0.3 to 6.0mU/l 
Total T4 60 to 150nmol/l 
     
Table 7-1:  Normal reference ranges (Royal Liverpool University Hospitals NHS Trust, 
http://www.rlbuht.nhs.uk/jps/) 
 
Intrinsic factor and gastric parietal cell antibodies were detected by 
enzyme linked immunoassay using human recombinant antigen (reference 
range < 20U/ml) and immunofluorescence microscopy using rodent tissue 
substrate (reference range negative) respectively. These were measured 
at the RLBUHT immunology laboratory. 
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7.3 Statistical analyses 
 
7.3.1 ANOVA (one-way analysis of variance)  
ANOVA was used to analyse the significance of means between the 
three groups of ECL-cell hyperplasia in sections 7.4.2 and 7.4.3. p<0.05 
was considered to be statistically significant. 
 
7.3.2 χ2 test 
Univariate analysis using χ2 test was used in defining relationships 
between categorical variables (section 7.4.2). p<0.05 was considered to be 
statistically significant. 
 
7.4 Results 
7.4.1 Demographics of cohort 
A total of 49 patients were recruited between 2003 and 2010. 34 
(69.4%) were female with a median age of 63.7 years (range 20.8-86.1 
years). All patients had histological evidence of atrophic gastritis on corpus 
biopsy and some degree of ECL-cell hyperplasia.  9 (18.4%) patients were 
on a concurrent PPI at the time of diagnosis. Only 3 (6.1%) patients had 
evidence of current H. pylori infection on histology. The extent or degree of 
ECL-cell hyperplasia, median age of patients and the number and size of 
polyps seen at gastroscopy is detailed in table 7-2. 
224 
 
 
 
ECL-cell 
hyperplasia 
Number of 
patients          
(% 
female) 
Median 
age years 
(IQR) 
Mean 
number of 
nodules 
(range) 
Mean 
maximum 
size of 
nodules 
mm 
(range) 
Linear 6 (83.4) 62.2 (53.8, 
69.7) 
3 (0-12) 3.8 (0-15) 
Nodular 31 (70.9) 63.2 (51.1, 
69.3) 
4.8 (0-20) 2.9 (0-12) 
Carcinoid 
tumours 
12 (58.3) 65.3 (60.6, 
75.5) 
9.3 (2-20) 12 (5-50) 
 
Table 7-2: Demographics of patients with atrophic gastritis 
 
Table 7-3 below summarises the prevalance of vitamin B12 and iron 
deficiency, presence of gastric parietal and intrinsic factor antibody, 
hypothyroidism, H. pylori infection and the mean serum gastrin 
concentrations in patients with linear, nodular and carcinoid ECL-cell 
hyperplasia.  
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ECL-cell 
hyperplasia 
(Total no.) 
Vitamin 
B12 
deficiency 
(%) 
Iron 
deficiency 
(%) 
+ve 
gastric 
parietal 
cell 
antibody 
(%) 
+ve 
intrinsic 
factor 
antibody 
(%) 
Hypothyroid 
(%) 
Number of patients and 
range of fasting serum 
gastrin concentrations 
(%) 
H. pylori 
histology 
(%) 
H. pylori 
serology 
(%) 
<100 
pM 
100-
400 
pM 
>400 
pM 
  
Linear 
(6) 
3 
(50%) 
3 
(50%) 
4 
(66.7%) 
1 
(16.7%) 
1 
(16.7%) 
0 3 
(50) 
3 
(50) 
0 
1 
(16.7%) 
Nodular 
(31) 
20 
(64.5%) 
14 
(45.2%) 
21 
(67.7%) 
4 
(12.9%) 
7 
(22.6%) 
0 10 
(32.3) 
21 
(67.7) 
3 
(9.7%) 
7 
(22.6%) 
Carcinoid 
(12) 
9 
(75%) 
3 
(25%) 
11 
(91.7%) 
0 5 
(41.7%) 
0 7 
(58.3) 
5 
(41.7) 
0 
2 
(16.7%) 
 
Table 7-3: Prevalence of vitamin B12, iron deficiency, presence of gastric parietal cell and intrinsic factor antibodies, concomitant hypothyroidism and H. 
pylori infection in patients with various degrees of ECL-cell hyperplasia or type-1gastric carcinoid tumours. 
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7.4.2 Age of patients and presence of ECL-cell hyperplasia 
Patients with type-1 gastric carcinoid tumours had a higher median 
age compared to patients with linear ECL-cell hyperplasia however this 
difference did not reach statistical significance (p=0.342, ANOVA). 
 
7.4.3 Polyp numbers and size 
Patients with type-1 gastric neuroendocrine tumours had more 
polyps (p=0.067, ANOVA) and significantly larger lesions (p=0.0033, 
ANOVA) compared with patients with lesser degrees of ECL-cell 
hyperplasia. 
 
7.4.4 Extent of gastric atrophy 
7.4.4.1 Mean fasting serum gastrin concentrations 
As a group, all patients had elevated fasting serum gastrin concentrations 
(all >100 pM). 20 patients (41%) had fasting serum gastrin concentrations 
between 100 and 400 pM and the remaining 29 patients (59%) had fasting 
serum gastrin concentrations greater than 400 pM (table 7-4). No 
significant differences were found with different degrees of ECL-cell 
hyperplasia. 
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Degree of 
ECL-cell 
hyperplasia 
(total number) 
Total number 
of patients with 
fasting serum 
gastrin 
concentrations 
between 100-
400 pM 
Total number 
of patients with 
fasting serum 
gastrin 
concentrations 
>400 pM 
p value,  
χ
2
 test 
 
Linear (6) 3 3 
0.262 Nodular (31) 10 21 
Carcinoid (12) 7 5 
 
Table 7-4: Univariate analysis of fasting serum gastrin concentrations and varying 
degrees of ECL-cell hyperplasia 
 
7.4.4.2 Vitamin B12 deficiency 
Although a higher percentage of vitamin B12 deficiency (75%) was 
observed in patients with type-1 gastric carcinoid tumours as compared to 
patients with either nodular (64.5%) or linear (50%) ECL-cell hyperplasia, 
this association was again not statistically significant (p=0.82, χ2 test). 
7.4.4.3 Presence of antibodies (gastric parietal cell and intrinsic factor 
antibodies) 
As with vitamin B12 deficiency, a higher percentage of patients with 
type-1 gastric carcinoid tumours were observed to have concurrent gastric 
parietal cell antibodies (91.7%) compared to patients with nodular (67.7%) 
or linear (66.7%) ECL-cell hyperplasia. However this association was not 
statistically significant (p=0.69, χ2 test). In this cohort, none of the patients 
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with type-1 gastric carcinoid tumours had coexisting intrinsic factor 
antibodies.  
7.4.4.4 Iron deficiency anaemia 
No significant association was observed between the presence of 
iron deficiency anaemia and the degree of ECL-cell hyperplasia (p=0.60, 
χ2 test). 
7.4.4.5 Associated hypothyroidism 
A higher percentage of patients with type-1 carcinoid tumours were 
observed to have associated hypothyroidism (41.7%) compared to patients 
with linear (16.7%) or nodular (22.6%) ECL-cell hyperplasia. However this 
association was not statistically significant (p=0.97, χ2 test). 
7.4.4.6 Concurrent H. pylori infection 
Concurrent H. pylori infection was rare in this cohort of patients with 
ECL-cell hyperplasia. No correlation was observed between the presence 
of H. pylori infection (by histology or serology) and the degree of ECL-cell 
hyperplasia (p= 0.41, χ2 test). 
 
7.4.5 Discussion 
In this study we have analysed the potential role played by several 
factors including age, extent and characteristics of gastric atrophy (as 
estimated by the severity of the associated hypergastrinaemia, associated 
vitamin B12 and iron deficiency and presence of anti-intrinsic factor and 
anti-gastric parietal cell antibodies), presence of previous or co-existent H. 
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pylori infection and the presence of another autoimmune disease namely 
hypothyroidism, that may influence the progression of ECL-cell hyperplasia 
to type-1 gastric NETs in some patients with chronic autoimmune atrophic 
gastritis.  
All gastroscopies and polyp assessment were performed by the 
same endoscopist (Consultant Gastroenterologist) thereby reducing inter-
observer error. All patients had two biopsies taken from the antrum and 
two biopsies taken from the gastric corpus to establish atrophic body 
gastritis as well as to assess ECL-cell hyperplasia. The number and site of 
gastric biopsies taken was deemed sufficient to demonstrate atrophy and 
ECL-cell hyperplasia as this is associated with autoimmune gastritis where 
there is a field change as opposed to sporadic NETs (Rindi et al., 1999a).  
We have demonstrated in this cohort of 49 patients that patients 
with more advanced degrees of ECl-cell hyperplasia and those with type-1 
gastric carcinoid tumours were older, but this difference was not 
statistically significant. The youngest patient to develop type-1 gastric NET 
was aged 43.9 years and the youngest to develop nodular hyperplasia was 
20.8 years. Hence it is likely that the duration of hypergastrinaemia (in the 
presence of chronic atrophic gastritis) rather than the age of the patient 
appears to influence the progression to ECL-cell hyperplasia and 
subsequent development of type-1 gastric NETs in some patients with 
chronic atrophic gastritis. This confirms the previously proposed 
hypothesis that longstanding hypergastrinaemia confers a greater risk for 
the development and progression of ECL-cell hyperplasia and type-1 
gastric NETs. Also, patients with the more advanced degrees of ECL-cell 
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hyperplasia and type-1 gastric NETS not only exhibited a higher number of 
nodules, but these nodules were also larger in size compared to patients 
with lesser degrees of ECL-cell hyperplasia. 
This study has demonstrated that factors such as the presence of 
autoantibodies (gastric parietal cell or intrinsic factor antibodies), 
concurrent or past H. pylori infection or coexisting hypothyroidism were not 
significantly associated with the presence of more advanced degrees of 
ECL-cell hyperplasia or type-1 gastric carcinoid tumours. However 
although the associations did not reach statistical significance, a greater 
proportion of patients with more advanced degrees of ECL-cell hyperplasia 
had autoantibodies to gastric parietal cells, vitamin B12 deficiency and 
hypothyroidism. This suggests a possible role played by these factors in 
the progression of ECL-cell hyperplasia to type-1 gastric carcinoid 
tumours, but the cohort size was not large enough to confirm a statistically 
significant effect. 
Similar findings have recently been in another recent study of 
patients with chronic autoimmune atrophic gastritis (Vannella et al., 2011). 
In this study, patients with type-1 gastric carcinoid tumours were reported 
to have significantly higher mean fasting serum gastrin concentrations and 
a greater total number of polyps. However the presence of gastric parietal 
cell antibodies, anaemia or hypothyroidism were not found to be 
significantly associated with more advanced degrees of ECL-cell 
hyperplasia. 
There are certain limitations to our study. Firstly we have utilised 
two different methods to measure fasting serum gastrin concentrations. 
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Most patients (67.3%) had their fasting serum gastrin concentrations 
measured at the University of Liverpool Physiological laboratories using 
the previously described radioimmunoassay (RIA) method of estimation of 
serum gastrin concentrations (section 2.3). However the remaining 
patients (32.7%) had their fasting serum gastrin concentrations measured 
at the Hammersmith Hospital, London, using an in-house RIA method 
(using a different rabbit polyclonal antibody). Although accurate, when 
fasting serum gastrin concentration was greater than 400pM, the serum of 
such patients measured at the Royal Hammersmith Hospital, was not 
subjected to further analysis for estimation of the actual serum gastrin 
concentration.  On the other hand, if higher concentrations were observed 
whilst measuring serum gastrin concentrations at the Physiological 
Laboratories, University of Liverpool, further subsequent measurements 
were made following serial dilutions of patients’ sera (using the RIA 
method as described in section 2.3). This enabled accurate estimation of 
the actual serum gastrin concentration. Hence in our analyses, the range 
of serum gastrin concentrations had to be used rather than comparing 
actual concentrations. 
The other main limitation of the current study is the small sample 
size of only 49 patients. The study was therefore not adequately powered 
to achieve statistically significant outcomes in certain analyses. In addition 
there is a possibility of referral bias as only patients who are found to have 
nodules at gastroscopy are usually referred for further specialist 
evaluation. Patients without nodules may not have undergone biopsy for 
assessment of ECL-cell hyperplasia. Finally as older people with 
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pernicious anaemia secondary to autoimmune gastritis are not often 
referred for a gastroscopy but instead commenced on treatment with 
replacement vitamin B12 and this may have further affected our findings.   
There are several other potential factors (both host and 
environmental) that have been proposed to influence the progression of 
ECL-cell hyperplasia and the development of type-1 gastric NETs. It is well 
known that hypergastrinaemia alone is probably insufficient to cause 
progression of ECL-cell hyperplasia and development of type-1 gastric 
NETs. For example, chronic proton pump inhibitor therapy and vagotomy, 
although associated with chronic hypergastrinaemia and hypochlorhydria, 
are rarely associated with the development of type-1 gastric NETs.  It has 
therefore been suggested that factors including genetic, host response and 
exogenous environmental factors such as diet, smoking and alcohol could 
play an important role in the progression of ECL-cell hyperplasia and 
development of type-1 gastric NETs. These factors have not been 
addressed in the current study, but have been analysed in other studies. 
Genetic factors that influence development of gastric NETs have 
been well characterised in animal models, especially in Mastomys, which 
has a genetic predisposition to develop gastric NETs (Nilsson et al., 1992). 
Approximately 40-60% of Mastomys develop gastric NETs by 2 years of 
age and this process is accelerated by the administration of acid 
suppressing drugs. ECL-cell hyperplasia develops within 8 weeks and 
gastric NETs between 12 and 16 weeks following treatment with acid 
suppressing drugs (Bilchik et al., 1989). However the genetic reasons for 
this increased susceptibility to the development of ECL-cell tumours are 
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still poorly understood. One explanation for this predisposition is explained 
by the finding that Mastomys have polymorphisms in the CCK-2 receptor 
gene, thereby conferring increased sensitivity to circulating gastrin (Reubi 
et al., 1992). Also gastric NETs in Mastomys have been demonstrated to 
exhibit increased numbers of CCK-2 receptors suggesting a gastrin 
stimulated growth of such tumours.  
Studies in rats treated with acid suppressing drugs have also 
demonstrated an increase in the number of ECL-cells, which appears to be 
reversible if the hypergastrinaemia was short lived. However lifelong acid 
suppression eventually led to the development of gastric NETs. Changes 
in the endocrine cell population in the antrum have also been observed in 
rats with hypergastrinaemia secondary to acid suppression. An increase in 
G cells and a reciprocal decrease in D cells (with a overall increase in G:D 
ratio) has been noted in such rats with a subsequent loss of inhibitory 
effect of somatostatin on ECL-cell growth (Creutzfeldt et al., 1986). 
Patients with multiple endocrine neoplasia type-1 syndrome (MEN-
1) are at increased risk of developing type-2 gastric NETs and the 
underlying genetic defect is an autosomal dominant mutation in the MEN-1 
gene coding for the MENIN protein. This MENIN protein is thought to act 
as a tumour suppressor protein through interactions with numerous 
nuclear and cytoplasmic factors that regulate cell and DNA repair and 
processing. A recent study of MEN-1 patients reported that 100% of the 
patients had abnormal ECL-cell distribution and 23% had gastric NETs 
(Berna et al., 2008). 
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Several growth factors have also been studied as potential factors 
that may influence the progression of ECL-cell hyperplasia and type-1 
gastric NET formation. Reg peptide, initially described in 1984 in 
association with regenerating pancreatic tissue, has been shown to be 
secreted by human ECL and chief cells. Reg peptides have been 
demonstrated to be up regulated following gastric mucosal injury and also 
in rats with hypergastrinaemia induced by proton pump inhibitor drugs 
(Higham et al., 1999; Kinoshita et al., 2004). 
There are likely to be other as yet unexplained factors that could 
also influence the progression of ECL-cell hyperplasia. It has been 
proposed that several non-Helicobacter pylori bacteria colonise the 
stomach in the setting of achlorhydria. Monstein et al. and Bik et al. have 
demonstrated several different bacterial species in the human stomach by 
DNA sequence analysis (Bik et al., 2006; Monstein et al., 2000). Similarly 
non-Helicobacter pylori bacteria were demonstrated in gastric biopsies of 
patients on long standing treatment with acid suppressing drugs 
(Sanduleanu et al., 2001). Such organisms which have been demonstrated 
to colonise the gastric mucosa may therefore play a role in the 
development and progression of ECL-cell hyperplasia through as yet 
unknown mechanisms. Also host responses and genetic predispositions 
which influence gastric epithelial cell apoptosis and cell proliferation may 
also play an important role in the progression of ECL-cell hyperplasia. It is 
therefore possible that as yet unidentified bacteria and host-bacterial 
responses could influence the progression of ECL-cell hyperplasia and 
subsequent development of type-1 gastric NETs. 
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7.4.6 Conclusions 
Although our study has not demonstrated any statistically significant 
associations, there does appear to be some correlation between the 
presence of factors such as hypothyroidism, gastric parietal and intrinsic 
factor antibodies, iron deficiency and vitamin B12 deficiency and more 
advanced degrees of ECL-cell hyperplasia. We therefore recommend 
further prospective studies involving greater numbers of patients to verify 
these potential associations. Additional immunohistochemical analysis of 
gastric biopsies for G-cells and somatostatin may provide some 
information regarding the role played by somatostatin in ECL-cell 
hyperplasia and type-1 gastric NET development. 
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Chapter 8 
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8 Does the octreotide suppression test predict response to 
antrectomy in patients with type-1 gastric neuroendocrine tumours 
(NETs)  
 
8.1 Introduction 
Type-1 gastric neuroendocrine (carcinoid) tumours are thought to 
arise as a result of hypergastrinaemia. Small tumours (<1cm) rarely 
metastasise and hence are usually associated with an excellent prognosis. 
Such tumours are often managed by endoscopic surveillance or 
occasionally polypectomy (endoscopic mucosal resection). However larger 
tumours (>1 to 2 cms) have malignant potential and hence the 
management of such tumours remains controversial. This may involve 
endoscopic or surgical techniques (including resection of polyp, 
antrectomy or gastrectomy) or medical treatment with long acting 
somatostatin analogues.  
Endoscopic resection has been recommended for large tumours 
(>1cm) that are deemed resectable at endoscopic ultrasound (no evidence 
of muscularis propria involvement) (Delle et al., 2012).  Local surgical 
resection of polyps is adviced when such polyps are not amenable to 
endoscopic resection. Antrectomy (resulting in removal of G-cells) has 
been shown to be effective in reducing serum gastrin concentrations and 
has been reported to cause complete resolution of small type-1 gastric 
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NETs in a number of case series (Hirschowitz et al., 1992; Dakin et al., 
2006).  
Antrectomy (and therefore removal of gastrin secreting G-cells) may 
be an effective surgical treatment in those patients with type-1 gastric 
NETs greater than 1cm in size and also in those with a high polyp burden 
(> 5 polyps). Antrectomy has also been advocated in those patients with 
polyp recurrence following endoscopic polyp resection and in those 
patients undergoing endoscopic surveillance for type-1 gastric NETs who 
develop further gastric type-1 NETs or demonstrate an increase in size of 
existing type-1 NETs.  
 
Type-1 gastric NETs
< 1cm size
Endoscopic surveillance
Possible endoscopic resection
>1-2cms
Endoscopic resection
Surgery
•Antrectomy
•Total gastrectomy
Long acting somatostatin analogues
Endoscopic surveillance
Endoscopic surveillance
Local spread
Total gastrectomy
If recurrence or growth
Surgery – antrectomy or 
gastrectomy
 
Figure 8-1: Proposed algorithm for management of type-1 gastric NETs  
(Plockinger et al., 2004). 
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Total gastrectomy rather than antrectomy has however been 
advocated for the management of larger type-1 gastric NETs, due to the 
observation that some tumours do not appear to regress following 
antrectomy (Wangberg et al., 1990).   
Hence should antrectomy therefore only be considered in those 
type-1 gastric NETs which are gastrin-responsive? The role of an 
octreotide suppression test in determining those patients with type-1 
gastric NET who may respond to antrectomy has previously been studied 
in a single case (Higham et al., 1998).  
Octreotide administration has been shown to decrease serum 
gastrin concentrations, reduce ECL-cell and gastrin cell function and with 
long term use has also been shown to reduce the size of type-1 gastric 
NETs (Fykse et al., 2004; Jianu et al., 2011). Gastrin stimulates histamine 
release from ECL-cells by stimulation of the genes encoding the enzyme 
histidine decarboxylase (HDC). It has been demonstrated that elevated 
tissue HDC concentrations are observed in conditions associated with 
hypergastrinaemia such as gastrinomas. We have therefore utilised this 
enzyme as a surrogate marker for ECL-cell function and to determine the 
ECL-cell response to octreotide infusion. Octreotide mediated reduction in 
serum gastrin concentrations as well as a decrease in ECL-cell function 
can hence be potentially demonstrated by a fall in measured HDC mRNA 
levels in corpus and polyp/tumour biopsies. Such a response may suggest 
that these tumours are still gastrin responsive and hence removal of the 
source of gastrin may result in cessation of tumour growth and possibly 
even tumour regression. 
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8.2 Aim 
To determine the role of the ‘octreotide suppression test’ in 
identifying those patients with type-1 gastric NETs in whom the tumours 
regress following antrectomy. 
 
8.3 Methods  
Local ethics committee approval and informed patient consent were 
obtained.  Six patients with either >1cm and/or > 5 type-1 gastric NETs 
were studied (4 female, mean age 64.7 years). The initial diagnosis of 
type-1 gastric NETs was made either at diagnostic gastroscopy performed 
at Royal Liverpool and Broadgreen University Hospital NHS Trust 
(RLBUHT) or at other hospitals in the North West of England and 
subsequently referred to Prof. D.M.Pritchard at the RLBUHT and 
University of Liverpool for specialist management of their type-1 gastric 
NETs. Each patient’s demographic data including concurrent medication 
use (proton pump inhibitors) was recorded. 
Serological analysis for Helicobacter infection (anti-IgG antibodies 
to Helicobacter pylori) was performed by the microbiology department at 
RLBUHT.  Serum concentrations of vitamin B12 and ferritin, presence of 
gastric parietal cell and intrinsic factor antibodies and thyroid function tests 
were also measured at the biochemistry and immunology laboratories at 
RLBUHT as part of initial clinical assessment. CT (computerised 
tomography) scan of the abdomen and a 111In-octreotide scan 
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(somatostatin scintigraphy) were performed in order to rule out other 
gastrointestinal NETs and the presence of metastatic disease. 
Patients were admitted to Royal Liverpool and Broadgreen 
University Hospital NHS Trust for the octreotide suppression test. On day 
1 of the test, an initial diagnostic gastroscopy was performed. This was 
followed by a 72 hour intravenous octreotide infusion at a rate of 
25mcg/hour. 10mls of blood was obtained before the commencement of 
the test (fasting) and subsequently at timed intervals during the 72 hour 
octreotide infusion as previously demonstrated in a previous single case 
study (Higham et al., 1998). Blood samples were centrifuged and the 
serum obtained was subsequently analysed for serum gastrin 
concentrations by radioimmunoassay (as detailed in section 2.3). 
At gastroscopy, biopsies were obtained from the gastric antrum, the 
corpus and carcinoid polyps using standard biopsy forceps. Biopsies taken 
from the antrum, corpus and carcinoid polyp(s) were formalin fixed and 
paraffin embedded for subsequent histological analysis by a GI 
histopathologist. Histological analysis was performed following staining 
with H&E (haematoxylin and eosin and immunochemistry for chromogranin 
A and synaptophysin). Antral and corpus biopsies were analysed for the 
presence of ECL-cell hyperplasia and the extent of this hyperplasia was 
classified by an experienced GI histopathologist based on well defined 
criteria as outlined in section 5.2. These biopsies were also analysed for 
the presence of Helicobacter pylori infection. Biopsies obtained from the 
carcinoid polyp(s) and corpus were stored in RNA-Later® at 4˚C for 
subsequent RNA extraction.  
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A rapid urease test (PRONTO Dry®, MIC France) was also 
performed using two gastric antral biopsies in all patients in order to obtain 
a rapid diagnosis of Helicobacter  pylori infection. Following the octreotide 
infusion, repeat corpus and carcinoid polyp biopsies were obtained and 
subsequently processed as described above. 
Octreotide suppression test
15h           23h      31h             41h          55h                72h
0h 24h 48h 72h
OGD 1 OGD 2
Biopsy 1 Biopsy 2
Octreotide 25mcg/h
Serum 
Gastrin
 
Figure 8-2: Schematic representation of the octreotide suppression 
test. 
 
8.3.1.1 RNA extraction from gastric corpus and polyp biopsies 
Corpus and polyp biopsies taken at endoscopy were initially stored 
in separate containers containing RNA-Later® at 4◦C overnight and then at 
-20◦C (after removal of RNA-Later®) if stored for longer. Extraction of RNA 
from the biopsy specimens was based on the ‘single-step’ method that is 
widely used for isolating RNA (Chomczynski and Sacchi, 2006). This is 
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based on the principle that RNA is separated from DNA after extraction 
with an acidic solution (containing guanidine thiocyanate, sodium acetate, 
phenol and chloroform) followed by centrifugation. Acidic conditions render 
the RNA in the upper aqueous phase of the supernatant, with the DNA in 
the middle (interphase) and other organic matter in the lower layer. RNA 
was subsequently recovered by precipitation with isopropanol.   
8.3.1.2 Real time quantitative polymerised chain reaction  
The technique of real time quantitative PCR (rt-qPCR) was utilised to 
analyse the abundance of HDC mRNA in the biopsy samples. 25µl of 
master mix/sample was analysed in triplicate using the following thermal 
profile (the whole process being completed in 90 minutes): 
 Stage 1 – 50oC for 2 minutes (1 repeat) 
 Stage 2 – 95oC for 10 minutes (1 repeat) 
 Stage 3.1 – 95oC for 15 seconds (40 repeats) 
 Stage 3.2 – 60oC for 1 minute 
The master mix solution was titrated using the following components:  
 Forward Primer - 2.2µl 
 Reverse primer - 21µl  
 Probe - 2.5µl  
 Water - 20.3µl per reaction 
The probes and primer used are as follows: 
 Probe (hGAPDH): 71T CGT CGC CAG CCG AGC CAC A;  
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   Forward primer (hGAPDH): 34F GCT CCT CCT GTT CGA CAG    
   TCA and  
   Reverse primer (hGAPDH): 113R ACC TTC CCC ATG GTG TCT  
   GA 
 Probe (hHDC91): CTC TGT TAA ACT CTG GTT CGT GAT TCG  
   GTCC 
   Forward (hHDC-F91): CCC TGA GCC GAC GGT TT 
   Reverse (hHDC-R91): GTA CCA TGT CTG ACA TGT GCT TGA 
Both the RNA extraction and rt-qPCR were performed by Dr. Islay Steele. 
 
8.4 Results  
8.4.1.1 Demographics 
The clinical features of the six patients studied are outlined in tables 
8-1 to 8-3: 
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Patient 
Number 
Sex 
Age 
(years) 
Findings at initial 
endoscopy 
PPI 
Antral 
Histology 
Corpus 
Histology 
Histology 
of polyps 
Total no. 
of 
polyps 
Size of 
largest 
polyp 
(mm) 
Patient  
1 
F 67.4 20 7 No 
Atrophic 
gastritis 
Atrophic gastritis, 
intestinal 
metaplasia, 
Micronodular 
ECL-cell 
hyperplasia 
Carcinoid tumour 
Patient 
2 
M 43.5 4 10 No 
Reactive 
gastritis 
Atrophic gastritis, 
intestinal 
metaplasia, 
Linear ECL-cell 
hyperplasia 
Carcinoid 
Patient  
3 
F 65.3 18 10 No Normal 
Atrophic gastritis, 
intestinal 
metaplasia and 
Micronodular 
ECL-cell 
hyperplasia 
Carcinoid 
Patient  
4 
F 70.57 5 15 No Normal 
Atrophic gastritis, 
intestinal 
metaplasia and 
Micronodular 
ECL-cell 
hyperplasia 
Carcinoid 
Patient 
5 
M 75.7 4 16 No 
Atrophic 
gastritis 
Atrophic gastritis, 
intestinal 
metaplasia and 
Linear ECL-cell 
hyperplasia 
Carcinoid 
Patient 
6 
F 66.3 10 5 No 
Reflux 
gastritis 
Atrophic gastritis, 
intestinal 
metaplasia and 
Micronodular 
ECL-cell 
hyperplasia 
Microcarcinoid 
 
Table 8-1: Demographics and endoscopic findings of patients undergoing octreotide suppression 
test including concurrent PPI treatment and histology of antrum, corpus and polyp. 
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Patient 
Number 
Fasting 
serum 
gastrin 
concentration 
(pM) 
Fasting 
serum 
chromogranin 
A 
concentration 
(pM) 
Rapid 
urease 
test 
(RUT) 
Hp 
histology 
Hp 
serology 
CT 
abdomen 
 
111
In-
Octreotide 
Scan 
Patient  
1 
2800 
 
104 
 
ND Negative ND Normal ND 
Patient 
2 
680 50 Negative Negative Negative Normal Normal 
Patient  
3 
190 45 Negative Negative Negative Normal Normal 
Patient  
4 
838 33 Negative Negative Negative 
Gastric 
carcinoid 
tumour 
Normal 
Patient 
5 
2116 60 Negative Negative Negative Normal Normal 
Patient 
6 
340 11 Negative Negative Negative 
Soft 
tissue 
mass in 
stomach 
Normal 
 
Table 8-2: Patients undergoing octreotide suppression test: fasting serum gastrin and 
chromogranin A concentrations, H. pylori status and CT and 
111
In-octreotide scan 
findings. (ND=not done) 
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Patient 
Number 
Vitamin 
B12 
deficiency 
Iron 
deficiency 
anaemia 
Hypothyroidism 
Anti 
gastric 
parietal 
cell 
antibody 
Anti 
intrinsic 
factor 
antibody 
Patient 
1 
Y N Y Positive Negative 
Patient 
2 
Y N Y Positive Negative 
Patient 
3 
Y N N Negative Negative 
Patient 
4 
Y N N Positive Negative 
Patient 
5 
Y N Y Positive Negative 
Patient 
6 
Y Y N NA* NA* 
 
Table 8-3: Patients undergoing octreotide suppression test: presence of vitamin B12 and 
iron deficiency, hypothyroidism and anti gastric parietal cell and intrinsic factor antibodies.  
* Unable to accurately assess due to interfering anti-nuclear antibodies. 
 
8.4.1.2 Response of serum gastrin concentration to octreotide infusion 
Fasting serum was obtained prior to the first endoscopy of the 
octreotide suppression test. Immediately following the first endoscopy, 
patients were commenced on an intravenous infusion of octreotide at 
25µg/hour and this was continued for a total of 72 hours. This was then 
followed by a second endoscopy. Serum was obtained for estimation of 
248 
 
gastrin concentrations at 15, 23, 31, 47, 55 and 72 hours of infusion. 
Serum gastrin concentrations were measured by radioimmunoassay as 
previously described in section 2.3 and the results are shown in Figure 8-3 
and table 8-4. 
 
 
 
 
 
 
 
 
 
 
 
Figure 8-3: Change in serum gastrin concentrations during the 72 
hour octreotide infusion. 
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time 
in 
hours 
patient 
1 
patient 
2 
patient 
3 
patient 
4 
patient 
5 
patient 
6 
Mean Gastrin 
concentration 
(pM) 
0 2800 680 190 838 2117 340 995 
15 300 127 90 802 466 124  
23 175 147 163 930 460 148  
31 145 130 155 732 456 ND  
47 270 140 58 630 700 32  
55 280 180 47 510 304 49  
72 360 27 220 278 472 68 214 
 
Table 8-4: Serum gastrin concentrations at timed intervals during intravenous octreotide 
infusion. 
 
8.4.1.3 Change in Histidine Decarboxylase (HDC) mRNA  in gastric 
corpus and polyp biopsies following octreotide infusion 
 
Biopsies taken from the polyp and surrounding gastric corpus 
mucosa were analysed for the abundance of HDC mRNA by real time 
quantitative polymerase chain reaction (RT-qPCR) as previously described 
in section 8.3.1.2. There was a reduction in mRNA abundance in both the 
corpus and polyp in all patients following octreotide infusion and this is 
summarised in figures 8-3 and 8-4 and tables 8-3 and 8-4. 
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Figure 8-4: HDC mRNA abundance in the corpus and its response 
to intravenous octreotide infusion. 
 
Patient patient 1 patient 2 patient 3 patient 4 patient 5 patient 6 
HDC 
mRNA 
abundance 
(% of pre 
octreotide 
abundance) 
33% 47% 30% 31.7% 5.7% 29.5% 
 
Table 8-5: Response of HDC mRNA abundance in corpus to 
intravenous octreotide infusion.  
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The mean mRNA HDC abundance was therefore 29% of basal 
abundance post octreotide infusion (range 5.7 – 47%) in the corpus 
biopsies. 
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Figure 8-5: HDC mRNA abundance in the polyp/tumour and its response to intravenous 
octreotide infusion. 
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Patient 
patient 
1 
patient 
2 
patient 
3 
patient 
4 
patient 
5 
patient 
6 
HDC 
mRNA 
abundance 
(% of pre 
octreotide 
abundance) 
21.6% 3% 0.2% 8.7% 2.6% 29% 
 
Table 8-6: Response of HDC mRNA abundance in polyp/tumour to intravenous octreotide 
infusion 
 
The mean mRNA HDC abundance was 11% of basal abundance 
post octreotide infusion (range 2.6 – 29%) in the polyp biopsies. 
8.5 Follow up 
5 patients underwent a subsequent antrectomy and further 
surveillance gastroscopies, with follow up periods ranging from 2 to 10 
years. The change in fasting serum gastrin concentration immediately post 
antrectomy is shown in figure 8-6. One patient (number 6) chose to have 
endoscopic surveillance in preference to antrectomy especially as no 
actual carcinoid histology was found and all polyps in this patient 
measured <10mm. At follow up gastroscopy, the number and size of 
carcinoid polyps and degree of ECl-cell hyperplasia were assessed. 
Serum was also analysed where possible for fasting gastrin concentration. 
The individual patient follow up is summarised in the following tables (8-7 
to 8-12). 
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Figure 8-6: Graph demonstrating the change in fasting serum 
gastrin immediately following antrectomy in patient 1. 
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Patient 
1 
Antrectomy-
Date, Type of 
surgery 
(open/ 
laparoscopic) 
Post 
antrectomy 
OGD 
 
Findings at 
endoscopy 
 
Corpus Histology 
Polyp 
histology 
Fasting 
serum gastrin 
concentration 
post 
antrectomy 
(pmol/L) 
total 
no. of 
polyps 
size of 
largest 
polyp 
(mm) 
Chronic 
atrophic 
gastritis 
Intestinal 
metaplasia 
ECl-cell 
hyperplasia 
L=Linear 
N= Nodular 
M=Microcarcinoid 
 
Open 
2001 
2004 2 3 + + M M 112 
2005 2 3 + + M M 42 
2007 2 3 + + N L and M 104 
2012 0 0 + - N L and M 23 
 
Table 8-7: Patient 1- follow up gastroscopy, corpus and polyp histology and fasting serum gastrin concentration. 
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Patient 
2 
Antrectomy-
Date, Type of 
surgery 
(open/ 
laparoscopic) 
Post 
antrectomy 
OGD 
 
Findings 
at 
endoscopy 
(total no. 
of polyps, 
size of 
largest 
polyp in 
mm) 
Corpus histology 
Polyp 
histology 
Fasting 
serum gastrin 
concentration 
post 
antrectomy 
(pmol/L) 
Chronic 
atrophic 
gastritis 
Intestinal 
metaplasia 
ECl-cell 
hyperplasia 
L=Linear 
N= Nodular 
M=Microcarcinoid 
 
2006 
Laparoscopic 
 
2006 No polyps + + L None <10 
2007 No polyps + + L None <5 
2008 No polyps + + L None ND 
2010 No polyps + + None None ND 
 
Table 8-8: Patient 2- follow up gastroscopy, corpus and polyp histology and fasting serum gastrin concentration
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Patient 
3 
Antrectomy-
Date, Type of 
surgery 
(open/ 
laparoscopic) 
Post 
antrectomy 
OGD 
 
Findings 
at 
endoscopy 
(total no. 
of polyps, 
size of 
largest 
polyp in 
mm) 
Corpus histology 
Polyp  
histology 
Fasting 
serum 
gastrin 
concentration 
post 
antrectomy 
(pmol/L) 
Chronic 
atrophic 
gastritis 
Intestinal 
metaplasia 
ECl-cell 
hyperplasia 
L=Linear 
N= Nodular 
M=Microcarcinoid 
 
2008, 
Laparoscopic 
 
2009 No polyps + + L None 7 
2010 No polyps + + L+M None < 4 
 
Table 8-9: Patient 3- follow up gastroscopy, corpus and polyp histology and fasting serum gastrin concentration. 
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Patient 
4 
Antrectomy-
Date, Type of 
surgery 
(open/ 
laparoscopic) 
Post 
antrectomy 
OGD 
 
Findings at 
endoscopy 
 
Corpus Histology 
Polyp 
histology 
Fasting 
serum gastrin 
concentration 
post 
antrectomy 
(pmol/L) 
total 
no. of 
polyps 
size of 
largest 
polyp 
(mm) 
Chronic 
atrophic 
gastritis 
Intestinal 
metaplasia 
ECl-cell 
hyperplasia 
L=Linear 
N= Nodular 
M=Microcarcinoid 
 
2009, 
Laparoscopic 
 
2010 3 10 + + L+M Carcinoid 40.6 
2010 3 7 + + M 
Carcinoid 
 
ND 
2011 1 2 + + N Carcinoid 23 
2012 1 2 + - N L and M 35 
 
Table 8-10: Patient 4- follow up gastroscopy, corpus and polyp histology and fasting serum gastrin concentration. 
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Patient 
5 
Antrectomy-
Date, Type of 
surgery 
(open/ 
laparoscopic) 
Post 
antrectomy 
OGD 
 
Findings at 
endoscopy 
 
Corpus Histology 
Polyp 
histology 
Fasting 
serum gastrin 
concentration 
post 
antrectomy 
(pmol/L) 
total 
no. of 
polyps 
size of 
largest 
polyp 
(mm) 
Chronic 
atrophic 
gastritis 
Intestinal 
metaplasia 
ECl-cell 
hyperplasia 
L=Linear 
N= Nodular 
M=Microcarcinoid 
 
2009, 
Laparoscopic 
 
2010 1 6 + + L+M Carcinoid 17.6 
2011 1 6 + + L+M Carcinoid ND 
 
Table 8-11: Patient 5- follow up gastroscopy, corpus and polyp histology and fasting serum gastrin concentration. 
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Following antrectomy in patient 5, although fasting serum gastrin 
concentrations were <40pM, the type-1 gastric NET did not appear to 
regress at follow up gastroscopy and biopsies confirmed persisting type-1 
gastric NET. Endoscopic ultrasound did not show any evidence of local 
invasion and the patient was deemed suitable for an endoscopic mucosal 
resection of the polyp. However subsequent endoscopic mucosal resection 
of the carcinoid polyp was complicated by haemorrhage during the 
procedure requiring endoscopic haemostasis. This patient has now 
undergone a subtotal gastrectomy. Macroscopically the gastric NET was 
15mmx10mm and reached the subserosa (but did not breach the serosal 
surface). Microscopically it was in keeping with a well differentiated gastric 
NET (grade 1) with a Ki 67 index of 3%. 
In patient 4, all the type-1 gastric NETs that were visualised pre-
antrectomy had regressed completely post-antrectomy.  However this 
patient’s latest surveillance endoscopy (three years since the antrectomy) 
demonstrated a small persistent 2mm polyp, but this was at a different site 
from the largest polyp pre-antrectomy and biopsies of this persisting poly 
showed no microscopic evidence of type-1 gastric NET. 
Table 8-12 summarises the response of the number and size of 
gastric polyps, histology of the type-1 gastric NETs and fasting serum 
gastrin concentrations following antrectomy. 
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Patient 
No. 
Age Sex 
Pre-antrectomy 
Follow up 
post 
antrectomy 
(years) 
No. of post 
antrectomy 
gastroscopies 
Post antrectomy – latest surveillance 
gastroscopy findings 
Latest fasting 
serum gastrin 
concentration 
(pM) 
No. of 
polyps 
Maximum 
polyp 
size 
(mm) 
Serum 
gastrin 
concentration 
(pM) 
% 
reduction 
of serum 
gastrin 
(OST) 
HDC mRNA 
abundance 
(% of pre 
octreotide 
abundance) 
(OST) 
HDC mRNA 
abundance 
(% of pre 
octreotide 
abundance) 
(OST) 
No. of 
polyps 
Maximum 
polyp 
size 
(mm) 
Carcinoid 
histology 
1 67 F 20 7 2800 95 21.6 33 6 3 2 3 Micronodular 104 
2 43 M 4 10 680 96 3 47 4 4 0 0 None <5 
3 65 F 18 10 190 75 0.2 30 2 2 0 0 None 7 
4 70 F 5 15 838 67 8.7 31.7 2 3 1 2 Carcinoid 23 
5 75 M 4 16 2117 86 2.6 5.7 2 2 1 6 Carcinoid 18 
 
Table 8-12: Summary of response of number and size of polyps, histology of gastric type-1 NETs and fasting serum 
gastrin concentration following antrectomy. 
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8.6 Discussion 
Management of type-1 gastric NETs is currently largely determined 
by the size of the tumour (Plockinger et al., 2004; Ramage et al., 2005b). 
Small tumours (<1cm) are managed by endoscopic surveillance for tumour 
growth or endoscopic polypectomy. Large tumours (≥1cm) present a 
dilemma due to the uncertain nature of such tumours and the associated 
malignant and metastatic potential. Different treatment modalities have 
been advocated for the treatment of type-1 gastric NETs ≥1 cm in size and 
these include endoscopic polypectomy, antrectomy (Borch et al., 2005; 
Modlin et al., 2003b), total gastrectomy and long acting somatostatin 
analogues (Campana et al., 2008; Fykse et al., 2004; Grozinsky-Glasberg 
et al., 2008b).  
Endoscopic polypectomy has been advocated for small tumours 
(<1cm) and for gastric NETs >1cm but with low tumour burden (less than 5 
tumours in total) and in the absence of invasion of muscularis propria 
(Plockinger et al., 2004). The effectiveness of this modality of treatment 
has been demonstrated in several case series. Endoscopic treatment of 
gastric NETs is different to the conventional polypectomy techniques used 
for the removal of polyps elsewhere in the gastrointestinal tract due to the 
submucosal location of gastric NETs. In an initial study by Ichikawa et al., 
5 patients with type-1 gastric carcinoid NETs showed no evidence of 
recurrence at follow up (ranging from 6 to 66 months) following endoscopic 
mucosal resection of these tumours (Ichikawa et al., 2003). In a 
subsequent study involving 8 patients with gastric NETs (7 with type-1 
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gastric NETs and 1 with type-3 gastric NET) endoscopic removal of the 
gastric polyps was achieved by endoscopic resection using a multi band 
mucosectomy device (Hopper et al., 2009). Although long term follow up of 
these patients has not been reported, endoscopic resection was reported 
in this study to be safe with complete removal of the gastric NETs. In a 
Japanese study, 8 patients with small type-1 gastric NETs underwent 
endoscopic resection and no recurrence was observed at follow up 
gastroscopy (follow up period of 30 months) (Higashino et al., 2004). 
Endoscopic tumour resection may however not be feasible with a high 
tumour burden or very large gastric NETs. 
Therefore in patients with multiple large (>1cm) type-1 gastric NETs 
antrectomy has been shown to be an effective treatment modality. First 
described in a single patient in 1987 (Richards et al., 1987) and 
subsequently in two patients in 1988 (Eckhauser et al., 1988),  it has since 
become the surgical treatment of choice in those patients with type-1 
gastric NETs who have not responded to endoscopic therapy or in whom 
the tumours that have demonstrated an increase in size at endoscopic 
surveillance (Borch et al., 2005; Dakin et al., 2006). Hirschowitz et. al. 
demonstrated in a study of three patients with type-1 gastric NETs the 
effect of antrectomy on serum gastrin concentrations. Following 
antrectomy, all patients were observed to have normal serum gastrin 
concentrations and at follow up (30 months) neither ECL-cell hyperplasia 
nor type-1 gastric NETs were detected (Hirschowitz et al., 1992). In a 
study of 18 patients with type-1 gastric NETs, Dakin et al. have 
demonstrated that following antrectomy (10 patients), mean serum gastrin 
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concentrations decreased by 94% compared to 37.2% in medically treated 
patients (8 patients) (Dakin et al., 2006). However the effect of the different 
treatment strategies (antrectomy or medical) on existing type-1 gastric 
NETs (size, number) or on the development of new type-1 gastric NETs 
and progression of ECL-cell hyperplasia has not been studied. In a study 
by Borch et al., following antrectomy in 10 patients with type-1 gastric 
NETs, fasting serum gastrin concentrations normalised and 9 patients 
were tumour free after 65 months of follow up (Borch et al., 2005). Tumour 
progression was however observed in one patient. In studies by Hoshino 
et al (2 patients with type-1 gastric NETs) and Ozao-Choy (8 patients with 
type-1 gastric NETs), although antrectomy (laparoscopic) resulted in 
normalisation of fasting serum gastrin concentrations, it was not 
associated with regression of type-1 gastric NETs in all patients (Hoshino 
et al., 2010; Ozao-Choy et al., 2010). 
 Hence it would appear that not all patients with type-1 gastric NETs 
respond to antrectomy. Antrectomy, by removing the source of gastrin, is 
likely to be effective only in those patients with ‘gastrin responsive’ type-1 
gastric NETs. No surrogate markers are currently available that would 
determine this gastrin responsiveness or indeed that would enable us to 
monitor such tumours and their growth. 
A long acting somatostatin analogue (Octreotide) has also been used 
in the medical management of type-1 gastric NETs. The role of 
somatostatin in the regulation of acid secretion and gastrin synthesis has 
been described in section 1.2.3.2.2. In a study by Jianu et.al., 5 patients 
with type-1 gastric NET were initially treated with a long acting 
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somatostatin analogue (Sandostatin LAR, 20mg, administered 
intramuscularly monthly for a year) (Jianu et al., 2011). At the end of the 
first year of treatment, a reduction in serum gastrin (although fasting serum 
gastrin concentrations were still in the hypergastrinaemic range) and 
chromogranin A concentrations and a 50% reduction in the size of 
endoscopically visible nodules was observed. However at year 5 of follow 
up (following cessation after one year’s treatment with long acting 
octreotide), there was an increase in the size and number of 
endoscopically visible polyps. There was no change in the serum gastrin 
concentrations at year 5 of follow up compared to the concentrations 
measured at the end of the first year of treatment.  A similar trend was 
observed with serum chromogranin A concentrations. Based on the 
outcome of this study, it was therefore recommended that long acting 
somatostatin analogues once commenced should be continued long term 
in patients with type-1 gastric NETs (Jianu et al., 2011).  
In our study, we have demonstrated that intravenous octreotide 
resulted not only in a decrease in serum gastrin concentrations but also a 
decrease in the abundance of HDC mRNA in corpus and polyp biopsies 
from all patients. This response, observed with the infusion of octreotide, 
was initially interpreted as suggesting that antrectomy, by eliminating the 
source of gastrin, should stop tumour growth and also possibly induce 
tumour regression. However not all patients studied were observed to 
have such an outcome. The time taken for regression of polyps varied and 
one patient has currently undergone surgery for removal of a type-1 gastric 
NET which has not regressed 2 years following antrectomy. This therefore 
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would suggest that following antrectomy, patients with type-1 gastric NETs 
should continue to undergo subsequent regular endoscopic follow up to 
assess tumour response. If tumours do not regress despite normalisation 
of serum gastrin concentrations, patients should be considered for 
evaluation by endoscopic ultrasound (EUS) for suitability for endoscopic 
resection of any persistent large type-1 gastric NETs (≥1 cms). EUS has 
been demonstrated in several case series to be highly accurate in 
assessing type 1 gastric NETs including tumour invasion of the muscularis 
propria layer of the gastric wall which would preclude endoscopic tumour 
resection (Varas et al., 2010; Yoshikane et al., 1998). 
It is possible that octreotide, as used in our study, may have 
influenced ECL-cells by mechanisms independent of gastrin. It has been 
well established that octreotide itself has an inhibitory effect on ECL-cell 
function (Grozinsky-Glasberg et al., 2008a). This effect, coupled with a 
reduction in serum gastrin concentration may well account for the 
suppression of ECL-cell function observed in our study. It is also plausible 
that some type-1 gastric NETs may have progressed to grow 
autonomously in those patients who did not respond to antrectomy. If this 
was indeed the case then such autonomous tumours would not respond 
appropriately (by showing a decrease in serum gastrin and a decrease in 
ECL-cell function) to the octreotide infusion thereby suggesting that such 
tumours were still under the influence of gastrin. Response to a 
gastrin/CCK-2 receptor antagonist, by eliminating other nonspecific effects 
of octreotide may therefore be a more robust method to confirm tumour 
sensitivity to gastrin. We would therefore recommend further studies using 
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gastrin receptor antagonists to ascertain whether this would be a more 
reliable and consistent method to determine those patients with type-1 
gastrin NETs who may respond to an antrectomy. Demonstration of CCK-2 
receptor status/concentration on type-1 gastrin NETs by 
immunohistochemistry may also help identify those type-1 gastric NETs 
exhibiting autonomous growth. 
In our study, the time taken for regression of type-1 gastric NETs in 
those patients who responded to antrectomy was variable with intervals 
ranging from 2 years to up to 5 years post antrectomy. However in all 
these patients microscopic evidence of gastric ECL-cell hyperplasia 
continued to persist post antrectomy.  
There may also have been the possible effect of the gastrin 
autocrine/paracrine pathway. It has been demonstrated that once 
malignant transformation of ECL-like cells occurs, activation of gastrin 
gene results in unregulated tumour production of precursor gastrins 
(progastrin and Gly-gastrin) and amidated gastrin (Smith et al., 1998). The 
proliferative effects of these peptides have been demonstrated to be 
mediated via as yet unkown receptors (unopposed by exogenously 
administered gastrin).  Earlier studies in colonic tumour cells have also 
demonstrated the possible role played by the gastrin autocrine pathway in 
tumour growth and proliferation (Hoosein et al., 1988; Hoosein et al., 1990)  
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8.7 Conclusion 
We conclude from this study that although the octreotide suppression 
test may help to identify type-1 gastric NETs that are gastrin responsive, it 
does not reliably identify those patients with type-1 gastric NETs who 
would benefit from an antrectomy. Further studies analysing the role of 
gastrin/CCK-2 receptor antagonists in predicting those patients with type-1 
gastric NETs who would respond to an antrectomy are therefore 
warranted.  
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9 General Discussion 
 
The human stomach acts not only as a reservoir for ingested food 
but also plays an important role in the digestion of food through the 
regulated synthesis and secretion of gastric acid and several 
gastrointestinal hormones. These hormones also regulate the growth of 
gastric epithelial and enterochromaffin like cells (ECL-cells). Gastrin is one 
such important gastrointestinal hormone which plays a major role in the 
regulation of not only gastric acid secretion, but also through its effects on 
cell proliferation, apoptosis and angiogenesis, it has an important role in 
the regulation of gastric epithelial and ECL-cell growth.  
Several factors have previously been demonstrated to regulate 
fasting serum gastrin concentrations (chapter 1, section 1.3.2.4 and table 
1:2) and hence interpretation of fasting serum gastrin concentrations is 
complicated in the presence of such factors. It is however not entirely 
known how these multiple factors interact to influence fasting serum 
gastrin concentrations. We have therefore investigated how multiple host, 
bacterial and environmental factors interact and influence fasting serum 
gastrin concentrations in a large cohort of adult patients (chapter 6). The 
bacterial factors analysed include the effects of H. pylori infection and 
infection with the cagA variant on fasting serum gastrin concentrations. 
Effects of host factors including age, gender, body mass index, positive 
family history of gastric cancer and the presence of gastric preneoplastic 
pathology on fasting serum gastrin concentrations were also analysed. 
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Finally the effects of environmental factors such as smoking, alcohol 
consumption and concurrent drug therapy with proton pump inhibitors on 
fasting serum gastrin concentrations were analysed in this cohort of adult 
patients. 
Our analyses confirmed that H. pylori infection, concurrent proton 
pump inhibitor therapy and the presence of gastric preneoplastic pathology 
were all individually associated with significantly elevated fasting serum 
gastrin concentrations as demonstrated in previous studies (Orlando et al., 
2007; Lamberts et al., 2001; Annibale et al., 2001b). Current H. pylori 
infection and concurrent therapy with proton pump inhibitor drugs were 
significantly associated with more pronounced elevations in fasting serum 
gastrin concentrations. This has also been demonstrated in previous 
studies (El-Nujumi et al., 1998). However, in our study, in those patients 
with past evidence of H. pylori infection only, concurrent acid suppression 
therapy was associated with significantly elevated fasting serum gastrin 
concentrations only in the absence of gastric preneoplastic pathology, 
suggesting that this may predominantly be a proton pump inhibitor driven 
hypergastrinaemia.  
In our analysis, patients with advancing age without H. pylori 
infection or associated gastric preneoplastic pathology and not on a 
concurrent proton pump inhibitor therapy did not demonstrate significantly 
elevated fasting serum gastrin concentrations contrary to previous studies 
(Jassel et al., 1999). This therefore suggests that the previously observed 
association between advancing age and elevated fasting serum gastrin 
concentrations may be explained due to the presence of other confounding 
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factors such as concurrent H. pylori infection, presence of gastric 
preneoplastic pathology or therapy with acid suppressing drugs. 
In addition to the observation of significantly elevated fasting serum 
gastrin concentrations in patients with a body mass index of over 40, in 
keeping with previous studies (Lindstedt et al., 1985a), we also observed 
that patients with a body mass index of less than 18.5 also had 
significantly elevated fasting serum gastrin concentrations.  
Cigarette smoking was associated with significantly elevated fasting 
serum gastrin concentrations, but alcohol consumption was noted to be 
associated with significantly lower fasting serum gastrin concentrations. 
These results therefore confirm our hypothesis that several host, 
bacterial and environmental factors interact to influence fasting serum 
gastrin concentrations. However these interactions remain complex and 
should be taken into consideration when interpreting individual patients’ 
fasting serum gastrin concentrations.  
Similarly several host, bacterial and environmental factors have also 
been described to influence the development and progression of gastric 
preneoplastic pathology.  H. pylori infection has been demonstrated in 
several previous studies as a gastric carcinogen and infection with the 
cagA positive variant has been shown to be associated with increased 
pathogenicity of the infecting H. pylori bacteria (Nomura et al., 2002). 
Increasing age, male sex and cigarette smoking have also been observed 
to be associated with an increased risk of developing gastric 
adenocarcinoma (Blaser et al., 1995; Steevens et al., 2010).   However it 
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remains unclear how these factors interact and influence the development 
and progression of gastric preneoplastic pathology. This was analysed in a 
large cohort of adult patients and the results from this analysis, detailed in 
chapter 5 of this thesis, confirm several of the earlier observations such as 
the significant association between advancing age and increased risk of 
gastric preneoplastic pathology.  However host factors such as male 
gender and elevated body mass index were not found to be significantly 
associated with an increased risk of gastric preneoplastic pathology in this 
cohort. Similarly cigarette smoking was not found to be significantly 
associated with the presence of gastric preneoplastic pathology contrary to 
previous studies. However alcohol consumption was observed to have a 
small protective effect on univariate analysis alone in this study.  
In chapter 5 we also analysed the possible role played by acid 
suppressing drug therapy (proton pump inhibitors), in the development of 
gastric preneoplastic pathology. No significant association with the 
presence of gastric preneoplastic pathology was observed, suggesting that 
although the long term use of acid suppressing medications is associated 
with hypergastrinaemia, it may not significantly influence the development 
or progression of gastric preneoplastic pathology.  
We also assessed the efficacy of the rapid urease test (PRONTO®) 
in the detection of H. pylori infection and analysed those factors that may 
influence the outcome of this test (chapter 4). The sensitivity and 
specificity of the rapid urease test in diagnosing H. pylori infection has 
been quoted  as between 85-95% and 95-100% respectively (Tseng et al., 
2005). Concomitant therapy with proton pump inhibitors has previously 
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been reported to be associated with false negative rapid urease test 
results. However it is not known to what extent other factors such as the 
presence of gastric preneoplastic pathology and infection with cagA 
positive strains of H. pylori would influence the outcome of the rapid 
urease test. We have demonstrated the efficacy of the rapid urease test 
(sensitivity of 70% and specificity of 98.8%) compared to histology. 
Concomitant therapy with proton pump inhibitors, a predominantly corpus 
location of infection with H. pylori and infection with less virulent strains of 
H. pylori (cagA negative) were all observed to be associated with a more 
likely false negative rapid urease test result.  Hence the rapid urease test 
should be used with caution as the sole method for diagnosing H. pylori 
infection, especially in those areas such as the UK which have a low or 
decreasing prevalance of infection with this organism. 
There are several strengths to this study. Patients were recruited as 
part of the National Institute of Health Research (NIHR) funded study 
‘Identification of factors that influence development of gastric neoplastic 
pathology in adults’ conducted by the Biomedical Research Centre in 
Microbial diseases at Royal Liverpool and Broadgreen University Hospitals 
NHS Trust, Liverpool, UK. All patients were prospectively recruited and 
were representative of the same population that hospital clinicians 
encounter in everyday clinical practice. This study recruited a 
predominantly ethinically homogenous population (Caucasian) compared 
to other studies. In addition to endoscopic and histological data, detailed 
demographic and clinical data were obtained in all patients. Fasting serum 
gastrin concentration was analysed by radioimmunoassay. The antibody  
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(L2 antibody) utilised in this technique of radioimmunoassay was directed 
against the α-amidated C-terminal portion of gastrin molecules, therefore 
binding all bioactive gastrins irrespective of N-terminal peptide length and 
degree of sulfation as explained in chapter 2. This therefore measures 
accurately the fasting serum gastrin concentrations. Very high fasting 
serum gastrin concentrations were subsequently analysed by serial 
dilutions. Quality controls were also used in each assay to detect inter 
assay variations. Hence this technique of measuring fasting serum gastrin 
concentration by radioimmunoassay remains both accurate and reliably 
reproducible.  
Detection of the cagA status of the infecting H. pylori was performed 
using the ELISA technique.  Although this was a commercially produced 
ELISA kit, it was demonstrated in this study to be accurate with low 
interassay variability (<10%).  Furthermore, stringent criteria were 
established and adhered to for establishing the diagnosis of current and 
past infection with H. pylori. All histological specimens, after an initial 
analysis by a Consultant Gastrointestinal Histopathologist at the Royal 
Liverpool University Hospital as part of the patients’ routine clinical 
management, were further analysed according to an established protocol 
by a specialist Gastrointestinal Histopathologist who remained blinded to 
endoscopic and clinical data. All histological samples were reported using 
a standardised histology report. This report was based on internationally 
accepted descriptions and classifications including the modified Sydney 
classification system for H. Pylori-associated inflammation, Padova 
classification and modified Vienna classification for dysplasia.  
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One of the weaknesses of the study is that there were incomplete 
data sets in some patients. However, those patients with incomplete data 
sets were subsequently excluded from the final analyses. Also, in 
hindsight, we realise that further in-depth data regarding alcohol 
consumption and cigarette smoking may have provided additional 
information regarding the role played by environmental factors in the 
development of gastric preneoplastic pathology. Similarly further 
information regarding the presence of a family history of gastric and 
duodenal ulcer disease (in addition to gastric adenocarcinoma) may also 
have provided further information regarding the role of familial risk of 
gastric preneoplastic pathology.   
Studies in the past have mostly addressed the role played by 
individual factors (bacterial, host or environmental) in influencing the 
development of gastric preneoplastic pathology. This current study has not 
only addressed the role played by individual factors, but also the 
interaction between these factors in the development of gastric 
preneoplastic pathology.  Similarly previous studies have focussed 
predominantly on individual factors which influence fasting serum gastrin 
concentrations. In our current study we have addressed the role played by 
individual factors and also the interaction between host, environmental and 
bacterial factors in influencing fasting serum gastrin concentration. 
Overall our current study has helped address some of the important 
issues faced by clinicians in their everyday practice. The importance of a 
multi test strategy in establishing the diagnosis of H. pylori infection in low 
prevalance areas has been demonstrated in chapter 4. Factors that 
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influence the development of gastric preneoplastic pathology have been 
studied in detail in chapter 5 and this in conjunction with tumour marker 
studies will hopefully guide clinicians in developing risk prediction scores 
for gastric neoplasia development in susceptible patients. This would 
therefore enable risk stratification and development of appropriate 
surveillance strategies.  
A further 400 patients have been subsequently recruited to the 
NIHR study and an additional analysis will take place at the end of this 
recruitment. As part of this NIHR study, potential tumour markers to 
identify risk of developing gastric neoplastic pathology are also being 
assessed in this cohort of patients. Hopefully this, as well as further 
analyses on the entire data set of 1400 patients, may hopefully provide 
further important information regarding development of gastric 
preneoplastic and neoplastic pathology. Linkage with the regional cancer 
registry will enable identification of those patients from this cohort who 
develop gastric adenocarcinoma in the future. This would potentially also 
enable risk stratification strategies along with the tumour marker studies. 
Chronic hypergastrinaemia secondary to hypochlorhydria resulting 
from long standing autoimmune gastritis can lead to the development of 
ECL-cell hyperplasia. In some patients with long standing autoimmune 
gastritis this ECL-cell hyperplasia can progress to type-1 gastric 
neuroendocrine tumour formation. However factors which may influence 
this progression have not been entirely characterised. We hypothesised 
that factors such as the extent of gastric atrophy, presence of anti-gastric 
parietal cell antibodies and coexisting autoimmune conditions, such as 
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hypothyroidism, might influence this progression to type-1 gastric 
neuroendocrine tumours. In a prospective study of 49 patients with 
histologically confirmed atrophic body gastritis and ECL-cell abnormalities, 
we analysed the role of these factors in the development of type-1 gastric 
neuroendocrine tumours (chapter 7). We observed that the duration of 
hypergastrinaemia was definitely associated with significant ECL-cell 
abnormalities. However although the extent of gastric atrophy (as 
determined by the presence of vitamin B12 and iron deficiency anaemia),  
presence of anti-gastric parietal cell antibodies, and the presence of 
hypothyroidism, were more common in patients with the more advanced 
degrees of ECL-hyperplasia, this association did not reach statistical 
significance.  
 A similar association between these factors and advanced degrees 
of ECL-cell hyperplasia was observed in a recent study (Vannella et al., 
2011). Several other factors including host factors (genetic and as yet 
unidentified growth factors), bacterial factors (non-Helicobacter species) 
and environmental factors (smoking, alcohol consumption and diet) may 
therefore play an important role in the progression of atrophic gastritis to 
type-1 gastric neuroendocrine tumours in some susceptible patients. It is 
possible that the small sample size of our study may have been a 
shortcoming and further studies with larger sample sizes may help to 
understand further the development of type-1 gastric neuroendocrine 
tumours. Also a longer duration of follow up of our patients may help 
provide further information regarding progression of ECL-cell hyperplasia 
and development of type-1 gastric neuroendocrine tumours.  
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The current consensus guidelines on the management of type-1 
gastric neuroendocrine tumours are based on the size of these tumours 
(Plockinger et al., 2004). Small (<1cm) type-1 gastric neuroendocrine 
tumours have very low malignant potential and rarely metastasise whilst 
large (> 2cms) tumours have inherent malignant potential. Hence small, <1 
cm, tumours can be managed by endoscopic surveillance alone. However 
if unsuitable for endoscopic surveillance, then endoscopic resection of 
such tumours is advocated (Ichikawa et al., 2003). If the type-1 gastric 
neuroendocrine tumours are large (>1-2cms) then gastrectomy, wedge 
resection or antrectomy and removal of the source of hypergastrinaemia 
have all been advocated as appropriate treatment strategies (Dakin et al., 
2006). However not all patients with type-1 gastric neuroendocrine 
tumours who undergo antrectomy demonstrate subsequent complete 
resolution of type-1 gastric neuroendocrine tumours. Therefore should 
antrectomy be considered only in those patients with gastrin responsive 
type-1 gastric neuroendocrine tumours? The role of the octreotide 
suppression test in determining gastrin responsiveness of type-1 gastric 
neuroendocrine tumours and therefore response to antrectomy has been 
previously described in a single patient (Higham et al., 1999).  
We assessed the role of the octreotide suppression test in 
determining gastrin responsiveness of type-1 gastric neuroendocrine 
tumours in 6 patients and subsequent response to antrectomy in 5 patients 
with type-1 gastric neuroendocrine tumours. All patients had at least one 
>1cm type-1 gastric neuroendocrine tumour and a minimum of at least 5 
tumours overall.  All 6 patients responded to a 72 hour infusion of 
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octreotide (‘octreotide suppression test’) with an appropriate decrease in 
serum gastrin concentration and also a corresponding decrease in ECL-
cell function measured by a reduction in the abundance of mRNA for  the 
enzyme histidine decarboxylase (HDC) in both the corpus and tumour 
biopsies. This response to octreotide therefore would suggest that these 
patients with gastrin responsive type-1 gastric neuroendocrine tumours 
would respond to antrectomy with regression of tumours. However not all 
of the 5 patients who subsequently underwent antrectomy (one patient 
elected to have endoscopic surveillance) were observed to have such a 
response to antrectomy. The time taken for regression of the type-1 gastric 
neuroendocrine tumours following antrectomy varied (between 2-5 years) 
except in the one patient in whom the tumour persisted. This patient has 
subsequently undergone a subtotal gastrectomy. In all 5 patients, fasting 
serum gastrin concentrations were within normal limits (<40 pM) following 
antrectomy. In some patients, ECL-cell hyperplasia persisted although no 
new type-1 gastric neuroendocrine tumours were observed at subsequent 
follow up surveillance endoscopies. From this study it would therefore 
appear that although the octreotide suppression test may be useful in 
determining the gastrin responsiveness of type-1 gastric neuroendocrine 
tumours, it does not appear to reliably identify all those patients with type-1 
gastric neuroendocrine tumours who may benefit from an antrectomy. 
Octreotide may have had an effect on ECL-cell function through 
mechanisms independent of gastrin. Hence antagonists of the gastrin 
CCK-2 receptor may therefore eliminate such nonspecific effects of 
octreotide. Future studies assessing the role of gastrin/CCK-2 receptor 
280 
 
antagonists in determining gastrin responsiveness of type-1 gastric 
neuroendocrine tumours and to subsequent antrectomy are therefore 
advocated. 
In conclusion, gastrin plays a major role not only in the regulation of 
gastric acid secretion, but also in the regulation of gastric epithelial and 
ECL-cell function. Several bacterial, host and environmental factors 
interact to influence fasting serum gastrin concentrations and these factors 
have to be taken into account when interpreting individual patient’s fasting 
serum gastrin concentration. Similarly several host, bacterial and 
environmental factors influence the progression and development of 
gastric preneoplastic pathology. Rapid urease testing may not be the most 
reliable diagnostic test for infection with H. pylori in regions of low 
prevalance of infection with this organism due to the effects of several 
bacterial and environmental factors including concurrent acid suppression 
therapy. It would also appear that several factors may influence the 
progression of ECL-cell hyperplasia to type-1 gastric neuroendocrine 
tumours and further studies with sufficiently larger sample size may 
therefore be required. Determining gastrin responsiveness of type-1 
gastric neuroendocrine tumours and therefore responsiveness to 
antrectomy remains elusive. Further studies using gastrin/CCK-2 receptor 
antagonists to assess the gastrin responsiveness of type-1 gastric 
neuroendocrine tumours are needed. 
 
 
 
281 
 
 
 
282 
 
 
 
 
 
 
 
 
 
 
Appendix
283 
 
Appendix 1 
Clinical data sheet – page 1 
 
Factors which affect the outcome of Helicobacter pylori infection in the stomach- 
CLINICAL DATA 
 
 
 
 
 
Demographics: 
 
Age:    Sex: M ⁭  F⁭    
 
Ethnicity: 
 
Height (cms):   Weight (Kg):   BMI/comment: 
 
Symptoms for which endoscopy performed: 
 Reflux/Heartburn:   Y⁭ N⁭ 
Indigestion:     Y⁭ N⁭ 
 Abdominal Pain:    Y⁭ N⁭ 
 Vomiting:     Y⁭ N⁭ 
 Weight loss:     Y⁭ N⁭ 
 Anaemia:    Y⁭ N⁭ 
 Dysphagia:    Y⁭ N⁭ 
 Haemetemesis/Malaena:  Y⁭ N⁭ 
 
Type of Referral: 
 2 week rule:     Y⁭ N⁭ 
 Open Access Endoscopy:  Y⁭ N⁭ 
 Hospital referral:   Y⁭ N⁭ 
 
Past Medical History: 
Previous Gastric surgery:    Y⁭ N⁭ 
If Y   when: 
 Indication: 
 Type of surgery: 
Diabetes:     Y⁭ N⁭  if Y:  Type I  Y⁭      
N⁭  
              Or Type II  Y⁭
 N⁭ 
Ischemic Heart Disease:    Y⁭ N⁭ 
Cerebrovascular Disease:    Y⁭ N⁭ 
Arthritis:     Y⁭ N⁭ 
Respiratory Disease:    Y⁭ N⁭………………………. 
Others …………………………………………………………………………… 
 
Family History of Gastric disease:   Y⁭ N⁭ 
Specify if Y: 
 
Smoking history: 
Smoker:  Y⁭ N⁭  If Y: CPD:                    Years: 
Non-smoker: Y⁭ N⁭ 
Exsmoker: Y⁭ N⁭  when stopped:             Cpd:          Years:  
 
Please affix patient label and BRC 
data no. 
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Trust R&D No:3592 
 
Alcohol:  Y⁭ N⁭.   If Y: ……………units per week 
 
Current drug use: 
 PPI H2RA Aspirin Clopidogrel NSAID 
Name      
Dose      
Last taken      
 
 
Endoscopic findings: 
 
 
 
 
 
 
H pylori status: 
 
a) H pylori test result: 
 Positive Negative Indeterminate Not 
Done 
Rapid urease test 
(PRONTO/ CLO): 
    
Histology:     
Serology:     
13
C Urea breath 
test: 
    
 
 
b) Previous eradication therapy: Y⁭ N⁭  Unknown⁭ 
If Y:  
i. Eradication therapy used: 
 Name Dose Schedule Duration 
1     
2     
3     
 
ii. When/How long ago: 
iii. Previous testing method:  
Serology:   Y⁭ N⁭ 
13
C Urea breath test:  Y⁭ N⁭ 
RUT:   Y⁭ N⁭ 
Histology:  Y⁭ N⁭ 
Not Known:  Y⁭ N⁭ 
 
Other relevant information: 
 
285 
 
Appendix 2 
Gastric Biopsy Report 
Gastric Biopsy report page-1 
 
 
 
 
 
 
 
 
Histology study code: ………  
 
Gastric biopsy 
Standard histopathological report 
Patient identification 
Name (given name / family name):…………………………………..Birth:.……………… 
Gender (M / F):…. 
Endoscopy pocedure:…………………………..…………………………….…………… 
Clinical diagnosis:…………………………………………………………….…..  ……… 
Serum sample available (Y / N) 
----------------------------------------------------------------------------------------------------------- 
Clinical data:…………………………………………………………………………….. 
        Basic sampling: (representative / not representative) 
 
 
     
Special stains: H&E, PAS-AK, Giemsa, Congo, other.:………………………………………. 
Immunohistochemistry:……………………………………………………………………….. 
HISTOPATHOLOGY 
Type of gastritis: A / B / C  / other  / other alterations:………………………………………… 
…………………………………………………………………………………………………… 
Helicobacter pylori-associated inflammation                                       
(Modified Sydney classification: Dixon, DF. Am.J.Surg.Pathol.1996) 
extension, localisation (antrum / body; superficial / transmucosal) 
lymphocytes, monocytes :   0 1 2 3 4 5 6 
activity (granulocytes)      0  1 2 3 4 5
 6 
mucosal atrophy (body)    0 1 2 3 4 5
 6 
Helicobacter pylori colonisation  0 1 2 3 4 5 6 
Foveolar epithel damage   0 1 2 3 4 5 6 
Intestinal metaplasie (type, extension)  0 1 2 3 4 5 6 
Sydney score:                  
 ………/ 36 
  
Others:      MALT acquisition / MALT lymphoma / other lymphoma 
Pancreas acinaris metaplasia (PAM) 
Neuroendocrine hyperplasia 
Foveolar hyperplasia 
Chief cell / parietal cell hyperplasie / dilated glands 
Blood capillar dilatation / lymphangiectasie 
IEL / granuloma / eosinophilia / mastocytosis 
Erosion / ulcer 
Other microbas (f.e. H. heilmanni):………………………………….. 
Other/s:……………………………………………………………….. 
 
University of Szeged 
Department of Pathology 
Pathologiai Intézet 
H-6720 Szeged, Állomás u. 2. (6701 Szeged Pf. 427.) 
Hungary 
Tel: 62-545 878 Fax: 62-545 868 
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Gastric Biopsy Report 
Gastric biopsy report page-2 
 
Padova classification (1998) 
1. Negative for dysplasia 
   1.0. normal 
   1.1 reactive foveolar hyperplasia 
   1.2. intestinale metaplasia 
    1.2.1. IM complet (I.type) 
    1.2.2. IM incomplet (II. and III. type) 
2. Indefinitive for dysplasia 
  2.1. foveolar hyperproliferation 
  2.2. hyperproliferative IM 
3. Non-invasive neoplasia („flat” or „elevated”, synonyma.: adenoma) 
  3.1. LG 
  3.2. HG  
   3.2.1. carcinoma suspicion without invasion  
   3.2.2. carcinoma without invasion  
4. Invasíve carcinoma suspicion 
5. Invasíve adenocarcinoma 
 
Modified Vienna classification  (2000, 2002) 
  1. category: 0 (negativ for neoplasia / dysplasia) 
2. category: ANDD (indefinitive for neoplasia / dysplasia)  
3. category:  LGD/LGA   
4. category: „intramucosal borderline neoplasia „ 
4.1. HGD/HGA 
4.2. intramucosalis carcinoma (pTis), well differentiated   
5. definite  carcinoma  
   5.1. Intramucosal carcinoma, moderately or poorly differenciated                                                                                                      
5.2. Submucosal carcinoma or beyond   
 
Comment:…………………………………………………………………………………………………………………………
…………………………………......................................... 
 
Histological diagnosis: 
…………………………………………………………………………………………………. 
 
 
Szeged, ………………………. 
 
 
1. Senior pathologist    2. Junior pathologist 
Dr. Laszlo Tiszlavicz PhD 
tiszlats@yahoo.com 
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Appendix 3 
 
Published abstracts/papers 
Published Papers 
1. Nørsett KG, Steele I, Duval C, Sammut SJ, Murugesan SV, Kenny S, 
Rainbow L, Dimaline R, Dockray GJ, Pritchard DM, Varro A. ‘Gastrin 
stimulates expression of plasminogen activator inhibitor (PAI) -1 in 
gastric epithelial cells.’ American journal of Physiology. 
Gastroenterology and Liver Physiology. 2011 Sep; 301(3):G446-53. 
 
2. Murugesan SV, Varro A, Pritchard DM. ‘Strategies to determine 
whether hypergastrinemia is due to Zollinger Ellison Syndrome rather 
than a more common benign cause.’ Aliment Pharmacol Ther. 2009; 
May 15; 2 9(10):1055-68.  
 
Published abstracts 
1. ‘Determinants of human fasting serum gastrin concentration–
interaction between H. pylori infection, gastric preneoplastic pathology 
and proton pump inhibitor use.’ Poster of Distinction, DDW – 2011. 
Senthil V. Murugesan, László Tiszlavicz, Islay Steele, Tracey 
Farragher, Andrew R. Moore, Andrea Varro, David M. Pritchard.  
 
2. ‘The effects of host, environmental and bacterial factors on 
development of gastric preneoplastic pathology.’ Poster presentation, 
DDW – 2011. Senthil V. Murugesan, László Tiszlavicz, Islay Steele, 
Tracey Farragher, Andrew R. Moore, Andrea Varro, David M. 
Pritchard.  
 
3. ‘Factors that determine the sensitivity of rapid urease tests for the 
detection of Helicobacter pylori infection.’ Poster presentation, DDW – 
2011. Senthil V. Murugesan, László Tiszlavicz, Islay Steele, Tracey 
Farragher, Andrew R. Moore, Andrea Varro, David M. Pritchard.  
 
4. ‘Octreotide suppression test predicts suitability for antrectomy in type-
1 gastric carcinoid tumours’. Poster presentation, Gastro 2009 
(UEGW/WGO). Senthil V. Murugesan, Islay Steele, Andrea Varro, 
David M. Pritchard. 
 
5. ‘Investigation of factors which affect the development of type-1 gastric 
carcinoid tumours’. Poster presentation, Gastro 2009 (UEGW/WGO). 
Senthil V. Murugesan, Islay Steele, Andrea Varro, David M. Pritchard. 
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